Page last updated: 2024-11-04

norethindrone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Norethindrone: A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

norethisterone : A 17beta-hydroxy steroid that is testosterone in which the hydrogen at position 17 is replaced by an ethynyl group and in which the methyl group attached to position 10 is replaced by hydrogen. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6230
CHEMBL ID1162
CHEBI ID7627
SCHEMBL ID23390
MeSH IDM0014969

Synonyms (289)

Synonym
bdbm50148732
BRD-K92073408-001-03-3
gtpl2880
(17beta)-17-ethynyl-17-hydroxyestr-4-en-3-one
17alpha-hydroxy-19-norpregn-4-en-20-yn-3-one
LMST02030097
norcept-e
ccris 484
jenest-28
synphase
nora-be
ovysmen 0.5 35
brevinor 28
anovulatorio
estrinor
triella
norcolut
19-nor-17alpa-ethynyltestosterone
17-alpha-ethinylestra-4-en-17-beta-ol-3-one
(17-alpha)-17-hydroxy-19-norpregn-4-en-20-yn-3-one
norethin
nelova
tri-norinyl
mini-pill
brevinor 21
noretisterona [inn-spanish]
19-nor-17-ethinyl testosterone
ai3-26422
norethisterone [progestins]
noretisterone [dcit]
17-ethinyl-19-nortestosterone
ortho 7 7 7
primolut-n
norethadrone
utovlan
17-alpha-ethynyl-17-beta-hydroxy-19-norandrost-4-en-3-one
ortho-novum 7 7 7
brevinor-1 21
nodiol
norpregneninotone
19-norethinyltestosterone
trinovum 21
ethynylmortestosterone
einecs 200-681-6
milli
ortho-novum 1 50
ortho 1 35
noriday 28
norethisteronum [inn-latin]
ciclovulan
hsdb 3370
brevinor-1 28
ovysmen 1 35
ortho-novum 1 35
combipatch
ethinyl-19-nortestosterone
estr-4-en-3-one, 17alpha-ethynyl-17-hydroxy-
noraethisteronum
19-nor-ethinyl--4,5-testosterone
brn 1915671
17alpha-ethinyl-17beta-hydroxy-delta(sup:4)-estren-3-one
norethynodron
activella
17-alpha-19-norpregn-4-en-20-yn-3-one, 17-hydroxy-
microneth
19-nor-17-ethinyltestosterone
17-alpha-ethinyl-17-beta-hydroxy-delta(sup:4)-estren-3-one
synphasic 28
gencept
19-nor-17alpha-pregn-4-en-20-yn-3-one, 17-hydroxy-
genora
camila
19-nor-17-alpha-pregn-4-en-20-yn-3-one, 17-hydroxy-
nor-qd
D00182
primolut-n (tn)
norethisterone (jp17)
micronor (tn)
camila (tn)
norethindrone (usp)
BSPBIO_000066
ethynylnortestosterone
norpregneninlone
noralutin
primolut n
norpregneninolone
sc 4640
mini-pe
norfor
norethisteron
19-nortestosterone, 17-ethynyl-
ethinylnortestosterone
proluteasi
micronovum
norethisterone
norluten
noriday
conludaf
norlutin
noresthisterone
norethyndron
gestest
utovlar
norethynodrone
anhydrohydroxynorprogesterone
micronor
conludag
anovule
norluton
norgestin
nsc-9564
micronett
PRESTWICK_646
cas-68-22-4
norethisteronum
NCGC00179669-01
noretisterona
CHEBI:7627 ,
(17alpha)-17-hydroxy-19-norpregn-4-en-20-yn-3-one
17-ethynyl-17beta-hydroxyestr-4-en-3-one
BPBIO1_000074
PRESTWICK2_000253
(14beta,17alpha)-17-ethynyl-17-hydroxyestr-4-en-3-one
19-nor-17alpha-ethynyl-17beta-hydroxy-4-androsten-3-one
norethindrone
68-22-4
19-norethisterone
C05028
19-norethindrone, >=98%, powder
17-alpha-ethynyl-4-estren-17-ol-3-one
17-alpha-ethynyl-19-norandrost-4-en-17-beta-ol-3-one
17alpha-ethinylestra-4-en-17beta-ol-3-one
19-nor-17alpha-ethynylandrosten-17beta-ol-3-one
17-hydroxy-19-nor-17-alpha-pregn-4-en-20-yn-3-one
(17alpha)-17-ethynyl-17-hydroxyestra-4,8(14),9-trien-3-one
17alpha-ethynyl-19-norandrost-4-en-17beta-ol-3-one
19-nor-17-alpha-ethynylandrosten-17-beta-ol-3-one
4-estren-17alpha-ethynyl-17beta-ol-3-one
19-nor-17-alpha-ethynyl-17-beta-hydroxy-4-androsten-3-one
17alpha-ethynyl-19-nortestosterone
17alpha-ethynyl-17-hydroxy-4-estren-3-one
17-hydroxy-19-nor-17alpha-pregn-4-en-20-yn-3-one
19-nor-17-alpha-ethynyltestosterone
DB00717
17alpha-ethynyl-4-estren-17-ol-3-one
17beta-hydroxy-19-norpregn-4-en-20-yn-3-one
19-nor-17alpha-ethynyltestosterone
17alpha-ethynyl-17beta-hydroxy-19-norandrost-4-en-3-one
17alpha-ethynyl-19-nor-4-androsten-17beta-ol-3-one
17-alpha-ethynyl-17-hydroxy-4-estren-3-one
19-nor-ethindrone
17-beta-hydroxy-19-norpregn-4-en-20-yn-3-one
17alpha-ethinyl-19-nortestosterone
17-alpha-ethynyl-19-nortestosterone
NCGC00094738-01
PRESTWICK0_000253
SPBIO_002285
PRESTWICK1_000253
PRESTWICK3_000253
norethindirone
19-norethindrone
MLS001076679
smr000499579
MLS001163874 ,
HMS2090D21
AC-11100
CHEMBL1162 ,
sc-4640
N0449
HMS1568D08
(8r,9s,10r,13s,14s,17r)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
cpd000499579
A836053
AKOS005267172
NCGC00179669-02
HMS3259C16
HMS2095D08
dtxsid9023380 ,
dtxcid303380
NCGC00255187-01
tox21_302427
tox21_111322
HMS2231E18
S4040
menzol
normapause
n.e.e.
t18f433x4s ,
norethisterone [inn]
unii-t18f433x4s
errin
noretisterone
ec 200-681-6
norethindrone [usp]
femcon fe component norethindrone
norethindrone [hsdb]
norethindrone [mi]
aranelle component norethindrone
vyfemla component norethindrone
norinyl component norethindrone
norquest fe component norethindrone
norethindrone [usp impurity]
norethindrone component of femcon fe
norethisteronum [who-ip latin]
taytulla component norethindrone
norethindrone component of aranelle
levonorgestrel impurity u [ep impurity]
norethindrone [vandf]
norethindrone [usp-rs]
norethisterone [ep impurity]
norethindrone [orange book]
norethisterone acetate impurity a [ep impurity]
minastrin 24 fe component norethindrone
norethisterone [mart.]
norethisterone [who-ip]
brevicon component norethindrone
norethindrone component of norquest fe
norethisterone [who-dd]
lo minastrin fe component norethindrone
norethindrone [usp monograph]
norethisterone [jan]
CCG-220253
HY-B0554
NC00576
SCHEMBL23390
tox21_111322_1
NCGC00179669-04
17-hydroxy-19-nor-17alpha-pregn-4-en-20yn-3-one
VIKNJXKGJWUCNN-XGXHKTLJSA-N
13-methyl-17alpha-ethynyl-17-hydroxygon-4-en-3-one
norethisterone (norethindrone)
W-104686
AC-33117
sr-01000765382
SR-01000765382-3
(8r,9s,10r,13s,14s,17r)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3h-cyclopenta[a]phenanthren-3-one
norethindrone, united states pharmacopeia (usp) reference standard
19-norethindrone, vetranal(tm), analytical standard
norethindrone (norethisterone), pharmaceutical secondary standard; certified reference material
norethisterone for system suitability, european pharmacopoeia (ep) reference standard
norethisterone, european pharmacopoeia (ep) reference standard
HMS3712D08
17alpha-ethynyl-3-oxo-4-estren-17beta-ol
17-ethynyl-17-hydroxyestr-4-en-3-one (acd/name 4.0)
17-alpha-ethynyl-17-beta-hydroxy-4-estren-3-one
17beta-hydroxy-17alpha-ethynylestr-4-en-3-one
17-ethinyl-19-nor-testosterone
17alpha-ethynyl-17beta-hydroxyestr-4-en-3-one
17alpha-ethynyl-17-hydroxyest-4-en-3-one
17-hydroxy-17-alpha-19-norpregn-4-en-20-yn-3-one
17alpha-pregn-4-en-20-yn-3-one
17alpha-ethynyl-17-hydroxy-estr-4-en-3-one
17alpha-ethinyl-17alpha-ethinyl-19-nortestosterone
17-ethynyl-19-nortestosterone
17-hydroxy-(17alpha)-19-norpregn-4-en-20-yn-3-one
norethisterone, british pharmacopoeia (bp) reference standard
Q421352
norethisterone; 19-norethisterone; 17?-ethynyl-19-nortestosterone; 17-hydroxy-19-nor-17?-pregn-4-en-20-yn-3-one
levonorgestrel ep impurity u
BCP28306
BRD-K92073408-001-16-5
C76161
AS-56451
norethisterone 100 microg/ml in acetonitrile
CS-0694821
HY-B0554R
norethindrone (standard)
lyleq
deblitane
norethisterone (mart.)
jencycla
heather
levonorgestrel impurity u (ep impurity)
tulana
norethindrone (usp impurity)
affodel
norlyroc
noretisterona (inn-spanish)
incassia
norlyda
nora be
sharobel
norethindrone (usp-rs)
17alpha-ethynyl-19-norandro-st-4-en-17beta-ol-3-one
lyza
norethisterone (ep impurity)
norethindrone (usp monograph)
norethisteronum (inn-latin)
emzahh

Research Excerpts

Toxicity

Norethindrone-4 beta,5 beta-epoxide was toxic to Walker cells in culture.

ExcerptReferenceRelevance
" Also examined was the probability that a side effect would occur in the 2nd or 3rd cycle if the user had not experienced such an effect in the 1st cycle."( The probability of side effects with ovral, norinyl 1/50 and norlestrin.
Berger, GS; Edelman, DA; Talwar, PP, 1979
)
0.26
" The most common side effect was inter-menstrual bleeding with the 35-microgram pill."( Side effects and compliance with low- and conventional-dose oral contraceptives among adolescents.
Jay, MS; Litt, IF; Neel, EU, 1987
)
0.27
" Norethindrone-4 beta,5 beta-epoxide was toxic to Walker cells in culture."( Cytotoxic effects of norethindrone-4 beta,5 beta-epoxide to Walker cells in culture and to rat liver in vivo.
Suzangar, M; White, IN, 1980
)
0.26
" These data suggest that the use of Neten-20 for one year does not lead to adverse metabolic effects analogous to those seen with combination type oral contraceptives."( Low dose injectable contraceptive norethisterone enanthate 20mg monthly - II. Metabolic side effects.
Bamji, MS; Prema, K; Safaya, S, 1981
)
0.26
"Contraceptive efficacy, median serum NET levels, adverse events."( Contraceptive efficacy, pharmacokinetics, and safety of Annuelle biodegradable norethindrone pellet implants.
Archer, DF; Baker, J; Cole, D; Raymond, EG; Saxena, BB; Singh, M, 1996
)
0.29
" The main side effect was bleeding abnormalities, which persisted in half the participants for up to 2 years."( Contraceptive efficacy, pharmacokinetics, and safety of Annuelle biodegradable norethindrone pellet implants.
Archer, DF; Baker, J; Cole, D; Raymond, EG; Saxena, BB; Singh, M, 1996
)
0.29
"Annuelle shows potential as an effective, safe contraceptive with distinct advantages over other long-acting agents, because it is biodegradable but can be removed if problems arise or if fertility is desired."( Contraceptive efficacy, pharmacokinetics, and safety of Annuelle biodegradable norethindrone pellet implants.
Archer, DF; Baker, J; Cole, D; Raymond, EG; Saxena, BB; Singh, M, 1996
)
0.29
"Our goal was to determine if the addition of norethindrone acetate (NETA) to leuprolide acetate (LA) has an adverse effect on controlled ovarian stimulation (COH) during in vitro fertilization (IVF)."( The addition of norethindrone acetate to leuprolide acetate for ovarian suppression has no adverse effect on ovarian stimulation.
Ditkoff, EC; Lindheim, S; Prosser, R; Sauer, MV; Zimmermann, RC, 1997
)
0.3
"No adverse effect on ovarian stimulation was evident on the addition of NETA to LA."( The addition of norethindrone acetate to leuprolide acetate for ovarian suppression has no adverse effect on ovarian stimulation.
Ditkoff, EC; Lindheim, S; Prosser, R; Sauer, MV; Zimmermann, RC, 1997
)
0.3
" Overnight soaking of the ring before first use has the potential to reduce the side effect of transient nausea, presumed attributable to the accumulation of ethinyl estradiol on the ring surface during storage."( Effect of different insertion regimens on side effects with a combination contraceptive vaginal ring.
Fraser, IS; Jackanicz, T; Lacarra, M; Mishell, DR; Weisberg, E, 1997
)
0.3
" With further investigation, such regimens may allow safe prolongation of GnRH analogue use without sacrificing efficacy in those endometriosis patients with severe pelvic pain."( Add-back therapy: extending safety and efficacy of GnRH analogues in the gynecologic patient.
Surrey, ES, 1998
)
0.3
"No serious adverse effects were observed in either group."( A triphasic oral contraceptive pill, CTR-05: clinical efficacy and safety.
Ledger, WJ; Saxena, BB; Singh, M; Singh, R; Thomas, D, 1996
)
0.29
" There were indications, however, that both steroids were toxic to endometrial cells at concentrations of approximately 5 micrograms/ml, and both drugs showed signs of potential teratogenicity at 10 micrograms/ml."( In vitro cytotoxicity and teratogenicity of norethisterone and levonorgestrel released from hollow nylon monofilaments.
Gard, PR; Malhi, JS; Ostad, SN, 1998
)
0.3
" This study indicates that use of a single CVR releasing EE and NET-Ac over a period of 12 months constitutes an acceptable, safe and effective contraceptive method."( Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring.
Alvarez, F; Brache, V; Fraser, IS; Lacarra, M; Mishell, DR; Nash, HA; Weisberg, E, 1999
)
0.3
" The adverse events reported in both treatment groups are consistent with those expected with the use of combined hormonal contraceptives."( Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lu
Cromie, MA; Garceau, RJ; Kaunitz, AM, 1999
)
0.3
"Change in bone mineral density, lipoprotein metabolism, climacteric symptoms, and adverse effects."( Piperazine oestrone sulphate and interrupted norethisterone in postmenopausal women: effects on bone mass, lipoprotein metabolism, climacteric symptoms, and adverse effects.
Alexandersen, P; Byrjalsen, I; Christiansen, C, 2000
)
0.31
" The incidence of other adverse events was similar among treatment groups, an observation that supports the safety of both formulations."( Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial.
Kaunitz, AM, 2000
)
0.31
" The incidences of adverse events were similar in all groups."( Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest for continuous combined hormone replacement therapy in postmenopausal women.
Gräser, T; Koytchev, R; Müller, A; Oettel, M, 2000
)
0.31
" The Workshop members endorse injectable contraceptives as safe and effective and recommend that they be made available to all women."( Injectable contraceptives: safe and effective.
, 1982
)
0.26
" This side effect was mainly noted in the first few months of use."( Vaginal discharge: a perceived side effect and minor reason for discontinuation in hormonal injectable users in South Africa.
Beksinska, ME; Rees, HV, 2001
)
0.31
" We investigated the role of synthetic progestins in initiating the adverse events associated with estrogen therapy."( Progestins initiate adverse events of menopausal estrogen therapy.
Clark, L; Garces, A; Rhodin, J; Thomas, T, 2003
)
0.32
" No adverse drug reactions specific to E2V/MPA triphasic were observed."( Endometrial safety and tolerability of triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate therapy regimen.
Engelstein, M; Kuhl, H; Mäenpää, J; Mattila, L; Mustonen, M; Rees, MC, 2004
)
0.32
" Both treatments were generally well tolerated, with most adverse events (>90%) being mild to moderate, although minor differences in the tolerability profile were observed between treatments."( Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study.
Arguinzoniz, M; Boschitsch, E; Concin, H; De Geyter, C; Ehrenborg, A; Heikkinen, J; Hobson, R; Ibarra de Palacios, P; Samsioe, G; Scheurer, C; Schmidt, G, 2006
)
0.33
"New low-dose formulations of combination oral contraceptives (COCs) are safe and effective, but they may be associated with an increased risk of breakthrough bleeding."( Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe).
Archer, DF; Ellman, H; Nakajima, ST, 2007
)
0.34
" The overall incidence of adverse events (AEs) was comparable in both groups, and the majority was mild-to-moderate in intensity."( One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women.
Arguinzoniz, M; Dvorak, V; Ferreira, A; Genazzani, AR; Hamann, B; Heikkinen, J; Kawakami, FT; Mueck, AO; Samsioe, G; Sun, D; Suzin, J, 2007
)
0.34
" Adverse events occurring from the first trial-related activity, whether related or not related to the study medication, were recorded for the entire population (n = 575) of the trial."( Optimal tolerability of ultra-low-dose continuous combined 17beta-estradiol and norethisterone acetate: laboratory and safety results.
Hruska, J; Samsioe, G, 2010
)
0.36
" The incidence of serious adverse events was only 1% in respective treatment groups."( Optimal tolerability of ultra-low-dose continuous combined 17beta-estradiol and norethisterone acetate: laboratory and safety results.
Hruska, J; Samsioe, G, 2010
)
0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Most treatment-emergent adverse events were mild, and all resolved by study end."( Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive.
Bush, M; Lewis, E; Scott, R; Watanalumlerd, P; Zhi, H, 2012
)
0.38
"The development of a safe and effective reversible method of male contraception is still an unmet need."( Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men.
Anderson, RA; Behre, HM; Callahan, MM; Colvard, DS; Festin, MP; Habib, NA; Handelsman, DJ; Lestari, SW; Linton, KA; McLachlan, RI; Meriggiola, MC; Misro, MM; Noe, G; Vogelsong, KM; Wu, FC; Zitzmann, M, 2016
)
0.43
" The most common adverse events were acne, injection site pain, increased libido, and mood disorders."( Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men.
Anderson, RA; Behre, HM; Callahan, MM; Colvard, DS; Festin, MP; Habib, NA; Handelsman, DJ; Lestari, SW; Linton, KA; McLachlan, RI; Meriggiola, MC; Misro, MM; Noe, G; Vogelsong, KM; Wu, FC; Zitzmann, M, 2016
)
0.43
" The aim of this study was to evaluate the incidence of TE using the Japanese Adverse Drug Event Report (JADER) database."( Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database.
Abe, J; Fukuda, A; Hane, Y; Hasegawa, S; Hatahira, H; Hirade, K; Kinosada, Y; Matsui, T; Motooka, Y; Naganuma, M; Nakamura, M; Sasaoka, S; Takahashi, Y, 2017
)
0.46
"E2 concentrations, bleeding pattern, exploratory bone metabolism biomarkers, and adverse events."( Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109.
Fawkes, N; Gotteland, JP; Loumaye, E; Marchand, L; Pohl, O, 2018
)
0.48
" Add-back therapy may be required to prevent adverse effects on bone in women treated with the 200-mg dose (at 100 mg in some women)."( Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109.
Fawkes, N; Gotteland, JP; Loumaye, E; Marchand, L; Pohl, O, 2018
)
0.48

Pharmacokinetics

Norethindrone acetate showed an initial rapid disappearance of 3H with an average half-life of 7. Etravirine 200 mg bid was coadministered on Day 1 to Day 15 of Cycle 3.

ExcerptReferenceRelevance
" Pharmacokinetic parameters were evaluated by using a two-compartment open model and by graphical and regression analysis of plasma NET data."( The rabbit as an animal model to study pharmacokinetics of norethindrone in women.
Narasinga Rao, BS; Prasad, KV; Sivakumar, B, 1979
)
0.26
" The half-life of plasma NET clearance was relatively shorter in women of low socio-economic group with poor nutritional status as indicated by anthropometric indices, as compared to that in well nourished women of high socio-economic group."( Pharmacokinetics of norethindrone in Indian Women.
Prasad, KV; Prema, K; Rao, BS; Sivakumar, B, 1979
)
0.26
" Anthropometric indexes showed the low SES group with poor nutritional status had shorter half-life clearances than the relatively well-nourished high SES group."( Pharmacokinetics of norethindrone in Indian Women.
Prasad, KV; Prema, K; Rao, BS; Sivakumar, B, 1979
)
0.26
" No significant difference in pharmacokinetic parameters between the two drugs was observed."( [Pharmacokinetics of norethindrone-3-oxime and norethindrone in rhesus monkeys].
Fu, GM; Li, DZ; Li, ZX; Wang, GP; Wang, XL; Wei, ZN; Zhao, XL; Zhou, MY; Zuo, MD, 1991
)
0.28
" These differences in serum concentrations are determined by the different pharmacokinetic behaviour of the gestagens, which in turn is largely determined by their binding to serum proteins."( Potency and pharmacokinetics of gestagens.
Fotherby, K, 1990
)
0.28
" The pharmacokinetic properties of desogestrel were characterized by the following parameters: (1) maximum serum concentration, (2) time to maximum serum concentration, (3) total area under the serum concentration versus time curve, and (4) serum half-life of elimination."( Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin.
Assendorp, R; Bergink, W; Kloosterboer, L; Qvist, I; van Lier, W; Voortman, G, 1990
)
0.28
" The pharmacokinetic properties of desogestrel were characterized by the following parameters: maximum serum concentration, time to maximum serum concentration, total area under the serum concentration vs time curve, and serum 1/2 life of elimination."( Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin.
Assendorp, R; Bergink, W; Kloosterboer, L; Qvist, I; van Lier, W; Voortman, G, 1990
)
0.28
"A pharmacodynamic and pharmacokinetic study of the Chinese No."( A pharmacodynamic and pharmacokinetic study of the Chinese No. 1 pill.
Chen, JK; Fan, SB; Fotherby, K; Gui, YL; He, ML; Li, LM; Song, S; Yang, PJ, 1990
)
0.28
" A trial with a 2 mg NET preparation made with NET utilizing the 44 microns same material displayed a Tmax similar to the 1 mg NET preparation having the same particle size while the Cmax reached a level of 17."( Pharmacokinetics of norethindrone: effect of particle size.
Combs, DL; Dorr, A; Edgren, RA; Fong, JC; Jung, D; Kushinsky, S; Lee, GJ; Mroszczak, EJ; Pritchard, R; Saperstein, S, 1989
)
0.28
" Pharmacokinetic parameters of NET were more or less comparable between the two pills."( Pharmacokinetics of norethisterone from two different combination contraceptive pills in Indian women.
Narasinga Rao, BS; Prasad, KV; Ramalakshmi, BA; Ravinder, P; Sivakumar, B,
)
0.13
" Pharmacokinetic parameters of NET were more or less comparable between the 2 pills."( Pharmacokinetics of norethisterone from two different combination contraceptive pills in Indian women.
Narasinga Rao, BS; Prasad, KV; Ramalakshmi, BA; Ravinder, P; Sivakumar, B,
)
0.13
"We have examined the pharmacokinetic parameters derived from the analysis of plasma ethinyl estradiol (EE) and norethindrone levels after administration of a single dose of three bioequivalent norethindrone-1mg/mestranol (ME)-50 micrograms formulations (Ortho-NovumR 1/50, NorinylR 1/50 and Norcept-MR 1/50) and three norethindrone-1mg/ethinyl estradiol-35 micrograms formulations (Ortho-Novum 1/35R, NorinylR 1/35, Norcept-ER 1/35) in a randomized crossover design involving 24 women for the 35 micrograms and 27 women for the 50 micrograms agents."( Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are "low-dose" pills really lower?
Brody, SA; Goldzieher, JW; Turkes, A, 1989
)
0.28
" The pharmacokinetic parameters of the compounds were also compared."( [Pharmacokinetics of norethindrone-oxime and norethindrone in rabbits after oral administration].
Li, DZ; Liu, J; Pang, XB; Wang, GP; Zhao, XL; Zhou, MY, 1989
)
0.28
"Plasma concentration profiles and pharmacokinetic parameters have been obtained following single dose administration of three commonly used oral contraceptive steroid preparations, Ovral, Nordette and Norminest to Egyptian women."( Pharmacokinetics of oral contraceptive steroids in Egyptian women: studies with Ovral, Nordette and Norminest.
Back, DJ; el-Raghy, I; Fathalla, M; Makeram, M; Orme, ML; Osman, F; Salem, H, 1986
)
0.27
" This evidence of a pharmacodynamic interaction between contraceptive steroids and ethanol in rats is consistent with a recent clinical report of significant contraceptive steroid-related improvement in tolerance to ethanol with no apparent effect on the pharmacokinetics of ethanol."( Kinetics of drug action in disease states. XXII. Effects of contraceptive steroids on the pharmacodynamics of ethanol in rats.
Levy, G; Wanwimolruk, S, 1987
)
0.27
"The pharmacokinetics and pharmacodynamic effects of two doses of norethisterone (5mg and 3mg) used as a 'visiting pill' were investigated."( A pharmacokinetic and pharmacodynamic study of a 'visiting pill' containing norethisterone.
Chen, JK; Cheng, DH; Fotherby, K; Liu, WY; Song, S; Yang, PJ, 1986
)
0.27
" The results indicate that NET was readily absorbed by all three routes but the Cmax and AUC of NET were significantly greater by the sublingual route."( Pharmacokinetics of norethisterone following its oral administration and by spraying it nasally or sublingually to male bonnet monkeys.
Anand Kumar, TC; Dhanasekaran, K; Hamied, YK; Nayak, VG; Pongubala, JM; Puri, CP; Vajifdar, BS, 1987
)
0.27
" There were large inter-subject variations in the pharmacokinetic parameters, the elimination half-life and bioavailability showing 3- and 5- fold variability, respectively."( Pharmacokinetics of norethisterone in humans.
Fotherby, K; Gu, J; He, CH; Shi, YE, 1987
)
0.27
" Due to the large inter-subject variation and the small number of subjects studied in each center, few of the correlations between the pharmacokinetic parameters or of the parameters with the ponderal index in each center were significant although in 10 of the 14 centers there was a significant correlation of the serum NET concentration at 24 hours with the elimination half-life."( Pharmacokinetics of norethisterone in humans.
Fotherby, K; Gu, J; He, CH; Shi, YE, 1987
)
0.27
" It was found that neither the 24-hr plasma levels nor the pharmacokinetic parameters of norethindrone following intravenous dosing were significantly altered by aspirin."( Influence of aspirin on the pharmacokinetics of norethindrone.
Gomaa, AA; Makarm, MH, 1987
)
0.27
" It appears that during the first 3-9 months of low dose oral contraceptive treatment, these steroids do not alter the pharmacokinetic behaviour of theophylline in adolescent females."( Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives.
Chin, TF; Correia, J; Koren, G; MacLeod, SM; Tesoro, A, 1985
)
0.27
" time curve (AUC), and (e) plasma half-life (t1/2)."( Plasma levels and pharmacokinetics of norethindrone and ethinylestradiol administered in solution and as tablets to women.
Goebelsmann, U; Henzl, M; Ling, T; Miyakawa, I; Mroszczak, EJ; Runkel, R; Stanczyk, FZ, 1983
)
0.27
" As expected for a highly cleared drug, enzyme induction had no measurable effect on the terminal half-life of norethindrone in the perfused liver preparation."( An investigation of the effects of phenobarbitone on the pharmacokinetics of norethindrone in the rat using liver perfusion and everted gut sacs.
Back, DJ; Macnee, CM; Orme, ML; Rowe, PH; Smith, E, 1984
)
0.27
" Due to wide intersubject variations there were no statistically significant differences in the pharmacokinetic parameters for the different groups but there were significant correlations between the dose and the mean values for these parameters."( Pharmacokinetics of different doses of norethisterone oenanthate.
Bye, PG; Elder, M; Fotherby, K; Hamawi, A; Howard, G, 1984
)
0.27
" Due to wide intersubject variations, there were no statistically significant differences in the pharmacokinetic paraetmers for the different groups but there were significant correlations between the dose and the mean values for these parameters."( Pharmacokinetics of different doses of norethisterone oenanthate.
Bye, PG; Elder, M; Fotherby, K; Hamawi, A; Howard, G, 1984
)
0.27
" The plasma values were subjected to pharmacokinetic analysis."( Effect of food restriction (undernutrition) on pharmacokinetics of norethindrone in rabbits.
Narasinga Rao, BS; Prasad, KV; Sivakumar, B, 1981
)
0.26
" There was no significant difference in a number of pharmacokinetic parameters between the two times of administration, suggesting that morning or evening administration of the contraceptive are equally effective."( Pharmacokinetics of oral contraceptive steroids after morning or evening administration.
Fotherby, K; Kiriwat, O, 1983
)
0.27
" There were no significant differences between morning and evening administration of the OC for any of the pharmacokinetic parameters of EE."( Pharmacokinetics of oral contraceptive steroids after morning or evening administration.
Fotherby, K; Kiriwat, O, 1983
)
0.27
" Extremely wide variations were observed between women in the various calculated pharmacokinetic parameters."( Variability of pharmacokinetic parameters for contraceptive steroids.
Fotherby, K, 1983
)
0.27
" Absorption phase half-life ranged from 14-22 minutes, distribution phase varied from 1-3 hours, and the elimination half life ranged from 6-14 hours."( Plasma levels and pharmacokinetics of ethynyl estrogens in various populations. I. Ethynylestradiol.
de la Pena, A; Dozier, TS; Goldzieher, JW, 1980
)
0.26
" The purpose of the study was to assess the pharmacokinetic and pharmacodynamic properties of the 2 formulations (depot medroxyprogesterone acetate and norethisterone enanthate)."( A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate.
Diczfalusy, E; Fotherby, K; Hingorani, V; Landgren, BM; Saxena, BN; Shrimanker, K; Takker, D, 1980
)
0.26
"Our purpose was to compare the pharmacokinetic parameters of oral administration of a 35 micrograms ethinyl estradiol, 1 mg norethindrone pill in peritoneal dialysis patients and normal women."( Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis.
Carr, BR; Droegemueller, W; Dupuis, RE; Lobo, RA; Price, TM; Stanczyk, FZ, 1993
)
0.29
" Pharmacokinetic parameters were calculated by noncompartmental analysis and statistical analysis performed with Mann-Whitney U testing."( Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis.
Carr, BR; Droegemueller, W; Dupuis, RE; Lobo, RA; Price, TM; Stanczyk, FZ, 1993
)
0.29
"There is no difference in the pharmacokinetic parameters for norethindrone in peritoneal dialysis patients compared with normal women."( Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis.
Carr, BR; Droegemueller, W; Dupuis, RE; Lobo, RA; Price, TM; Stanczyk, FZ, 1993
)
0.29
"In a single-dose and multiple-dose study, gynecologists from California, North Carolina, and Texas, compared pharmacokinetic parameters of the low dose oral contraceptive (OC), Ortho-Novum 1/35, (35 mcg ethinyl estradiol and 1 mg norethindrone) in premenopausal women with renal failure on peritoneal analysis and in age and weight matched controls."( Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis.
Carr, BR; Droegemueller, W; Dupuis, RE; Lobo, RA; Price, TM; Stanczyk, FZ, 1993
)
0.29
" None of the norethindrone pharmacokinetic parameters changed significantly in the presence of topiramate."( Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy.
Doose, DR; Nayak, RK; Rosenfeld, WE; Walker, SA, 1997
)
0.3
" The elimination half-life was 5-10 days."( Pharmacokinetics of orally administered norethisterone enanthate in rabbit, monkey, and women.
Nair, KM; Ravinder, P; Shatrugna, V; Sivakumar, B, 1997
)
0.3
" No changes were observed for other pharmacokinetic parameters assessed for either ethinyl estradiol or norethindrone."( Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone.
Abernethy, DR; Collins, JM; Donahue, SR; Flockhart, DA; Thacker, D; Trapnell, CB, 1998
)
0.3
" Furthermore, no changes were seen for other pharmacokinetic parameters assessed for thalidomide between days 1 and 21."( Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone.
Abernethy, DR; Collins, JM; Donahue, SR; Flockhart, DA; Thacker, D; Trapnell, CB, 1998
)
0.3
" Pharmacokinetic profiles of EE and NE were determined on day 21 of the second and third cycles."( Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent.
Knowlton, P; Koup, JR; Loi, CM; Sedman, AJ; Stern, R; Vassos, AB, 1999
)
0.3
" The pharmacokinetic profiles of plasma concentrations of thalidomide were evaluated with both noncompartmental and compartmental methods, whereas those of ethinyl estradiol and norethindrone were calculated with noncompartmental methods."( Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics.
Colburn, W; Kook, KA; Scheffler, MR; Thomas, SD, 1999
)
0.3
" There were no significant differences between pharmacokinetic parameters for thalidomide after 1 dose and those after 18 consecutive doses."( Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics.
Colburn, W; Kook, KA; Scheffler, MR; Thomas, SD, 1999
)
0.3
" Lack of pharmacokinetic effect was prospectively defined as 90% CI for the point estimate (PE) of the ratio (RSG + OC):(P + OC) contained within a 20% equivalence range for both ethinylestradiol and norethindrone (analyzed by ANOVA)."( Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers.
Culkin, KT; Finnerty, D; Freed, MI; Inglis, AM; Jorkasky, DK; Miller, AK; Patterson, SD, 2001
)
0.31
" The pharmacokinetic profile of the serum concentrations of estradiol was measured on day 1, 21 and 28 each immediately before and 1, 2, 4, 6, 8, and 10 hours after intake of a tablet, and the AUC (area under the curve) was calculated."( [Cross-over comparison of the pharmacokinetics of estradiol during hormone replacement therapy with estradiol valerate or micronized estradiol].
Fink, T; Kuhl, H; Lang, E; Leukel, P; Rohr, UD; Wiegratz, I, 2001
)
0.31
" Washing the skin after 10 min does not influence the pharmacokinetic profile and thus significantly reduces the risk of contamination of female partners or infants."( Pharmacokinetics of a new transdermal testosterone gel in gonadotrophin-suppressed normal men.
Eickenberg, U; Kemper, S; Lemmnitz, G; Nieschlag, E; Rolf, C, 2002
)
0.31
"Concomitant administration of NVP at steady state with EE/NET resulted in a significant (29%) median reduction in the area under the plasma concentration time curve (AUC(infinity)) and a significant reduction in mean residence time (MRT) and half-life (t(1/2)) of EE."( Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women.
Hutman, HW; Lamson, M; Marshak, A; McDonough, M; Mildvan, D; Robinson, P; Yarrish, R, 2002
)
0.31
" The determination of salivary steriod concentrations may therefore replace those in plasma and they may be useful in fertility control programs and pharmacokinetic studies."( Pharmacokinetic studies of norethisterone in plasma and saliva by enzyme immunoassay.
Dyas, J; Kisnisci, HA; Riad-fahmy, D; Turkes, A, 1980
)
0.26
"To study the pharmacokinetics of a combination oral contraceptive (OC) containing norethindrone and ethinyl estradiol during OC monotherapy, concomitant OC and topiramate (TPM) therapy, and concomitant OC and carbamazepine (CBZ) therapy in order to comparatively evaluate the pharmacokinetic interaction, which may cause contraceptive failure."( Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects.
Bialer, M; Doose, DR; Jacobs, D; Padmanabhan, M; Schwabe, S; Wang, SS, 2003
)
0.32
"To compare the pharmacokinetic parameters and safety of the progestagen, Org 30659, (17alpha)-17-hydroxy-11-methylene-19-norpregna-4,15-dien-20-yn-3-one), and ethinyl estradiol (EE) in Caucasian and Japanese women after single and multiple doses."( Pharmacokinetic differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659 and EE).
Cohen, AF; de Visser, SJ; Fukazawa, I; Machielsen, CS; Uchida, E; Uchida, N; van den Heuvel, MW; van Doorn, MB; van Vliet-Daskalopoulou, E, 2003
)
0.32
"The peak concentration and extent of exposure of Org 30659, and to a lesser extent of EE, in Japanese women are higher than in Caucasian women."( Pharmacokinetic differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659 and EE).
Cohen, AF; de Visser, SJ; Fukazawa, I; Machielsen, CS; Uchida, E; Uchida, N; van den Heuvel, MW; van Doorn, MB; van Vliet-Daskalopoulou, E, 2003
)
0.32
" Although isotretinoin and estradiol are metabolized largely by cytochrome P450 (CYP) 3A4 and glucuronidation, the potential for clinical drug interaction, with subsequent pharmacodynamic impact, has not been evaluated."( The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone.
Guidos, A; Hendrix, CW; Jackson, KA; Khoo, KC; Kretzer, R; Liss, CM; McLane, J; Shah, LP; Trapnell, CB; Whitmore, E, 2004
)
0.32
" The pharmacokinetics of ethinyl estradiol and norethindrone (INN, norethisterone) (the components of Ortho Novum 7/7/7; Ortho-McNeil Pharmaceutical, Inc, Raritan, NJ) and pharmacodynamic assessments of oral contraceptive effectiveness (concentrations of serum progesterone, luteinizing hormone, and follicle-stimulating hormone) were determined on days 6 and 20 of 2 separate oral contraceptive cycles, before and during isotretinoin treatment."( The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone.
Guidos, A; Hendrix, CW; Jackson, KA; Khoo, KC; Kretzer, R; Liss, CM; McLane, J; Shah, LP; Trapnell, CB; Whitmore, E, 2004
)
0.32
" Isotretinoin did not cause any statistically significant increases in pharmacodynamic markers, although a majority of women had increases in these measures."( The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone.
Guidos, A; Hendrix, CW; Jackson, KA; Khoo, KC; Kretzer, R; Liss, CM; McLane, J; Shah, LP; Trapnell, CB; Whitmore, E, 2004
)
0.32
"The small reduction in ethinyl estradiol and norethindrone levels associated with isotretinoin was not associated with any pharmacodynamic changes in our study."( The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone.
Guidos, A; Hendrix, CW; Jackson, KA; Khoo, KC; Kretzer, R; Liss, CM; McLane, J; Shah, LP; Trapnell, CB; Whitmore, E, 2004
)
0.32
"Two separate open-label, parallel-group, single-centre, pharmacokinetic and pharmacodynamic interaction studies."( Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive.
Tang-Liu, DD; Walker, PS; Yu, D; Yu, Z, 2004
)
0.32
" Pharmacokinetic parameters of plasma norethindrone and ethinylestradiol were compared before and after tazarotene administration (cycle day 6 of the second and third cycles, respectively)."( Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive.
Tang-Liu, DD; Walker, PS; Yu, D; Yu, Z, 2004
)
0.32
"1 mg), the area under the plasma concentration-time curve from zero to 24 hours (AUC24) and the peak concentration in plasma (Cmax) for tazarotenic acid were 121 +/- 27 microg."( Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive.
Tang-Liu, DD; Walker, PS; Yu, D; Yu, Z, 2004
)
0.32
" Using the rationale of the BCS, it can be argued that biowaivers can, however, also be granted on the basis of standard pharmacokinetic data."( Biowaivers for oral immediate-release products: implications of linear pharmacokinetics.
Faassen, F; Vromans, H, 2004
)
0.32
"Several antiepileptic drugs have clinically significant pharmacokinetic interactions with oral contraceptives (OCs) that may result in contraceptive failure."( Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
Dai, Y; Griffith, SG, 2004
)
0.32
"035 mg and norethindrone [NOR] 1 mg) and on pharmacodynamic variables that may be increased in the event of reduced contraceptive efficacy (concentrations of serum luteinizing hormone [LH], follicle-stimulating hormone [FSH], and progesterone)."( Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
Dai, Y; Griffith, SG, 2004
)
0.32
" There was no pharmacodynamic evidence that zonisamide is likely to reduce the contraceptive effectiveness of OCs containing EE and NOR."( Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
Dai, Y; Griffith, SG, 2004
)
0.32
"Using an optimized pharmacokinetic design, this study indicated men exhibit significantly higher zidovudine-monophosphate and zidovudine-triphosphate exposure following zidovudine oral administration, having implications for drug toxicity and overall tolerance of zidovudine therapy."( The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine.
Aberg, J; Aweeka, FT; Bardeguez, A; Coombs, RW; Lizak, P; Rosenkranz, SL; Segal, Y; Thevanayagam, L; Watts, DH, 2006
)
0.33
" This validated HPLC method was successfully applied to pharmacokinetic study of mifepristone in human plasma samples collected from volunteers after oral administration of 10 mg mifepristone."( Development of a high-performance liquid chromatographic method for the determination of mifepristone in human plasma using norethisterone as an internal standard: application to pharmacokinetic study.
Guo, Z; Wang, S; Wei, D; Zhai, J, 2007
)
0.34
" Pharmacokinetic assessments were performed on day 14 for each session."( Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women.
De Pauw, M; Felicione, E; Guzman, SS; Hoetelmans, RM; Lefebvre, E; Sekar, VJ; Vangeneugden, T, 2008
)
0.35
"The pharmacokinetic interaction observed here is considered to be clinically relevant as EE concentrations are considerably reduced when DRV/r is co-administered with EE and NE."( Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women.
De Pauw, M; Felicione, E; Guzman, SS; Hoetelmans, RM; Lefebvre, E; Sekar, VJ; Vangeneugden, T, 2008
)
0.35
" Etravirine 200 mg bid was coadministered on Day 1 to Day 15 of Cycle 3, with pharmacokinetic assessments of ethinylestradiol, norethindrone and etravirine on Day 15."( Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone.
Aharchi, F; Hoetelmans, RM; Kakuda, TN; Peeters, M; Schöller-Gyüre, M; Vandermeulen, K; Woodfall, B, 2009
)
0.35
" Pharmacokinetic parameters, including AUC(0-24), C(max), and C(min), were calculated using noncompartmental methods, and drug interactions were evaluated using an ANOVA model by treatment group."( Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women.
Kasserra, C; Li, J; March, B; O'Mara, E, 2011
)
0.37
" Twenty-one subjects completed the study and were included in the pharmacokinetic analysis; 4 discontinued for reasons unrelated to study drug and 2 discontinued because of adverse events."( Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women.
Kasserra, C; Li, J; March, B; O'Mara, E, 2011
)
0.37
" The effect of vismodegib on rosiglitazone and OC pharmacokinetic parameters (primary objective) was evaluated through pharmacokinetic sampling over a 24-h period (Days 1 and 8)."( Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.
Colburn, D; Colevas, AD; Graham, RA; LoRusso, PM; Low, JA; Malhi, V; Mita, M; Piha-Paul, SA; Yin, M, 2013
)
0.39
" Three open-label phase 1 studies were conducted in healthy human participants to investigate potential pharmacokinetic (PK) and/or pharmacodynamic (PD) interactions between albiglutide and medications that may be used concomitantly."( Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive.
Bush, M; Lewis, E; Scott, R; Watanalumlerd, P; Zhi, H, 2012
)
0.38
" We sought to define the steady-state pharmacokinetic interaction between norethindrone (NET) and PI in HIV-infected women."( Effect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women.
Atrio, J; Cherala, G; Kovacs, A; Mishell, DR; Neely, M; Stanczyk, FZ, 2014
)
0.4
" NET half-life and maximum concentration were not significantly different between the 2 groups."( Effect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women.
Atrio, J; Cherala, G; Kovacs, A; Mishell, DR; Neely, M; Stanczyk, FZ, 2014
)
0.4
" Ethinyl estradiol Cmax was 21% lower with no change in AUC."( The effect of ezogabine on the pharmacokinetics of an oral contraceptive agent.
Buraglio, M; Crean, CS; Tompson, DJ, 2013
)
0.39
"Rilpivirine coadministration had no effect on (least square mean ratio, 90% confidence interval) ethinylestradiol Cmin (1."( Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers.
Buelens, A; Crauwels, HM; Hoetelmans, RM; Stevens, M; van Heeswijk, RP, 2014
)
0.4
" Areas covered: This review aims to offer the reader a complete overview of pharmacokinetic (PK) and clinical efficacy of progestins for the treatment of endometriosis."( Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis.
Barra, F; Ferrero, S; Scala, C, 2018
)
0.48
"In study 1, pharmacokinetic exposures for EE in period 2 increased by 30% and the norgestimate metabolites decreased by approximately 15% when coadministered with elagolix."( Pharmacokinetic and Pharmacodynamic Profiles of Ethinylestradiol/Norgestimate Combination or Norethindrone upon Coadministration with Elagolix 150 mg Once Daily in Healthy Premenopausal Women.
Chiu, YL; Feldman, RA; Klein, CE; Ng, J, 2021
)
0.62
"Coadministration of elagolix 150 mg once daily with oral contraceptives containing EE and norgestimate, or norethindrone, resulted in small pharmacokinetic changes in the oral contraceptive components."( Pharmacokinetic and Pharmacodynamic Profiles of Ethinylestradiol/Norgestimate Combination or Norethindrone upon Coadministration with Elagolix 150 mg Once Daily in Healthy Premenopausal Women.
Chiu, YL; Feldman, RA; Klein, CE; Ng, J, 2021
)
0.62

Compound-Compound Interactions

A collaborative study of the analysis of mestranol in combination with norethindrone or noreThynodrel is presented. Group 1 had 23 cases who used Tamoxifen (TMX) alone orally. Group 2 had 20 cases who use a suppository containing both TMX and 15-m-PGF2, combined with oral administration of TMX.

ExcerptReferenceRelevance
" Na+,K+ co-transport, measured as the ouabain-resistant, frusemide-sensitive component of 86Rb+ influx, and Na(+)-Na+ countertransport, measured as the ouabain-resistant, phloretin-sensitive component of 22Na+ influx, were both increased in women taking, on days 1-21 of their cycle, ethinyloestradiol (30-50 micrograms) combined with norethisterone (1000 micrograms or 500-1000 micrograms) for 3 or 6 months."( Effects of oral contraceptives containing oestrogen combined with norethisterone or levonorgestrel on erythrocyte cation transport in normal women.
Baber, R; Flemming, CL; Johnston, H; Jones, M; Monaghan, JC; Pinkerton, G; Stokes, GS, 1992
)
0.28
" We have characterized PCN or macrolides induced cytochromes P-450 by their specific ability to interact with macrolide derivatives and, using the cytochrome P-450 spectral binding assays, we have shown that some compounds, implicated in drug interaction with macrolides, interact preferentially with the same cytochromes."( Specific drug binding to rat liver cytochrome P-450 isozymes induced by pregnenolone-16 alpha-carbonitrile and macrolide antibiotics. Implications for drug interactions.
Delaforge, M; Sartori, E, 1990
)
0.28
"Gamete intra-Fallopian transfer (GIFT) was combined with a diagnostic laparoscopy on a routine operating list in a district general hospital."( Gamete intra-fallopian transfer combined with diagnostic laparoscopy: a treatment for infertility in a district hospital.
Bolton, VN; Campbell, S; Pampiglione, JS; Parsons, JH, 1989
)
0.28
" In the experiments performed in rats, under effect of ethinyl estradiol and norethisteron acetate, and especially at their combination with benactyzine, the first signs of overmaturation are revealed in oocytes situating in the follicular cavity."( [Effect of an estrogen-progestin preparation alone and in combination with amizil on the structure and electrophoretic parameters of oocytes and early rat embryos].
Kitaev, EM; Lupanova, GE; Makusheva, VP; Snetkova, MG, 1987
)
0.27
"A collaborative study of the analysis of mestranol in combination with norethindrone or norethynodrel by column chromatography and ultraviolet determination is presented."( Collaborative study of the analysis of mestranol in combination with norethindrone or norethynodrel.
Brunner, CA, 1971
)
0.25
"25 micrograms, oestrogens/gestagen alone or combined with 1,25(OH)2D3, and placebo."( Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis.
Christensen, MS; Christiansen, C; Hagen, C; Rødbro, P; Transbøl, I, 1981
)
0.26
"To assess prospectively the effect on bleeding patterns, transformation of the endometrium, and rate of endometrial hyperplasia of transdermal norethisterone acetate when administered sequentially in combination with transdermal estradiol (E2), and to compare it to a regimen using oral medroxyprogesterone acetate."( Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: effects on bleeding patterns and endometrial histology.
Boyd, ME; Colgan, TJ; Ferenczy, A; Fugere, P; Lorrain, J; Ross, AH, 1993
)
0.29
"These preliminary data suggest that the addition of cyclic sodium etidronate in combination with low-dose norethindrone to GnRH agonists is an effective means of ameliorating the hypoestrogenic side effects induced by GnRH agonist alone."( Effects of sodium etidronate in combination with low-dose norethindrone in patients administered a long-acting GnRH agonist: a preliminary report.
Fournet, N; Judd, HL; Surrey, ES; Voigt, B, 1993
)
0.29
" We thus performed a randomized, double-blind, placebo-controlled intervention study to prospectively investigate the effect of a low dose of fluoride, in combination with HRT, on BMD and biochemical markers of bone turnover."( Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study.
Alexandersen, P; Christiansen, C; Riis, BJ, 1999
)
0.3
"5 mg), administered alone or in combination with estradiol (E2; 1 mg), both after a single oral dose."( Bioavailability of norethisterone acetate alone and in combination with estradiol administered in single or multiple oral doses to postmenopausal women.
Aedo, AR; Cekan, SZ; Landgren, BM; Mattsson, LA; Stadberg, E; Westlund, P, 1999
)
0.3
"In the first, single-dose trial, pharmacokinetic parameters of NET were similar for NETA administered alone and its combination with E2."( Bioavailability of norethisterone acetate alone and in combination with estradiol administered in single or multiple oral doses to postmenopausal women.
Aedo, AR; Cekan, SZ; Landgren, BM; Mattsson, LA; Stadberg, E; Westlund, P, 1999
)
0.3
"The bioavailability of NET was not influenced by its combination with 1 mg E2."( Bioavailability of norethisterone acetate alone and in combination with estradiol administered in single or multiple oral doses to postmenopausal women.
Aedo, AR; Cekan, SZ; Landgren, BM; Mattsson, LA; Stadberg, E; Westlund, P, 1999
)
0.3
" We randomized 43 women with type 2 diabetes either to continuous transdermal estradiol (80-microg patches) in combination with oral norethisterone (1 mg daily) or to identical placebos."( The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study.
Connell, JM; Hillier, C; Lowe, GD; Lumsden, MA; Perera, M; Petrie, JR; Sattar, N; Small, M, 2001
)
0.31
" Group 1 had 23 cases who used Tamoxifen (TMX) alone orally; group 2 had 20 cases who used a suppository containing both TMX and 15-m-PGF2, combined with oral administration of TMX; group 3 had 20 cases who used injection of TMX with 15-m-Pgf2alpha combined with oral administration TMX; and group 4 used injection of Norethindrone (NET) with 15-m-Pgf2alpha combined with oral administration of NET."( [Clinical study of early pregnancy termination by administration of DL-15-methyl prostaglandin F2 alpha combined with tamoxifen or norethisterone].
Lu, XY; Yan, BY; Zhang, JH, 1992
)
0.28
"Overall, the results of this study suggest that the use of trimegestone in combination with estradiol may be preferable to norethisterone acetate because of the more favorable HDL and apo AI profile."( Randomized trial of effects of estradiol in combination with either norethisterone acetate or trimegestone on lipids and lipoproteins in postmenopausal women.
Al-Azzawi, F; Proudler, AJ; Sami, S; Stevenson, J; Thompson, J; Wahab, M, 2004
)
0.32
" As a prerequisite for a planned multicenter male contraceptive efficacy study, we studied the pharmacokinetics of 2 doses of TU alone or in combination with norethisterone enanthate (NETE) in a prospective 2-center study, randomized for TU dose in each center."( Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men.
Cerpolini, S; Christensen, PD; Hull, L; Lumbreras, L; Meriggiola, C; Ng, CM; Pelusi, G; Qoubaitary, A; Swerdloff, RS; Wang, C,
)
0.13
"To evaluate the pulse-wave velocity (PWV) and indirectly the arterial stiffness in hypertensive postmenopausal women submitted to hormone therapy with estradiol alone or combined with norethisterone acetate."( Effects of estradiol alone and combined with norethisterone acetate on pulse-wave velocity in hypertensive postmenopausal women.
Aldrighi, JM; Alecrin, IN; Arruda, CG; Bortolotto, LA; Ramires, JA, 2006
)
0.33
"PWV and arterial stiffness in postmenopausal hypertensive women did not reduce over a 12-week treatment with estradiol alone compared with the same period of treatment with estradiol combined with norethisterone acetate."( Effects of estradiol alone and combined with norethisterone acetate on pulse-wave velocity in hypertensive postmenopausal women.
Aldrighi, JM; Alecrin, IN; Arruda, CG; Bortolotto, LA; Ramires, JA, 2006
)
0.33
"Women were randomly allocated to either one of three different doses of norethisterone (50 microg/day, 175 microg/day, or 550 microg/day) continuously combined with a fixed dose of 17beta-estradiol (350 microg/day) for nasal administration, or 17beta-estradiol at 2 mg/day combined with oral norethisterone acetate at 1 mg/day."( Effects on serum lipid and leptin levels of three different doses of norethisterone continuously combined with a fixed dose of 17beta-estradiol for nasal administration in postmenopausal women: a controlled, double-blind study.
Ascaso, C; Balasch, J; Castelo-Branco, C; Ferrer, J; Palacios, S; Vázquez, F; Villero, J, 2007
)
0.34
" We compared the efficacy and tolerability of the aromatase inhibitor letrozole combined with norethisterone acetate versus norethisterone acetate alone in treating pain symptoms."( Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis.
Camerini, G; Ferrero, S; Ragni, N; Remorgida, V; Seracchioli, R; Venturini, PL, 2009
)
0.35
" Based on in vitro data, a clinical drug-drug interaction (DDI) assessment of cytochrome P450 (CYP) 2C8 was necessary; vismodegib's teratogenic potential warranted a DDI study with oral contraceptives (OCs)."( Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.
Colburn, D; Colevas, AD; Graham, RA; LoRusso, PM; Low, JA; Malhi, V; Mita, M; Piha-Paul, SA; Yin, M, 2013
)
0.39
"To compare the efficacy of norethisterone acetate (NETA; group N) or letrozole combined with NETA (group L) in treating endometriotic ovarian cysts."( Norethisterone acetate versus norethisterone acetate combined with letrozole for the treatment of ovarian endometriotic cysts: a patient preference study.
Ferrero, S; Leone Roberti Maggiore, U; Remorgida, V; Venturini, PL, 2014
)
0.4
"Letrozole combined with NETA is more efficacious than NETA alone in reducing the volume of endometriotic cysts but in none of the 40 patients included in the study did the endometriomas disappear."( Norethisterone acetate versus norethisterone acetate combined with letrozole for the treatment of ovarian endometriotic cysts: a patient preference study.
Ferrero, S; Leone Roberti Maggiore, U; Remorgida, V; Venturini, PL, 2014
)
0.4
" Based on these results, a series of clinical drug-drug interaction (DDI) studies were conducted to evaluate the effect of ivacaftor on sensitive substrates of CYP2C8 (rosiglitazone), CYP3A (midazolam), CYP2D6 (desipramine), and P-gp (digoxin)."( Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein.
Chavan, AB; Dubey, N; Gilmartin, GS; Higgins, M; Li, C; Luo, X; Mahnke, L; Robertson, SM, 2015
)
0.42
" Treatment with GnRHa combined with add-back therapy led to improved QOL, with no worsening of mood or menopausal side effects."( The Effects of Gonadotropin-Releasing Hormone Agonist Combined with Add-Back Therapy on Quality of Life for Adolescents with Endometriosis: A Randomized Controlled Trial.
DiVasta, AD; Feldman, HA; Gordon, CM; Hornstein, MD; Laufer, MR; Sadler Gallagher, J; Stokes, NA, 2017
)
0.46
" As women of childbearing potential may be prescribed insomnia drugs, a drug-drug interaction study was conducted."( Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug-Drug Interaction Study in Healthy Females.
Aluri, J; Dayal, S; Filippov, G; Hall, N; Landry, I; Moline, M; Reyderman, L, 2021
)
0.62
" Understanding drug-drug interactions (DDIs) is important in individuals taking fostemsavir with hormonal contraceptives or menopausal or gender-affirming hormonal therapies."( Fostemsavir and ethinyl estradiol drug interaction: Clinical recommendations for co-administration.
Ackerman, P; Clark, A; Mageau, AS; Magee, M; Mannino, F; Moore, K; Nwokolo, N; Post, E; Shah, R, 2023
)
0.91

Bioavailability

The influence of three diets (olestra, triglyceride oil, and water) on the bioavailability of a single dose of propranolol, diazepam, norethindrone, and ethinyl estradiol was evaluated. A comparative bioavailability study showed no significant differences in absorption characteristics.

ExcerptReferenceRelevance
" Disappointing results with levonorgestrel nonanoate and levonorgestrel undecylate showed that elongation of the fatty acid, esterified with the steroid, decreased the bioavailability of the latter due to incomplete hydrolysis of the ester."( A new principle of injectable depot contraceptives. I Drug selection and studies in monkeys.
Hümpel, M; Schulze, PE; Speck, U, 1979
)
0.26
"Measurement by radioimmunoassay of plasma norethisterone (NE) has been used to compare the bioavailability of tablets containing ethynodiol diacetate (EDA) with that of a standard oral solution of this progestogen in 12 normal women."( Bioavailability and pharmacokinetics of norethisterone in women after oral doses of ethynodiol diacetate.
Breckenridge, AM; Butler, JK; Orme, ML; Palmer, RF; Rose, DA; Serlin, MJ; Shelton, JR; Stafford, JE; Vose, CW; Williams, BM, 1979
)
0.26
" Plasma NE levels, measured by radioimmunoassay, were used to compare the bioavailability of EDA tablets (Ovulen 50; 1 mg EDA plus ."( Bioavailability and pharmacokinetics of norethisterone in women after oral doses of ethynodiol diacetate.
Breckenridge, AM; Butler, JK; Orme, ML; Palmer, RF; Rose, DA; Serlin, MJ; Shelton, JR; Stafford, JE; Vose, CW; Williams, BM, 1979
)
0.26
" Comparison of the results of the intravenous and oral administration of the steroid suggested that its oral bioavailability is 42%."( An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay.
Back, DJ; Breckenridge, AM; Crawford, FE; MacIver, M; Orme, ML; Rowe, PH; Watts, MJ, 1979
)
0.26
" In addition, the bioavailability of EE, by comparison of its pharmacokinetics after intravenous and oral ingestion, was determined."( An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay.
Back, DJ; Breckenridge, AM; Crawford, FE; MacIver, M; Orme, ML; Rowe, PH; Watts, MJ, 1979
)
0.26
" A comparative bioavailability study with norethindrone from 2 different manufacturers, formulated in the same manner, showed no significant differences in absorption characteristics and provided sufficient data for pharmacokinetic analysis."( Bioavailability of norethindrone in human subjects.
Glazko, AJ; Keeley, FJ; Okerholm, RA; Peterson, FE; Smith, TC, 1978
)
0.26
" Orally administered NETO was highly bioavailable (84."( Pharmacokinetics, hydrolysis and aromatisation of norethisterone-3-oxime in female cynomolgus monkey.
Hümpel, M; Li, QG,
)
0.13
" The absolute bioavailability for NETO and NET were found to be 64."( [Pharmacokinetics of norethindrone-3-oxime and norethindrone in rhesus monkeys].
Fu, GM; Li, DZ; Li, ZX; Wang, GP; Wang, XL; Wei, ZN; Zhao, XL; Zhou, MY; Zuo, MD, 1991
)
0.28
" WHO is conducting dose reduction trials and studies of bioavailability in various national populations."( Long-acting hormonal contraceptives for women.
Garza-Flores, J; Hall, PE; Perez-Palacios, G, 1991
)
0.28
" The effects of NET on gonadotropin secretion, its bioavailability to the ovary, and its effect on ovarian steroidogenesis in vivo and in vitro were assessed."( Effects of norethindrone on gonadotropin and ovarian steroid secretion when used for cycle programming during in vitro fertilization.
Anderson, RE; Lobo, RA; Paulson, RJ; Stanczyk, FZ; Stein, AL; Vijod, AG, 1990
)
0.28
"The influence of three diets (olestra, triglyceride oil, and water) on the bioavailability of a single dose of propranolol, diazepam, norethindrone, and ethinyl estradiol was evaluated."( Influence of absorbable and nonabsorbable lipids and lipidlike substances on drug bioavailability.
Leff, RD; Roberts, RJ, 1989
)
0.28
"The bioavailability of contraceptive steroids was studied in 12 women who were given an antacid and a contraceptive pill simultaneously."( Antacid does not reduce the bioavailability of oral contraceptive steroids in women.
Joshi, JV; Joshi, UM; Sankolli, GM; Shah, RS, 1986
)
0.27
" Apparently, self-dosing with this antacid will not affect bioavailability of oral contraceptive steroids."( Antacid does not reduce the bioavailability of oral contraceptive steroids in women.
Joshi, JV; Joshi, UM; Sankolli, GM; Shah, RS, 1986
)
0.27
" There were no significant differences in the pharmacokinetics of the two doses except for the peak concentration achieved and the bioavailability as assessed by the area under the serum norethisterone concentration - time curve."( A pharmacokinetic and pharmacodynamic study of a 'visiting pill' containing norethisterone.
Chen, JK; Cheng, DH; Fotherby, K; Liu, WY; Song, S; Yang, PJ, 1986
)
0.27
" There were large inter-subject variations in the pharmacokinetic parameters, the elimination half-life and bioavailability showing 3- and 5- fold variability, respectively."( Pharmacokinetics of norethisterone in humans.
Fotherby, K; Gu, J; He, CH; Shi, YE, 1987
)
0.27
"The metabolism of quingestanol acetate (QA) was studied in 3 women, and an assessment of the bioavailability of the oral dosage form was made."( Quingestanol acetate metabolism in women.
Aceto, T; Barr, WH; Di Carlo, FJ; Loo, JC; Zuleski, FR, 1974
)
0.25
" Thus the distribution of synthetic steroids between various protein bound and nonprotein bound components in serum may influence their bioavailability at different target tissues."( Distribution and percentages of non-protein bound contraceptive steroids in human serum.
Hammond, GL; Lähteenmäki, P; Lähteenmäki, PL; Luukkainen, T, 1982
)
0.26
" The pharmacokinetics and bioavailability of NET remain unchanged during early pregnancy."( Norethisterone acetate and ethinylestradiol in early human pregnancy.
Düsterberg, B; Hasan, H; Kivikoski, A; Laajoki, V; Pulkkinen, MO, 1984
)
0.27
" However, very little is known concerning the bioavailability and plasma levels of unmetabolized gestagens in the animal species used for chronic toxicity testing and pharmacological investigation."( Terminal half-lives in plasma and bioavailability of norethisterone, levonorgestrel, cyproterone acetate and gestodene in rats, beagles and rhesus monkeys.
Düsterberg, B; Hümpel, M; Speck, U, 1981
)
0.26
" The absorption rate constant (ka) and peripheral to central compartment transfer rate constant (k21) were similar for NET and EE2, but statistically significant differences were observed with respect to the distribution rate constant (alpha), the central to peripheral transfer rate constant (k12), the overall elimination rate constant (ke1), and volume of distribution (V1/F)."( Plasma levels and pharmacokinetics of norethindrone and ethinylestradiol administered in solution and as tablets to women.
Goebelsmann, U; Henzl, M; Ling, T; Miyakawa, I; Mroszczak, EJ; Runkel, R; Stanczyk, FZ, 1983
)
0.27
" Chronic treatment with dapsone does not appear to reduce the bioavailability of NET or EE."( Norethisterone and ethinyl estradiol kinetics during dapsone therapy.
Bhatki, S; Joshi, JV; Joshi, UM; Maitra, A; Sankolli, G, 1984
)
0.27
" Increased bioavailability may help in devising future formulations with a lesser amount of progestogen while still maintaining similar efficacy."( The effect of norethisterone (500 mcg) and ethinyl estradiol (35 mcg) capsules on the pituitary-ovarian axis.
Elstein, M; Fahmy, DR; Nuttall, ID, 1982
)
0.26
" There was a two-fold variation between the subjects in the bioavailability of NET, less than 5% of the bioavailable NET was released after day 60."( Pharmacokinetics of norethisterone oenanthate in humans.
Bye, PG; Elder, M; Fotherby, K; Howard, G; Sang, GW, 1981
)
0.26
" Bioavailability as measured by the area under the serum ethynyloestradiol concentration-time curve also showed more than a ten-fold variation."( Pharmacokinetics of ethynyloestradiol in women for different populations.
Abdel-Rahman, HA; Akpoviroro, J; Brenner, PF; Chan, T; Coutinho, EM; de Souza, JC; Dozier, TS; Fotherby, K; Goldzieher, JW; Gomez-Rogers, C; Gopalan, S; Grech, ES; Gual, C; Hickey, MV; Kim, SW; Koetsawang, S; Kwon, E; Landgren, BM; Lichtenberg, R; Mapa, MK; Molina, R; Nukulkarn, P; Plunkett, ER; Ratnam, SS; Shearman, RP; Sheth, UK; Toppozada, HK, 1981
)
0.26
"The bioavailability of lynestrenol and ethynyloestradiol from a capsule formulation was superior to a normal tablet formulation."( Bioavailability of Lynestrenol.
Akpoviroro, J; Fotherby, K; Shrimanker, K; Watson, J, 1980
)
0.26
"An in vivo research study demonstrated that the bioavailability of lynestrenol and ethynyloestradiol administrered in capsule form was equal to or slightly greater than when it was administered in normal tablet form."( Bioavailability of Lynestrenol.
Akpoviroro, J; Fotherby, K; Shrimanker, K; Watson, J, 1980
)
0.26
"Our purpose was to determine the relationship between bioavailability of contraceptive steroids and bleeding patterns."( A randomized trial of three oral contraceptives: comparison of bleeding patterns by contraceptive types and steroid levels.
Bell, WK; Burkman, RT; Kimball, AW; Kwiterovich, P; Saleh, WA; Zacur, HA, 1993
)
0.29
" Bioavailability of both contraceptive steroids as measured by baseline values and 1-hour slopes did not correlate with bleeding patterns at 3, 6, and 9 months of use."( A randomized trial of three oral contraceptives: comparison of bleeding patterns by contraceptive types and steroid levels.
Bell, WK; Burkman, RT; Kimball, AW; Kwiterovich, P; Saleh, WA; Zacur, HA, 1993
)
0.29
" The estimates of relative bioavailability ranged from 13 to 51% in rabbits, monkeys, and women."( Pharmacokinetics of orally administered norethisterone enanthate in rabbit, monkey, and women.
Nair, KM; Ravinder, P; Shatrugna, V; Sivakumar, B, 1997
)
0.3
"The bioavailability of NET was not influenced by its combination with 1 mg E2."( Bioavailability of norethisterone acetate alone and in combination with estradiol administered in single or multiple oral doses to postmenopausal women.
Aedo, AR; Cekan, SZ; Landgren, BM; Mattsson, LA; Stadberg, E; Westlund, P, 1999
)
0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"Using steady-state conditions we aimed to test if administration of oral activated charcoal affects the bioavailability of norethisterone acetate (NET Ac) and gestodene (GEST) by inhibiting their enterohepatic recirculation."( The possible role of enterohepatic cycling on bioavailability of norethisterone and gestodene in women using combined oral contraceptives.
Elomaa, K; Lähteenmäki, P; Ranta, S; Tuominen, J, 2001
)
0.31
" This delivery system provides many advantages over oral contraceptives (OCs), including avoidance of the first-pass effect through the liver, constant serum steroid levels, longer duration of use, and greater bioavailability of the hormones."( Contraceptive vaginal rings.
Harwood, B; Mishell, DR, 2001
)
0.31
" This levels off until at the 10th day the absorption rate is 15 mcg/day."( Contraceptive pellet: small size but long life.
, 1977
)
0.26
" The study results showed that the bioavailability of NET-EN is not complete and there is a wide variation among women as to the amount metabolized."( Factors affecting the duration of action of the injectable contraceptive norethisterone enanthate.
Fotherby, K, 1981
)
0.26
"As part of the development of a combination product containing norethindrone acetate and low-dose ethinyl estradiol for continuous hormone replacement therapy in postmenopausal women, a study was conducted to determine the effect of a high-fat meal on the bioavailability of norethindrone and ethinyl estradiol from tablets containing 1 mg norethindrone acetate/10 micrograms ethinyl estradiol."( The effect of food on the bioavailability of norethindrone and ethinyl estradiol from norethindrone acetate/ethinyl estradiol tablets intended for continuous hormone replacement therapy.
Boyd, RA; Eldon, MA; Zegarac, EA, 2003
)
0.32
" The effect of progestogens on IGF bioavailability could be an important determinant of the longer-term risks of specific HRT preparations by opposing the potentially beneficial effects of CEE alone on cardiovascular risk."( Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
Anderson, S; Durrington, PN; Gibson, MJ; Heald, A; Kaushal, K; Redpath, M; Selby, PL, 2005
)
0.33
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" In our desire to optimize the potency of 5, compounds 6 (3ξ-fluoro-) and 9 (3β-sulfamate-) designed to increase the stability and oral bioavailability of 5, respectively were evaluated in vivo."( Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.
Ates-Alagoz, Z; Brodie, AM; Bruno, RD; Gediya, LK; Godbole, AM; Njar, VC; Purushottamachar, P; Vasaitis, TS, 2011
)
0.37
" The objective was to prepare an oral Sustained Release/Controlled Release (SR/CR) Liquid Medicated Formulation (LMF) to enhance bioavailability and improve patient compliance."( Preparation and Characterization of an Oral Norethindrone Sustained Release/Controlled Release Nanoparticles Formulation Based on Chitosan.
Abu-Dahab, R; Al-Nimry, SS; Altaani, BM; Haddad, RH, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Doses were scaled from human doses to account for differences in bioavailability and body weight, and OCs were administered daily via oral gavage for 4 rat estrous cycles (20 days)."( The Effect of Oral Contraceptive Hormones on Anterior Cruciate Ligament Strength.
Chang, W; Dragoo, JL; Hsue, L; Konopka, JA; Thio, T, 2020
)
0.56

Dosage Studied

Norethindrone and dl-norgestrel greatly exceed those necessary to suppress endometrial proliferation effectively.

ExcerptRelevanceReference
" The intravaginal rings were designed to provide a sustained release of either the human dosage level of the hormone or ten times this level."( Treatment of rhesus monkeys (Macaca mulatta) with intravaginal rings impregnated with either progesterone or norethisterone.
Allen, DG; Heywood, R; Hossack, DJ; Sortwell, RJ; Wadsworth, PF; Walton, RM, 1979
)
0.26
" Knowledge of the relative amounts of estrogen and progestin in the available preparations permits a rational adjustment of dosage if side effects occur."( When patients 'can't' take the pill.
Freeman, WS, 1978
)
0.26
" The decreased glucose tolerance may be due as much to dosage levels as to any metabolic characteristics of the various oestrogens prescribed."( Effect of hormone replacement therapy on glucose tolerance in postmenopausal women.
Chakravarti, S; Oram, DH; Studd, JW; Thom, M, 1977
)
0.26
" Over the dosage range studied, the effects of the two kinds of estrogen were indistinguishable."( Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
Chenault, CB; de la Peña, A; Dozier, TS; Goldzieher, JW; Kraemer, DC, 1978
)
0.26
" Effects of the 2 kinds of estrogens were indistinguishable over the dosage range studied."( Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
Chenault, CB; de la Peña, A; Dozier, TS; Goldzieher, JW; Kraemer, DC, 1978
)
0.26
" The occurrence of a secondary peak in plasma at around 12 hours after dosing gave strong evidence that EE undergoes enterohepatic circulation in women; an event that may have considerable clinical significance."( An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay.
Back, DJ; Breckenridge, AM; Crawford, FE; MacIver, M; Orme, ML; Rowe, PH; Watts, MJ, 1979
)
0.26
" Dosage is 200 mg every 84 days, and it is not as effective as MPA."( [Pharmacological and clinical application of progestational hormone depot preparations].
Andor, J, 1978
)
0.26
" These values were measured twice a week for 4-6 months to determine 1) the effect of various serum NET concentrations upon hypothalamic/pituitary-ovarian function; 2) intersubject variability of this effect; 3) between-subject variability of serum NET values; 4) the effect of an increase in NET-EN dosage or in the volume of the vehicle; and 5) the correlation between uterine bleeding and serum NET, E and P patterns."( Serum norethindrone (NET) concentrations following intramuscular NET enanthate injection. Effect upon serum LH, FSH, estradiol and progesterone.
Brenner, PF; Gentzschein, EK; Goebelsmann, AE; Goebelsmann, U; Mishell, DR; Stanczyk, FZ, 1979
)
0.26
" The potency and dosage is correlated with the pathogenic effects observed."( Effects of contraceptive pills and intrauterine devices on urinary bladder.
Fayad, M; Kamel, M; Mooro, H; Osman, MI; Youssef, AF; Zahran, MM, 1976
)
0.26
" All the dose-response curves were drawn using logit-log transformation."( [Effect of oral contraceptive on the pituitary and plasma L.H. levels and on the hypothalamic LH-RH level (author's transl)].
Arai, K; Kanazawa, M; Okinaga, S; Sato, N; Yanaihara, T, 1976
)
0.26
"High dosage gestagen therapy is indicated for progressive endometrial carcinomas when there are recurring or metastasizing tumors or the presence of extensive tumors suggesting incomplete surgical removal."( [Results of high dosage progesterone therapy in carcinoma corporis uteri].
Böhm, W; Przesang, R; Seewald, HJ, 1977
)
0.26
"48 women, aged 17-41, were treated with weekly dosages of 1 mg ethinylestradiolsulfonate (EES) and a 10 mg dosage of norethisterone acetate (NEA) or a ."( [Changes of the endometrium during oral hormonal contraception with ethinyl estradiol sulfonate and norethisterone acetate or d-noregestrel].
Büttner, HH; Göretzlehner, G; Rudolf, K, 1976
)
0.26
" In the intermediate dosage range, both factors contributed to the decreased ratio."( Effect of 17alpha-ethinylestradiol on biliary excretion of bile acids.
Watanabe, H, 1975
)
0.25
" This study shows that estrogen/progestogen treatment in standard contraceptive dosage usually leads to only moderate and non-progressive stimulation of pituitary activity in women with hyperprolactinemic amenorrhea, but occasional excessive growth of a prolactinoma can occur and treatment needs to be monitored."( The effect of combined estrogen/progestogen treatment in women with hyperprolactinemic amenorrhea.
Fahy, UM; Foster, PA; Hartog, M; Hull, MG; Torode, HW, 1992
)
0.28
" Research on combination norethynodrel-containing products revealed that the dosage was too high."( Oral contraception: a review.
Edgren, RA, 1991
)
0.28
" MEL was administered in a dosage of 300 mg to 12 women for 4 months [to 8 women daily (days 1-30) and to 4 women on days 5-17 of the cycle]."( Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation.
Alberda, BT; Cohen, M; de Jong, FH; Drogendijk, AC; Euser, R; Fauser, BC; Verdonk, RE; Voordouw, BC, 1992
)
0.28
" Tumors of other reproductive tissues (mammary gland, ovary, oviduct, cervix, or uterus) demonstrated no discernible DES dose-response relationship."( Carcinogenicity of diethylstilbestrol in the Wistar rat: effect of postnatal oral contraceptive steroids.
Baggs, RB; Miller, RK; Odoroff, CL, 1991
)
0.28
" A further complication is the multiplicity of pharmacological effects elicited by the gestagens and each of these effects is likely to have its own dose-response relationship."( Potency and pharmacokinetics of gestagens.
Fotherby, K, 1990
)
0.28
"A comparative clinical trial of two combined oral contraceptives differing only in estrogen type and dosage was conducted at the Centro de Investigaciones Hideyo Noguchi in Merida, Yucatan, Mexico."( A comparative clinical trial of Norinyl 1 + 35 versus Norinyl 1 + 50 in Merida, Yucatan, Mexico.
de Cetina, TC; Dunson, TR; Gamboa, LV; Reyes, LP; Rowan, AJ; Waszak, CS; Weaver, MB, 1990
)
0.28
" Contraceptive agents with reduced dosage of steroid components (rigevidon or triquilar) produced less pronounced increase in systolic or diastolic blood pressure (less than by 2-3 mm Hg)."( [Changes in arterial blood pressure of women using hormonal contraceptives in relation to their cardiovascular history].
Dubnitskaia, LV; Korsakov, SG; Manuilova, IA, 1989
)
0.28
"In view of our previous studies that the plasma elimination of norethisterone (NET) from mini pill is faster in low socio-economic group Indian women, the present studies were contemplated to find the least effective dosage of NET from combination pills."( Pharmacokinetics of norethisterone from two different combination contraceptive pills in Indian women.
Narasinga Rao, BS; Prasad, KV; Ramalakshmi, BA; Ravinder, P; Sivakumar, B,
)
0.13
"In view of the previous studies that determined that the plasma elimination of norethisterone (NET) from the minipill is faster in low socioeconomic bracket Indian women, the present studies were undertaken to find the least effective dosage of NET from combination pills."( Pharmacokinetics of norethisterone from two different combination contraceptive pills in Indian women.
Narasinga Rao, BS; Prasad, KV; Ramalakshmi, BA; Ravinder, P; Sivakumar, B,
)
0.13
" Since the amount of norethindrone in the two dosage groups was the same, this difference in the pharmacokinetics between the 35 micrograms EE and the 50 micrograms ME formulations remains unexplained."( Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are "low-dose" pills really lower?
Brody, SA; Goldzieher, JW; Turkes, A, 1989
)
0.28
" This even occurs with those methods which do not usually suppress ovulation, but the disturbance is generally less severe with lower dosage systems."( Menstrual changes associated with progestogen-only contraception.
Fraser, IS, 1986
)
0.27
" Studies of the oral contraceptives in current use show that the coagulation effects depend on the dosage of estrogen and the type of progestogen used in combination."( Coagulation effects of oral contraception.
Bonnar, J, 1987
)
0.27
"Oral contraceptives were initially very high in estrogen and progestogen and had a uniform dosage schedule throughout the entire cycle."( Phasic approach to oral contraceptives.
Hale, RW, 1987
)
0.27
"Oral contraceptives were initially very high in estrogen and progestogen and had a uniform dosage schedule throughout the entire cycle."( Phasic approach to oral contraceptives.
Hale, RW, 1987
)
0.27
" This is the first dosing study of contraceptive steroids in a murine model of lupus."( Suppression of reproductive function in autoimmune NZB/W mice: effective doses of four contraceptive steroids.
Keisler, LW; Walker, SE, 1987
)
0.27
"The dose-response effects on serum lipids and lipoproteins were studied in 87 healthy post-menopausal women treated for 1 yr with three different doses of sequential oestrogen/progestogen (4 mg, 2 mg and 1 mg 17 beta-oestradiol cyclically combined with 1 mg norethisterone acetate) or placebo."( Dose-response effects on serum lipids and lipoproteins following combined oestrogen-progestogen therapy in post-menopausal women.
Christiansen, C; Jensen, J, 1987
)
0.27
" It is concluded that the NET:CHOL eutectic mixture is a modified release dosage form and a sound approach in regulating the drug access rate to the body's central compartment."( Norethisterone-cholesterol eutectic mixture as an oral sustained-release hormonal preparation: bioequivalence study in humans.
Díaz-Sánchez, V; Garza-Flores, J; Jung, H; Pérez-Palacios, G; Yáñez, L, 1988
)
0.27
" There was a significant negative correlation between the serum NET concentration and the time after dosing in all women."( Pharmacokinetics of norethisterone in humans.
Fotherby, K; Gu, J; He, CH; Shi, YE, 1987
)
0.27
" It was found that neither the 24-hr plasma levels nor the pharmacokinetic parameters of norethindrone following intravenous dosing were significantly altered by aspirin."( Influence of aspirin on the pharmacokinetics of norethindrone.
Gomaa, AA; Makarm, MH, 1987
)
0.27
" There was no relationship between the dosage of estrogen and the onset of cerebrovascular disease."( [Cerebral venous thrombosis associated with the use of oral contraceptives].
Kamezaki, T; Kobayashi, E; Maki, Y; Meguro, K; Tsuboi, K, 1986
)
0.27
" The results showed reduced levels of both estrogens in smokers as compared with nonsmokers in all three dosage groups."( Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause.
Christiansen, C; Jensen, J; Rødbro, P, 1985
)
0.27
" These changes are considered as a regulative phenomenon, without consequences for the application of the high dosage therapy with these steroid hormones in the treatment of excessive growth."( Effects of high doses of oestrogens and androgens on lipoproteins: observations in the treatment of excessive growth with sexual hormones.
Hanefeld, M; Hinkel, GK; Jaross, W; Leonhardt, W; Trübsbach, A, 1985
)
0.27
" This dosage seemed inadequate, since a total of 25."( Long-term contraceptive effect of injectable progestogens: inhibition and reestabilishment of fertility.
Zañartu, J,
)
0.13
" The dosage was 5 mg 3 times daily before meals on Days 16 and 26 of her menstrual cycle."( [Granulomatous panniculitis caused by progestational drugs during the course of progressive scleroderma].
Cabré, J; González, JA; Vidal, J,
)
0.13
" Patients had been treated with 4 different dosage combinations of estrogen and progestins over periods varying from 3 months to 24 months."( Progestational agents and blood coagulation. VI. Relationship of ABO blood types to changes induced by oral contraceptives.
Lillie, MA; Mink, IB, 1974
)
0.25
"The metabolism of quingestanol acetate (QA) was studied in 3 women, and an assessment of the bioavailability of the oral dosage form was made."( Quingestanol acetate metabolism in women.
Aceto, T; Barr, WH; Di Carlo, FJ; Loo, JC; Zuleski, FR, 1974
)
0.25
" However, the currently recommended dosage of norethindrone and dl-norgestrel greatly exceed those necessary to suppress endometrial proliferation effectively."( Actions of progestins on the morphology and biochemistry of the endometrium of postmenopausal women receiving low-dose estrogen therapy.
King, RJ; Lane, G; Pryse-Davies, J; Ryder, T; Siddle, N; Townsend, PT; Whitehead, MI, 1982
)
0.26
" It is concluded that the dosages of progestins currently added in post-menopausal estrogen therapy are greatly in excess of those necessary to suppress endometrial proliferation effectively; lowering the daily progestin dosage is unlikely to result in any lessening of this protective effect and will probably reduce the incidence of side effects, as these appear to be dose-dependent."( Dose-dependent effects of synthetic progestins on the biochemistry of the estrogenized post-menopausal endometrium.
King, RJ; Minardi, J; Siddle, NC; Townsend, PT; Whitehead, MI; Young, O, 1981
)
0.26
" A characteristic feature of cultured interstitial cells is the bell-shaped profile of the dose-response curve for gonadotropin stimulated androgen production."( Androgen and progestogen production in cultured interstitial cells derived from immature rat testis.
De Moor, P; Koninckx, P; Verhoeven, G, 1982
)
0.26
" With the same contraceptive reliability its cycle stability is very much better than the monophase preparations, which are 40% high dosed in the progestin proportion (levonorgestrel and desogestrel)."( [Progress in oral contraception. Advantages of a levonorgestrel-containing 3-stage preparation over low-dose levonorgestrel and desogestrel containing monophasic combination preparations].
Lachnit-Fixson, U, 1984
)
0.27
" A dose-response experiment carried out in healthy women indicated that 10 mg of norethisterone (NET) with 1 mg of ethinylestradiol (EE2) when given by intramuscular injection maintained NET serum levels above 1 ng/ml for at least 25 days."( Development of a low-dose monthly injectable contraceptive system: I. Choice of compounds, dose and administration route.
Diaz-Sanchez, V; Garza-Flores, J; Jimenez-Thomas, S; Rudel, HW, 1984
)
0.27
" A dose-response experiment carried out in healthy women indicated that intramuscular injection of 10 mg of NET with 1 mg of EE2 maintained NET serum levels above 1 ng/ml for at least 25 days."( Development of a low-dose monthly injectable contraceptive system: I. Choice of compounds, dose and administration route.
Diaz-Sanchez, V; Garza-Flores, J; Jimenez-Thomas, S; Rudel, HW, 1984
)
0.27
"In order to study dose-response relationships of estrogen in normal postmenopausal women, 100 volunteers were randomized to 12 months' treatment with placebo or one of three different doses (high, medium, or low) of natural estrogens (17 beta-estradiol and estriol), sequentially combined with norethisterone acetate for 10 of the 28 cycle days."( Dose-response evaluation of cyclic estrogen/gestagen in postmenopausal women: placebo-controlled trial of its gynecologic and metabolic actions.
Christensen, MS; Christiansen, C; Hagen, C; Transbøl, I, 1982
)
0.26
"We describe the plasma levels of FSH and LH in ten patients with gonadal dysgenesis during treatment with a low dosage sequential estrogen-progestogen preparation."( Plasma levels of FSH and LH in patients with gonadal dysgenesis during sequential estrogen and progestogen therapy.
Amann, K; Breckwoldt, M; Peters, F; Reck, G; Roll, H; Zahradnik, HP, 1980
)
0.26
" Since both estrogen and progestogen seem to be responsible in the etiology of hypertension the lowest possible dosage of OC should be chosen."( Oestrogens and hypertension.
Roberts, JM, 1981
)
0.26
" Conversely, evidence of lupus exacerbation did not develop in any of 11 patients who received pure progestogen oral contraceptive therapy with either continuous low-dose norsteroids (6 patients) or discontinuous progestogens at normal dosage (5 patients)."( Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus.
Bach, JF; Dougados, M; Jungers, P; Kuttenn, F; Lesavre, P; Pélissier, C; Tron, F, 1982
)
0.26
" Norlestrin, a combination of norethindrone acetate and ethinylestradiol (50:1) was given orally on a continuous cyclic regimen of 21 d of dosing followed by 7 d without treatment."( Ten-year oral toxicity study with Norlestrin in rhesus monkeys.
de la Iglesia, F; Fitzgerald, J; Goldenthal, EI, 1982
)
0.26
" Experiments have established dose-response capabilities of the system, which is an important prerequisite for achieving minimal intervention fertility control."( Biodegradable microsphere contraceptive system.
Beck, LR; Cowsar, D, 1980
)
0.26
"Noraethisterone acetate in a dosage of 5 mg/day led to a decrease of the triglyceride and beta-lipoprotein level in the blood serum in postclimacteric patients."( [The effect of norethisterone acetate and 17 alpha-cyanomethyl-estradiol-3-methyl ether on the serum lipid levels].
Müller, G, 1981
)
0.26
"Norethisterone acetate in a dosage of 5 mg/day led to a decrease in triglyceride and beta-lipoprotein levels in the blood serum in postclimacteric patients."( [The effect of norethisterone acetate and 17 alpha-cyanomethyl-estradiol-3-methyl ether on the serum lipid levels].
Müller, G, 1981
)
0.26
"To study the effects of exogenous estrogens on the postmenopausal endometrium, and to determine the time course and minimum dosage of added progestins necessary to oppose estrogen stimulation, we obtained endometrial specimens from symptomatic postmenopausal women being treated with various preparations of estrogens and progestins."( Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium.
King, RJ; Pryse-Davies, J; Ryder, TA; Townsend, PT; Whitehead, MI, 1981
)
0.26
" Four women in each group were taking either a low dosage progestogen compound like norethisterone (NET) 350 micrograms or d-norgestrel (d-Ng) 50 micrograms alone or low dosage combination pills containing NET 1 mg or d-Ng 150 micrograms with 30 micrograms ethinyl estradiol (EE2) or a biodegradable implant containing 25 mg NET or d-Ng."( Release of 19-nor-testosterone type of contraceptive steroids through different drug delivery systems into serum and breast milk of lactating women.
Mehta, S; Saxena, BN; Toddywalla, VS; Virkar, KD, 1980
)
0.26
"Albino rats were fed norethindrone acetate in the diet for 2 yr at dosage levels (0."( Studies of the components of an oral contraceptive agent in albino rats. II. Progestogenic component and comparison of effects of the components and the combined agent.
Schardein, JL, 1980
)
0.26
"01) suggest that a hypercoagulable state persists in low dosage OC users."( Large increase in plasmatic 11-dehydro-TxB2 levels due to oral contraceptives.
Donnez, J; Grandjean, P; Lavenne, E; Schlit, AF, 1995
)
0.29
" Three other groups of rats with E capsules received daily injections of norethindrone in corn oil, according to the following dosage schedules: 6 micrograms norethindrone/rat per day for 2 of every 4 weeks (cyclic; group 4); 3 micrograms norethindrone/rat per day every day (continuous; group 5); or 3 micrograms norethindrone/rat per day for 3 of every 6 days (interrupted; group 6)."( The effect of three hormone replacement regimens on bone density in the aged ovariectomized rat.
Casper, RF; Grynpas, MD; MacLusky, NJ; Vanin, CM, 1995
)
0.29
" Women who developed this tumor on sequential therapy in general received less than the recommended guidelines for daily dosage and monthly duration of progestin."( Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy.
Barbuto, DA; Judd, HL; Karlan, BY; Lagasse, LD; Leuchter, RS; McGonigle, KF, 1994
)
0.29
" During multiple dosing an increased area under the concentration curve and decreased apparent oral clearance was observed for ethinyl estradiol in peritoneal dialysis patients compared with normal women."( Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis.
Carr, BR; Droegemueller, W; Dupuis, RE; Lobo, RA; Price, TM; Stanczyk, FZ, 1993
)
0.29
" One month after ovariectomy, the rats were dosed once daily for 6 months with either a low dose of growth hormone (GH) (0."( Growth hormone normalizes vertebral strength in ovariectomized rats.
Andreassen, TT; Eschen, C, 1995
)
0.29
" Significant increases in the production of females were detected, but only in the groups receiving the highest dosage of estradiol-17 beta (1."( Steroid-induced sex determination at incubation temperatures producing mixed sex ratios in a turtle with TSD.
Crews, D; Wibbels, T, 1995
)
0.29
" No differences were observed for days of stimulation, peak oestradiol attained, total dosage of exogenous gonadotrophins, or number of aspirated oocytes."( A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin-releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation.
Ditkoff, EC; Sauer, MV, 1996
)
0.29
" They received continuously 17 beta estradiol in dosage 2 mg daily and 1 mg of norethisterone acetate daily during one year period."( [Effect of Kliogest therapy on serum blood lipids in postmenopausal women].
Dydowicz, M; Hadaś, K; Halerz-Nowakowska, B; Korcz-Maciejewska, M; Meczekalski, B; Warenik-Szymankiewicz, A; Wiza, M, 1995
)
0.29
" The NA-EE2 treatment groups had a significant linear dose-response trend for increasing BMD."( The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial.
Genant, H; Rowan, J; Speroff, L; Symons, J; Wilborn, W, 1996
)
0.29
" No differences were noted in days of stimulation, peak estradiol (E2) level attained, peak E2-to-oocyte ratio, dosage of exogenous gonadotropins, number of aspirated oocytes, fertilization rate, or oocyte and preembryo quality."( The addition of norethindrone acetate to leuprolide acetate for ovarian suppression has no adverse effect on ovarian stimulation.
Ditkoff, EC; Lindheim, S; Prosser, R; Sauer, MV; Zimmermann, RC, 1997
)
0.3
" Up to date a drastic dosage reduction of both steroid hormones has been accomplished ameliorating the side effects on the one hand, and being active compounds as contraceptives, in the other."( [Endometrial interference of synthetic estrogens in fertility regulation.Is it necessary to interfere with the antiovulatory mechanism at the central nervous system level in order to obtain contraception?].
Cortés-Gallegos, V; Rojas, T; Sojo Aranda, QI, 1997
)
0.3
" dosing with 100 mg kg-1 once a week for 6 successive weeks, the values of the number and area of gamma-glutamyltranspeptidase-positive foci were, as compared to controls, 15."( Induction of micronuclei and of enzyme-altered foci in the liver of female rats exposed to progesterone and three synthetic progestins.
Allavena, A; Brambilla, G; De Pascalis, CR; Ghia, M; Martelli, A; Mereto, E; Orsi, P, 1998
)
0.3
" Continuous combined transdermal delivery systems provide increased dosing flexibility and might improve convenience and compliance with hormone replacement therapy."( A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group.
Archer, DF; Dain, MP; Furst, K; Tipping, D; Vandepol, C, 1999
)
0.3
" The multiple dosage in the second trial did not cause any major changes in the pharmacokinetic parameters of NET, except for the AUC0-24 and AUC0-infinity values which were significantly higher than those seen in the first trial."( Bioavailability of norethisterone acetate alone and in combination with estradiol administered in single or multiple oral doses to postmenopausal women.
Aedo, AR; Cekan, SZ; Landgren, BM; Mattsson, LA; Stadberg, E; Westlund, P, 1999
)
0.3
" Women were randomly assigned to wear transdermal placebo patches or a transdermal patch releasing 50 microg/d 17beta-estradiol alone (Vivelle) for days 1 to 14 of each cycle and a combination patch releasing 50 microg/d 17beta-estradiol plus 1 of 3 dosage levels (140, 250, or 400 microg/d) of norethindrone acetate (CombiPatch) for days 15 through 28."( Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause.
Cassel, D; Dain, MP; Furst, KW; Hille, D; Notelovitz, M; Skarinsky, D; VandePol, C, 2000
)
0.31
" The findings of this study indicate that there is little potential for dosages as high as 30 mg/day, the maximum recommended dosing schedule, of rizatriptan to alter the plasma concentrations of oral contraceptives."( A double-blind, placebo-controlled evaluation of the effect of oral doses of rizatriptan 10 mg on oral contraceptive pharmacokinetics in healthy female volunteers.
Goldberg, MR; Liu, G; Shadle, CR, 2000
)
0.31
" The dosed radioactivity was predominantly excreted via urine."( Excretion balance and metabolism of the progestagen Org 30659 in healthy postmenopausal women.
Gloudemans, RH; Groothuis, GM; Rietjens, IM; Verhoeven, CH; Vos, RM, 2000
)
0.31
" Serum CrossLaps decreased by about 50% in the levormeloxifene groups, with no dose-response effect."( Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy.
Alexandersen, P; Christiansen, C; Delmas, PD; Riis, BJ; Stakkestad, JA, 2001
)
0.31
" Further studies are needed to reduce the dose of prostaglandin and to identify the optimum dosage and combination of NET and TMX with prostaglandin in order to improve the effectiveness of the abortifacient and reduce its side effects."( [Clinical study of early pregnancy termination by administration of DL-15-methyl prostaglandin F2 alpha combined with tamoxifen or norethisterone].
Lu, XY; Yan, BY; Zhang, JH, 1992
)
0.28
" Dosage is increased only when break through bleeding occurs."( Newer synthetic progestins for the treatment of endometriosis.
Kistner, RW, 1970
)
0.25
" In general, the lowest effective dose of any drug, including contraceptives, is the best practice, but as the dosage is decreased from 50 mcg, cycle control is less effective though side effects are minimized; therefore, reliance on bleeding patterns is necessary for deciding an individual's dosage schedule."( The choice of the dose of oestrogen in a combined oral contraceptive.
Smith, M, 1978
)
0.26
" DMPA as a contraceptive agent is generally given at a dosage of 150 mg every 90 days."( Statement on injectable contraception.
, 1982
)
0.26
" Lipid modifications provoked by combined OCs are a function of the nature and dosage of the components."( [Sex steroids and vascular risk].
Rozenbaum, H,
)
0.13
" Parameters like age of the patients, body mass index (BMI), dosage of the estrogen during pretreatment did not influence the results considerably."( [Amenorrhea rate after switch from sequential hormone replacement therapy to continuous combined administration of low dose estradiol and norethisterone acetate].
Kretschmar, S; Rakov, V; Von Holst, T, 2002
)
0.31
"d(-1) of estradiol decreased mammary size to control levels (inverted-U-shaped dose-response curve)."( Sensitivity and specificity of bioassay of estrogenicity on mammary gland and uterus of female mice.
Skarda, J, 2002
)
0.31
"Toxicity of 17alpha-ethynylestradiol (EE2) and norethindrone (NOR), constituents of low dosage oral contraceptives, was assessed for the freshwater cladoceran Daphnia magna."( Toxicity of 17alpha-ethynylestradiol and norethindrone, constituents of an oral contraceptive pill to the swimming and reproduction of cladoceran Daphnia magna, with special reference to their synergetic effect.
Goto, T; Hiromi, J, 2003
)
0.32
" This low dosage was also useful in the management of dysmenorrhea, menorrhagia and irregular menses."( OVULATION INHIBITORS.
CROCKER, KM; STITT, WD, 1964
)
0.24
"In this study, the benefits of add-back therapy during GnRHa treatment were not enhanced, and a deleterious effect upon the lipid profile was seen when using a constant dosage of 2 mg estradiol and 5 mg norethindrone as compared to 1 mg norethisterone acetate."( Dose effects of progesterone in add-back therapy during GnRHa treatment.
Cheung, TH; Haines, C; Lam, C; Lau, E; Lo, KW; Yim, SF, 2005
)
0.33
"We observed that endometrial polyp formation may be dependent on the type and dosage of the estrogen and progestogen."( The role of hormone replacement therapy in endometrial polyp formation.
Aytan, H; Kelekci, S; Mollamahmutoglu, L; Oguz, S; Sargin, A; Tapisiz, OL, 2005
)
0.33
" For EE, the mean (SD) AUC over a 24-hour dosing interval (AUC(tau)) was 1139 (317) pg."( Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
Dai, Y; Griffith, SG, 2004
)
0.32
"In these healthy volunteers, steady-state zonisamide dosing had no clinically significant effect on the pharmacokinetics of EE or NOR."( Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
Dai, Y; Griffith, SG, 2004
)
0.32
" They represent an improvement compared with transdermal delivery by patches because they offer more dosage flexibility, less irritation potential and a better cosmetic appearance."( Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery.
Alberti, I; Carrara, DN; Grenier, A; Kraus, H, 2005
)
0.33
"To estimate whether progestin type or estrogen dose influences bleeding patterns, adverse effects, or satisfaction with combined oral contraceptives dosed continuously."( Continuous oral contraceptives: are bleeding patterns dependent on the hormones given?
Edelman, AB; Jensen, JT; Koontz, SL; Nichols, MD, 2006
)
0.33
" We have compared the effects of estrogen, tibolone, and raloxifene on relevant markers of coagulation activation and investigated whether there is a dose-response relationship of oral HT."( Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation.
Andersen, TO; Eilertsen, AL; Qvigstad, E; Sandset, PM; Sandvik, L, 2006
)
0.33
"Serial plasma and intracellular zidovudine pharmacokinetics following oral and intravenous dosing were determined in 18 men and 20 women treated with zidovudine."( The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine.
Aberg, J; Aweeka, FT; Bardeguez, A; Coombs, RW; Lizak, P; Rosenkranz, SL; Segal, Y; Thevanayagam, L; Watts, DH, 2006
)
0.33
"Men exhibited higher area under the concentration versus time curve for intracellular zidovudine and zidovudine-monophosphate following oral and intravenous dosing and higher zidovudine triphosphate following oral dosing."( The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine.
Aberg, J; Aweeka, FT; Bardeguez, A; Coombs, RW; Lizak, P; Rosenkranz, SL; Segal, Y; Thevanayagam, L; Watts, DH, 2006
)
0.33
" The aims of the present study were to evaluate a possible dose-response relationship and differential effects of different HT regimens on functionality of the APC system."( Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
Eilertsen, AL; Hemker, HC; Liestøl, S; Mowinckel, MC; Sandset, PM, 2007
)
0.34
"To compare the effects of the abrupt discontinuation of postmenopausal hormone therapy (HT) and reduction of the daily dosage of the hormone on climacteric symptoms."( Effect of abrupt discontinuation versus gradual dose reduction of postmenopausal hormone therapy on hot flushes.
Azevedo, LH; Cunha, EP; Fernandes, CE; Ferreira, JA; Peixoto, S; Pompei, LM; Steiner, ML; Strufaldi, R, 2010
)
0.36
" The weight gain of the highest NETE plus TU dosage was mainly because of gain in muscle mass."( A placebo-controlled, randomized clinical trial using testosterone undecanoate with injectable norethisterone enanthate: effect on anthropometric, metabolic and biochemical parameters.
Cerpolini, S; Costantino, A; Meriggiola, MC; Pasquali, R; Pelusi, C; Pelusi, G, 2011
)
0.37
" Dose-response LHR using patient basophils was observed for different hormones but after 3 months persisted only for 5β-pregnanediol."( A case of progesterone-induced anaphylaxis, cyclic urticaria/angioedema, and autoimmune dermatitis.
Bernstein, DI; Bernstein, IL; Bernstein, JA; Lummus, ZL, 2011
)
0.37
" Blood samples were collected up to 24 hours after dosing on prespecified days."( Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women.
Kasserra, C; Li, J; March, B; O'Mara, E, 2011
)
0.37
" The nandrolone metabolites, 19-norepiandrosterone, estranediol and 19-noretiocholanolone, were also identified in the post-administration samples collected up to 8 h after dosing the treated animals."( Metabolism of norethisterone in the greyhound.
Biddle, ST; Creaser, CS; Houghton, E; O'Donnell, A, 2013
)
0.39
"Co-administration of rilpivirine, at the therapeutic dosing regimen, with ethinylestradiol/norethindrone does not affect hormone pharmacokinetics, and is, therefore, unlikely to affect the efficacy or safety of this oral hormonal contraceptive."( Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers.
Buelens, A; Crauwels, HM; Hoetelmans, RM; Stevens, M; van Heeswijk, RP, 2014
)
0.4
"The study group consisted of 92 postmenopausal women: 1) group G1 (n=30), treated with transdermal HT (17β-estradiol 50 μg/day plus NETA 170 μg/day); 2) group G2 (n=31), treated with the above transdermal HT and low dosage of acetylsalicylic acid (ASA); 3) control group P (n=31)."( Effect of transdermal hormone therapy on platelet haemostasis in menopausal women.
Pertyńska-Marczewska, M; Pertyński, T; Stachowiak, G, 2015
)
0.42
" Dose-response results further suggest that effects of contraceptives containing MPA on HIV-1 acquisition and disease progression may be critically dependent on dose, time after injection and intrinsic factors that affect serum concentrations in women."( Medroxyprogesterone acetate, unlike norethisterone, increases HIV-1 replication in human peripheral blood mononuclear cells and an indicator cell line, via mechanisms involving the glucocorticoid receptor, increased CD4/CD8 ratios and CCR5 levels.
Avenant, C; Bick, AJ; Govender, Y; Hapgood, JP; Maritz, MF; Ray, RM; Tomasicchio, M; Woodland, JG, 2018
)
0.48
"Prospective observational cohort study measuring adherence to daily dosing and timing of dose in patients prescribed a POP, with up to six months of follow-up, conducted from January to October 2020."( Adherence among a cohort taking progestin-only pills prescribed by a healthcare provider: Results of the BENCHMARK study.
Bradford, RD; Farnsworth, SJ; Glasier, A; Guillard, H; Laurora, I; Shiffman, S; Sober, S, 2022
)
0.72
" norethindrone acetate in adolescents, as optimal dosing is unknown."( Norethindrone dosing for adequate menstrual suppression in adolescents.
Compton, SD; Rager, TL; Rosen, MW; Winfrey, OK, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
synthetic oral contraceptiveAn oral contraceptive which owes its effectiveness to synthetic preparation.
progestinA synthetic progestogen.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
17beta-hydroxy steroidA 17-hydroxy steroid in which the hydroxy group at position 17 has a beta-configuration.
terminal acetylenic compoundAn acetylenic compound which a carbon of the C#C moiety is attached to a hydrogen atom.
tertiary alcoholA tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it.
3-oxo-Delta(4) steroidA 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (46)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency33.19330.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency27.72180.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency27.72180.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency25.92730.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency19.71400.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency1.87230.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID743035; AID743036; AID743040; AID743053; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency3.25370.000657.913322,387.1992AID1259377; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency2.66030.001022.650876.6163AID1224838
progesterone receptorHomo sapiens (human)Potency0.00140.000417.946075.1148AID1346784; AID1347036
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency13.80290.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency2.17760.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency20.51230.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency27.53570.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency48.61340.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency43.64120.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency41.02460.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency10.79790.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID743069; AID743075; AID743077; AID743078; AID743079
GVesicular stomatitis virusPotency9.77170.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency43.64860.00108.379861.1304AID1645840
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency48.97220.023723.228263.5986AID743222
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency24.33650.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency51.52020.001628.015177.1139AID1224843; AID1224895
Histone H2A.xCricetulus griseus (Chinese hamster)Potency23.48830.039147.5451146.8240AID1224845; AID1224896
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency12.41300.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency27.32980.000627.21521,122.0200AID743202; AID743219
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency28.18380.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency7.94330.004611.374133.4983AID624297
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency61.13060.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency12.32180.00339.158239.8107AID1347407; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency9.77170.01238.964839.8107AID1645842
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency61.13060.001551.739315,848.9004AID1259244
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency9.77170.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency9.77170.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)31.73000.11007.190310.0000AID1443980; AID1449628
Estrogen receptorHomo sapiens (human)IC50 (µMol)0.80800.00000.723732.7000AID625258
Estrogen receptorHomo sapiens (human)Ki0.23100.00000.42297.9070AID625258
Glucocorticoid receptorHomo sapiens (human)IC50 (µMol)0.43300.00000.495310.0000AID625263
Glucocorticoid receptorHomo sapiens (human)Ki0.19700.00010.38637.0010AID625263
Progesterone receptorHomo sapiens (human)IC50 (µMol)0.00320.00000.580710.0000AID162111
Progesterone receptorHomo sapiens (human)Ki0.00190.00030.03160.3997AID162298
Glycine receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)0.43300.00150.76005.0740AID625263
Glycine receptor subunit alpha-1Rattus norvegicus (Norway rat)Ki0.19700.00070.76537.0010AID625263
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)0.07110.00101.979414.1600AID255211; AID625228
Androgen receptorRattus norvegicus (Norway rat)Ki0.01500.00031.21858.9270AID625228
Glycine receptor subunit betaRattus norvegicus (Norway rat)IC50 (µMol)0.43300.00150.76005.0740AID625263
Glycine receptor subunit betaRattus norvegicus (Norway rat)Ki0.19700.00070.78467.0010AID625263
Glycine receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)0.43300.00150.80445.0740AID625263
Glycine receptor subunit alpha-2Rattus norvegicus (Norway rat)Ki0.19700.00070.78467.0010AID625263
Glycine receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)0.43300.00150.76005.0740AID625263
Glycine receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki0.19700.00070.78467.0010AID625263
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)4.53700.00010.86458.7096AID625222
Sodium-dependent serotonin transporterHomo sapiens (human)Ki2.41100.00000.70488.1930AID625222
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sex hormone-binding globulinHomo sapiens (human)Kd0.01070.00020.34964.7863AID318680
Estrogen receptorRattus norvegicus (Norway rat)Kd0.00060.00060.00060.0006AID69387
Progesterone receptorHomo sapiens (human)EC50 (µMol)0.00220.00010.40478.2000AID161792
Progesterone receptorHomo sapiens (human)Kd0.00040.00010.00030.0004AID162459
Estrogen receptor betaRattus norvegicus (Norway rat)Kd0.00060.00060.00060.0006AID69387
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (173)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
antral ovarian follicle growthEstrogen receptorHomo sapiens (human)
epithelial cell developmentEstrogen receptorHomo sapiens (human)
chromatin remodelingEstrogen receptorHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
signal transductionEstrogen receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEstrogen receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEstrogen receptorHomo sapiens (human)
androgen metabolic processEstrogen receptorHomo sapiens (human)
male gonad developmentEstrogen receptorHomo sapiens (human)
negative regulation of gene expressionEstrogen receptorHomo sapiens (human)
positive regulation of phospholipase C activityEstrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptorHomo sapiens (human)
response to estradiolEstrogen receptorHomo sapiens (human)
regulation of toll-like receptor signaling pathwayEstrogen receptorHomo sapiens (human)
negative regulation of smooth muscle cell apoptotic processEstrogen receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionEstrogen receptorHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
response to estrogenEstrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
fibroblast proliferationEstrogen receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEstrogen receptorHomo sapiens (human)
stem cell differentiationEstrogen receptorHomo sapiens (human)
regulation of inflammatory responseEstrogen receptorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
RNA polymerase II preinitiation complex assemblyEstrogen receptorHomo sapiens (human)
uterus developmentEstrogen receptorHomo sapiens (human)
vagina developmentEstrogen receptorHomo sapiens (human)
prostate epithelial cord elongationEstrogen receptorHomo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisEstrogen receptorHomo sapiens (human)
regulation of branching involved in prostate gland morphogenesisEstrogen receptorHomo sapiens (human)
mammary gland branching involved in pregnancyEstrogen receptorHomo sapiens (human)
mammary gland alveolus developmentEstrogen receptorHomo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongationEstrogen receptorHomo sapiens (human)
protein localization to chromatinEstrogen receptorHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptorHomo sapiens (human)
negative regulation of miRNA transcriptionEstrogen receptorHomo sapiens (human)
regulation of epithelial cell apoptotic processEstrogen receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
regulation of gluconeogenesisGlucocorticoid receptorHomo sapiens (human)
chromatin organizationGlucocorticoid receptorHomo sapiens (human)
regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
apoptotic processGlucocorticoid receptorHomo sapiens (human)
chromosome segregationGlucocorticoid receptorHomo sapiens (human)
signal transductionGlucocorticoid receptorHomo sapiens (human)
glucocorticoid metabolic processGlucocorticoid receptorHomo sapiens (human)
gene expressionGlucocorticoid receptorHomo sapiens (human)
microglia differentiationGlucocorticoid receptorHomo sapiens (human)
adrenal gland developmentGlucocorticoid receptorHomo sapiens (human)
regulation of glucocorticoid biosynthetic processGlucocorticoid receptorHomo sapiens (human)
synaptic transmission, glutamatergicGlucocorticoid receptorHomo sapiens (human)
maternal behaviorGlucocorticoid receptorHomo sapiens (human)
intracellular glucocorticoid receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
glucocorticoid mediated signaling pathwayGlucocorticoid receptorHomo sapiens (human)
positive regulation of neuron apoptotic processGlucocorticoid receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
astrocyte differentiationGlucocorticoid receptorHomo sapiens (human)
cell divisionGlucocorticoid receptorHomo sapiens (human)
mammary gland duct morphogenesisGlucocorticoid receptorHomo sapiens (human)
motor behaviorGlucocorticoid receptorHomo sapiens (human)
cellular response to steroid hormone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to glucocorticoid stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to dexamethasone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to transforming growth factor beta stimulusGlucocorticoid receptorHomo sapiens (human)
neuroinflammatory responseGlucocorticoid receptorHomo sapiens (human)
positive regulation of miRNA transcriptionGlucocorticoid receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
ovulation from ovarian follicleProgesterone receptorHomo sapiens (human)
glandular epithelial cell maturationProgesterone receptorHomo sapiens (human)
regulation of DNA-templated transcriptionProgesterone receptorHomo sapiens (human)
signal transductionProgesterone receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayProgesterone receptorHomo sapiens (human)
cell-cell signalingProgesterone receptorHomo sapiens (human)
positive regulation of gene expressionProgesterone receptorHomo sapiens (human)
negative regulation of gene expressionProgesterone receptorHomo sapiens (human)
paracrine signalingProgesterone receptorHomo sapiens (human)
negative regulation of phosphorylationProgesterone receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIProgesterone receptorHomo sapiens (human)
lung alveolus developmentProgesterone receptorHomo sapiens (human)
regulation of epithelial cell proliferationProgesterone receptorHomo sapiens (human)
progesterone receptor signaling pathwayProgesterone receptorHomo sapiens (human)
maintenance of protein location in nucleusProgesterone receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisProgesterone receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIProgesterone receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayProgesterone receptorHomo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (72)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
TFIIB-class transcription factor bindingEstrogen receptorHomo sapiens (human)
transcription coregulator bindingEstrogen receptorHomo sapiens (human)
transcription corepressor bindingEstrogen receptorHomo sapiens (human)
transcription coactivator bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
chromatin bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
nuclear receptor activityEstrogen receptorHomo sapiens (human)
steroid bindingEstrogen receptorHomo sapiens (human)
protein bindingEstrogen receptorHomo sapiens (human)
calmodulin bindingEstrogen receptorHomo sapiens (human)
beta-catenin bindingEstrogen receptorHomo sapiens (human)
zinc ion bindingEstrogen receptorHomo sapiens (human)
TBP-class protein bindingEstrogen receptorHomo sapiens (human)
enzyme bindingEstrogen receptorHomo sapiens (human)
protein kinase bindingEstrogen receptorHomo sapiens (human)
nitric-oxide synthase regulator activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor bindingEstrogen receptorHomo sapiens (human)
estrogen response element bindingEstrogen receptorHomo sapiens (human)
identical protein bindingEstrogen receptorHomo sapiens (human)
ATPase bindingEstrogen receptorHomo sapiens (human)
14-3-3 protein bindingEstrogen receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen receptorHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
core promoter sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activityGlucocorticoid receptorHomo sapiens (human)
RNA bindingGlucocorticoid receptorHomo sapiens (human)
nuclear receptor activityGlucocorticoid receptorHomo sapiens (human)
nuclear glucocorticoid receptor activityGlucocorticoid receptorHomo sapiens (human)
steroid bindingGlucocorticoid receptorHomo sapiens (human)
protein bindingGlucocorticoid receptorHomo sapiens (human)
zinc ion bindingGlucocorticoid receptorHomo sapiens (human)
TBP-class protein bindingGlucocorticoid receptorHomo sapiens (human)
protein kinase bindingGlucocorticoid receptorHomo sapiens (human)
identical protein bindingGlucocorticoid receptorHomo sapiens (human)
Hsp90 protein bindingGlucocorticoid receptorHomo sapiens (human)
steroid hormone bindingGlucocorticoid receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingGlucocorticoid receptorHomo sapiens (human)
estrogen response element bindingGlucocorticoid receptorHomo sapiens (human)
androgen bindingSex hormone-binding globulinHomo sapiens (human)
protein bindingSex hormone-binding globulinHomo sapiens (human)
steroid bindingSex hormone-binding globulinHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingProgesterone receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificProgesterone receptorHomo sapiens (human)
transcription coactivator bindingProgesterone receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificProgesterone receptorHomo sapiens (human)
DNA bindingProgesterone receptorHomo sapiens (human)
nuclear steroid receptor activityProgesterone receptorHomo sapiens (human)
G protein-coupled receptor activityProgesterone receptorHomo sapiens (human)
steroid bindingProgesterone receptorHomo sapiens (human)
protein bindingProgesterone receptorHomo sapiens (human)
zinc ion bindingProgesterone receptorHomo sapiens (human)
enzyme bindingProgesterone receptorHomo sapiens (human)
identical protein bindingProgesterone receptorHomo sapiens (human)
ATPase bindingProgesterone receptorHomo sapiens (human)
estrogen response element bindingProgesterone receptorHomo sapiens (human)
nuclear receptor activityProgesterone receptorHomo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (46)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleoplasmEstrogen receptorHomo sapiens (human)
transcription regulator complexEstrogen receptorHomo sapiens (human)
cytoplasmEstrogen receptorHomo sapiens (human)
Golgi apparatusEstrogen receptorHomo sapiens (human)
cytosolEstrogen receptorHomo sapiens (human)
plasma membraneEstrogen receptorHomo sapiens (human)
membraneEstrogen receptorHomo sapiens (human)
chromatinEstrogen receptorHomo sapiens (human)
euchromatinEstrogen receptorHomo sapiens (human)
protein-containing complexEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleoplasmGlucocorticoid receptorHomo sapiens (human)
cytoplasmGlucocorticoid receptorHomo sapiens (human)
mitochondrial matrixGlucocorticoid receptorHomo sapiens (human)
centrosomeGlucocorticoid receptorHomo sapiens (human)
spindleGlucocorticoid receptorHomo sapiens (human)
cytosolGlucocorticoid receptorHomo sapiens (human)
membraneGlucocorticoid receptorHomo sapiens (human)
nuclear speckGlucocorticoid receptorHomo sapiens (human)
synapseGlucocorticoid receptorHomo sapiens (human)
chromatinGlucocorticoid receptorHomo sapiens (human)
protein-containing complexGlucocorticoid receptorHomo sapiens (human)
extracellular regionSex hormone-binding globulinHomo sapiens (human)
extracellular exosomeSex hormone-binding globulinHomo sapiens (human)
plasma membraneProgesterone receptorHomo sapiens (human)
nucleoplasmProgesterone receptorHomo sapiens (human)
mitochondrial outer membraneProgesterone receptorHomo sapiens (human)
cytosolProgesterone receptorHomo sapiens (human)
chromatinProgesterone receptorHomo sapiens (human)
nucleusProgesterone receptorHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneGlycine receptor subunit betaRattus norvegicus (Norway rat)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (127)

Assay IDTitleYearJournalArticle
AID39454Relative binding affinity against androgen receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID69853Relative binding affinity against Estrogen receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID162459Dissociation constant for progesterone receptor2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID29360Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID126441Relative binding affinity for the mineralocorticoid receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID162462Relative binding affinity to the progesterone receptor.1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
PRO_LIGAND: an approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID69387Equilibrium dissociation constant for rat uterine estrogen receptor binding [3H]estradiol1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Steroids. 2. Synthesis of C-18 functionalized steroids via the Smith-Hughes route.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID255211Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID162617Relative binding affinity against progestin receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID161792Agonistic activity was measured for modulation of hPR-B (human progesterone receptor) in co-transfected CV-1 cells.1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as potent, orally active, nonsteroidal progesterone receptor agonists: the effect of D-ring substituents.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID39152Relative binding affinity for androgen receptor (AR) in human MCF-7 cells1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A potential radioiodinated ligand for androgen receptor: 7 alpha-methyl-17 alpha-(2'-(E)-iodovinyl)-19-nortestosterone.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1150124Relative binding affinity to guinea pig progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID162298The binding affinity measured using baculovirus-expressed hPR-A in sf21 cells.1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as potent, orally active, nonsteroidal progesterone receptor agonists: the effect of D-ring substituents.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID74389Relative binding affinity against glucocorticoid receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID162435Relative binding affinity for progesterone receptor(PgR) in human T47D cells1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A potential radioiodinated ligand for androgen receptor: 7 alpha-methyl-17 alpha-(2'-(E)-iodovinyl)-19-nortestosterone.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID74377Relative binding affinity to glucocorticoid receptor on cytosol from thymus at 24 hr1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID126435Relative binding affinity for mineralocorticoid receptor of rat kidney at 24 hr1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID161955Agonistic activity towards hPR-B (human progesterone receptor) in terms of efficacy expressed as percent relative to progesterone 100%.1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as potent, orally active, nonsteroidal progesterone receptor agonists: the effect of D-ring substituents.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID74375Relative binding affinity to glucocorticoid receptor on cytosol from liver at 24 hr1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID162111Binding affinity against Progesterone receptor in human TE85 osteosarcoma cells was determined using (Z)-[125I]-17-alpha-(2-iodovinyl)-19-nor-testosterone as radioligand1995Journal of medicinal chemistry, Dec-08, Volume: 38, Issue:25
Nonsteroidal progesterone receptor ligands. 2. High-affinity ligands with selectivity for bone cell progesterone receptors.
AID1150122Relative binding affinity to sheep progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID681612TP_TRANSPORTER: transepithelial transport in MDR1-expressing MDCK cells2004Pharmaceutical research, Jul, Volume: 21, Issue:7
P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1150121Relative binding affinity to human progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID162613Relative binding affinity for progestin receptor of uterus of rabbit at 24 hr1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1135910Binding affinity to progesterone receptor in rabbit uterine cytosol relative to progesterone1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Synthesis of 11 beta,13 beta- and 13 beta,16 beta-propano steroids: probes of hormonal activity.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID74373Relative binding affinity to glucocorticoid receptor on cytosol from hepatoma tissue cells at 24 hr1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID318680Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID212922Relative binding affinity to the testosterone receptor.1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
PRO_LIGAND: an approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID39320Relative binding affinity for androgen receptor of prostate of rat at 2 hr1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID1150123Relative binding affinity to rabbit progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID39318Relative binding affinity for androgen receptor (AR) in rat uterus1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A potential radioiodinated ligand for androgen receptor: 7 alpha-methyl-17 alpha-(2'-(E)-iodovinyl)-19-nortestosterone.
AID74376Relative binding affinity to glucocorticoid receptor on cytosol from liver at 4 hr1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID161643In vitro displacement of progesterone from oviduct progesterone receptor relative to progesterone1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Steroids. 2. Synthesis of C-18 functionalized steroids via the Smith-Hughes route.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1346851Human Progesterone receptor (3C. 3-Ketosteroid receptors)1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as potent, orally active, nonsteroidal progesterone receptor agonists: the effect of D-ring substituents.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4,030)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902524 (62.63)18.7374
1990's592 (14.69)18.2507
2000's569 (14.12)29.6817
2010's281 (6.97)24.3611
2020's64 (1.59)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials884 (20.58%)5.53%
Reviews187 (4.35%)6.00%
Case Studies185 (4.31%)4.05%
Observational4 (0.09%)0.25%
Other3,035 (70.66%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (94)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of a Combination of Daclatasvir, Asunaprevir, and BMS-791325 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone Acetate in Healthy Female Subjects [NCT02103569]Phase 120 participants (Actual)Interventional2014-04-30Completed
A Phase 1, Open-Label, Parallel, Sequential, Multi-part Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of an Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers [NCT03856970]Phase 187 participants (Actual)Interventional2019-03-11Completed
A Multicenter, Randomized, Double-Blind, Double Dummy Trial to Compare the Effects Tibolone and Transdermal Continuous Combined Estradiol/Norethisterone on Sexual Desire and Arousal in Postmenopausal Women With Sexual Dysfunction [NCT00413764]Phase 3358 participants (Actual)Interventional2004-03-23Completed
Regulation of Cervical Mucus Secretion [NCT02969590]Phase 45 participants (Actual)Interventional2015-03-29Completed
Norethindrone Versus Combined Oral Contraceptive Pills for the Delay of Menstruation [NCT03594604]Phase 417 participants (Actual)Interventional2007-06-15Completed
Combined Contraceptive Vaginal Ring or Norethisterone for Treatment of Idiopathic Menorrhagia [NCT01266759]95 participants (Actual)Interventional2008-07-31Completed
Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids [NCT02925494]Phase 3433 participants (Actual)Interventional2016-09-14Completed
Heart Failure Prevention for Women: Preservation of Cardiac Function in the Peri-Menopausal Woman Through Hormone Therapy [NCT02693002]Phase 44 participants (Actual)Interventional2016-02-29Terminated(stopped due to Enrollment goals not being met)
A Study to Evaluate Safety and Efficacy of Elagolix Alone or Elagolix With Hormonal Add-Back in Subjects With Endometriosis With Associated Moderate to Severe Pain [NCT03343067]Phase 311 participants (Actual)Interventional2017-12-27Terminated(stopped due to The study was terminated early for business reasons, not for safety concerns.)
A 12 Month Non-interventional (Observational), International, Multi-centre, Prospective Study to Evaluate the Bleeding Pattern of Ultra-low Dose Continuous Combined Hormone Replacement Therapy Containing 0.5 mg Estradiol and 0.1 mg Norethisterone Acetate [NCT01076621]176 participants (Actual)Observational2010-05-31Completed
LIBERTY 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associate [NCT03103087]Phase 3382 participants (Actual)Interventional2017-06-14Completed
Management of Uterine Leiomyomata and Adenomyosis : Role of Hysteroscopy in Diagnosis and Norethisterone in the Treatment [NCT05153928]100 participants (Anticipated)Observational2021-04-10Recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women [NCT02691494]Phase 3378 participants (Actual)Interventional2016-02-03Completed
Use of Norethindrone Acetate for Management of Bleeding Associated With the Etonogestrel Contraceptive Implant [NCT02353247]88 participants (Actual)Interventional2015-08-31Completed
Open-Label Study of the Safety and Efficacy of a Low Dose Oral Contraceptive Containing Norethindrone Acetate and Ethinyl Estradiol [NCT00391807]Phase 31,683 participants (Actual)Interventional2006-11-30Completed
LIBERTY 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associate [NCT03049735]Phase 3388 participants (Actual)Interventional2017-04-26Completed
A Study to Evaluate the Relative Bioavailability of Norethindrone/Ethinyl Estradiol 0.4 mg/0.035 mg Chewable Tablets (Teva Pharmaceuticals, USA) Compared to FEMCON® Fe (Norethindrone/Ethinyl Estradiol) 0.4 mg/0.035 mg Chewable Tablets (Warner Chilcott) in [NCT01344369]Phase 136 participants (Actual)Interventional2008-08-31Completed
The Effect of Dienogest vs. Norethindrone Acetate Treatment in Endometriosis [NCT05476172]70 participants (Actual)Interventional2021-04-01Completed
Effectiveness of Hormonal Intrauterine Device in Treating Pelvic Congestion Syndrome Compared to Oral Progestin [NCT05050357]104 participants (Actual)Interventional2021-12-01Completed
HIV-Target Cell Response in Women Initiating Various Contraceptive Methods in High HIV-Incidence Areas: Zim CHIC [NCT02038335]451 participants (Actual)Observational2014-02-28Completed
LIBERTY EXTENSION: An International Phase 3 Open-Label, Single-Arm, Long-Term Efficacy and Safety Extension Study to Evaluate Relugolix Co-Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated Wit [NCT03412890]Phase 3477 participants (Actual)Interventional2017-10-19Completed
SPIRIT EXTENSION: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Co-Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain [NCT03654274]Phase 3802 participants (Actual)Interventional2018-05-22Completed
A Prospective Open Randomized Trial on the Efficacy of Gonadotropin-releasing Hormone Agonist Depot-Triptorelin- to Prevent Chemotherapy Induced Premature Ovarian Failure in Lymphoma Patients. [NCT01160315]Phase 2/Phase 3118 participants (Actual)Interventional2002-07-31Completed
An Open Label Study to Evaluate the Contraceptive Efficacy and Safety of Norethindrone Acetate Transdermal Delivery System [NCT01140217]Phase 31,659 participants (Actual)Interventional2010-05-31Completed
A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women [NCT02654054]Phase 3413 participants (Actual)Interventional2015-12-22Completed
Safety of Oral Micronized Progesterone Versus Norethisterone Acetate in Continuous Combination With Oral Estrogen as Menopausal Hormone Therapy - a Double-blind Randomized Study- PROBES Study (Progesterone Breast Endometrial Safety Study) [NCT05586724]Phase 3390 participants (Anticipated)Interventional2022-02-25Recruiting
MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy [NCT05739136]530 participants (Anticipated)Observational2025-01-31Not yet recruiting
Gender Disparity and Hormones in Cystic Fibrosis [NCT02036879]Early Phase 155 participants (Actual)Interventional2014-02-28Completed
A Phase 1, Open-label Study in Healthy Female Subjects to Investigate the Effect of JNJ-63623872 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone [NCT02652650]Phase 118 participants (Actual)Interventional2015-12-31Completed
Effect of Tranexemic Acid and Norethisterone Acetate on Endometrial Vasculature in Women With Dysfunctional Uterine Bleeding. [NCT04290013]Phase 3120 participants (Anticipated)Interventional2020-04-22Not yet recruiting
Randomized Clinical Trial on the Effectts of Estradiol 2 mg + NETA 1 mg With or Without Clodronate on Bone Mineral Density and Bone Markers of Osteoporotic Postmenopausal 167 Finnish Women. [NCT00877097]167 participants (Actual)Interventional1996-07-31Completed
Pilot Study Examining the Pharmacokinetics of 0.35mg Norethindrone vs 5mg Norethindrone Acetate [NCT05294341]Phase 46 participants (Actual)Interventional2022-07-22Completed
Comparison of Standard and Physiologic Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure and the Assessment of Skeletal, Cardiovascular and Reproductive Parameters [NCT00732693]Phase 442 participants (Actual)Interventional2002-02-28Completed
Effects of a Progestin on Frequent and/or Prolonged Bleeding With Nexplanon™; a Randomized Double-Blinded Placebo-Controlled Trial [NCT04676061]Phase 4124 participants (Anticipated)Interventional2021-02-11Recruiting
A Phase Ib, Open-Label, Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to [NCT01209143]Phase 152 participants (Actual)Interventional2010-11-30Completed
A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg Versus Activella® (1 mg Estradiol/0.5 mg Norethindrone Acetate) Tablets in Normal, Healthy, Post-Menopausal Female Subjects. [NCT01181726]Phase 140 participants (Actual)Interventional2007-01-31Completed
Single Dose, Three-way, Cross-over, Relative Bioavailability Study With 3 Oral Formulations for Hormone Replacement Therapy in Postmenopausal Women: 0.5 mg Estradiol + 0.1 mg Norethisterone Acetate, 0.5 mg Estradiol + 0.25 mg Norethisterone Acetate, and 1 [NCT01477632]Phase 124 participants (Actual)Interventional2005-03-31Completed
PROMES: PROspective, Non-Interventional, Observational, Longitudinal Study to Describe the Safety Profile of MESIGYNA® (Norethisterone Enantate 50 mg and Estradiol Valerate 5 mg) as a Contraceptive Method for Women in Reproductive Age at the Outpatient Cl [NCT03901131]296 participants (Actual)Observational2019-08-26Completed
Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation [NCT00999479]0 participants (Actual)Interventional2009-10-31Withdrawn(stopped due to Poor enrollment)
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain [NCT03213457]Phase 3681 participants (Actual)Interventional2017-07-07Completed
[NCT00006133]970 participants Interventional2000-06-30Completed
A Two-Way Crossover, Open-Label, Single-Dose, Fasting, Bioequivalence Study of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg Versus Activella® (1 mg Estradiol/0.5 mg Norethindrone Acetate) Tablets in Normal, Healthy, Post-Menopausal Female Subjects [NCT01157182]Phase 136 participants (Actual)Interventional2007-02-28Completed
An Open Label Study of the Contraceptive Efficacy of Norethindrone and Ethinyl Estradiol. [NCT00477633]Phase 31,700 participants (Actual)Interventional2007-06-30Completed
The Effect of Oral Norethindrone on Coagulation Parameters in Women at Increased Risk for Venous Thromboembolic Events [NCT00580424]20 participants (Anticipated)Interventional2007-12-31Terminated
A Relative Bioavailability Study of 0.4 mg/35 Mcg Norethindrone and Ethinyl Estradiol Chewable Tablets Under Fasting Conditions [NCT01340625]Phase 136 participants (Actual)Interventional2006-12-31Completed
A Phase I, Open Label, Fixed Sequence, Single-Center Study to Evaluate the Effect of Multiple Dose Administration of VI-0521 on the Pharmacokinetics of a Single Dose of Oral Contraceptive in Healthy Female Subjects [NCT00821496]Phase 120 participants (Actual)Interventional2009-01-31Completed
Evaluation of 304 Danish Girls With Tall Stature: Phenotypic Characteristics and Effects of Oral Administration of Natural 17β-Estradiol [NCT02638922]304 participants (Actual)Observational2014-01-31Active, not recruiting
Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding [NCT01391052]Phase 480 participants (Anticipated)Interventional2011-01-31Recruiting
A Randomized Double-Blind Placebo-Controlled Trial to Assess the Effectiveness of Low-Dose Naltrexone in Combination With Standard Treatment in Women With Chronic Pelvic Pain Secondary to Endometriosis [NCT03970330]Phase 39 participants (Actual)Interventional2020-01-16Terminated(stopped due to Original PI left institution, lack of funding to continue)
Phase3,Open-label,Long-term,NSAID-Add-on,Clinical Trial of Mono-phase Low-dose Oral Contraceptive Pill for Treatment of Dysmenorrhea Associated With Endometriosis. [NCT00212277]Phase 30 participants Interventional2005-02-28Completed
A Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics of a Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Patients With Solid Tumors [NCT02705963]Phase 119 participants (Actual)Interventional2016-10-20Completed
Effect of Genistein on Endometrial Hyperplasia [NCT00453960]Phase 259 participants (Actual)Interventional2007-01-31Completed
Single Dose, Double-blind, Two-way Cross-over Bioequivalence Trial With 2 Different Oral Formulations of Estradiol and Norethisterone [NCT01596010]Phase 144 participants (Actual)Interventional2007-10-31Completed
Hormonal Contraception and Bacterial Vaginosis (HCBV): The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis Among Women at High Risk for HIV Infection in Kampala, Uganda [NCT02905890]Phase 4250 participants (Actual)Interventional2017-10-02Completed
A Randomized Controlled Pilot Study of the Use of Cannabidiol in the Management of Endometriosis Pain [NCT04527003]Phase 336 participants (Anticipated)Interventional2020-12-04Recruiting
Oral Contraceptives Versus Depot-Leuprolide Taken After Surgery for Endometriosis-Associated Pelvic Pain [NCT00229996]Phase 3194 participants (Anticipated)Interventional2004-07-31Completed
Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg) [NCT00458458]Phase 3112 participants (Anticipated)Interventional2004-08-31Active, not recruiting
Prospective Comparison of Hormone Withdrawal Symptoms of a 24/4 Regimen With a 21/7 Regimen of OC [NCT00475189]51 participants (Actual)Interventional2007-06-30Completed
Phase 3,Placebo Controlled,Randomized,Double-Blinded,NSAID-Add-on,Clinical Trial of Mono-phase Low Dose Oral Contraceptive Pill for Treatment of Dysmenorrhea Associated With Endometriosis. [NCT00212342]Phase 3100 participants (Actual)Interventional2004-12-31Completed
A Phase 1, Single-center, Open-label, Single-sequence Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 With Oral Contraceptives in Healthy Female Participants [NCT05891262]Phase 115 participants (Actual)Interventional2023-06-06Completed
A Pharmacokinetic Study to Evaluate the Effect of Colchicine on the Pharmacokinetic Profile of an Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone in Healthy Women [NCT01040845]Phase 130 participants (Actual)Interventional2007-08-31Completed
Deciphering the Hormonal and Nociceptive Mechanisms Underlying Bladder Pain [NCT02214550]Phase 4353 participants (Actual)Interventional2014-07-31Completed
A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition. [NCT01466114]Phase 264 participants (Anticipated)Interventional2011-10-31Recruiting
A Six Month Double-blind, Randomised, Parallel-group, Placebo-controlled, Multi-centre Trial to Investigate the Efficacy and Safety of Two Ultra-low Dose Combinations With 0.5 mg Estradiol and 0.1 mg or 0.25 mg Norethisterone Acetate (Activelle Low Dose 0 [NCT00184795]Phase 3576 participants (Actual)Interventional2004-05-28Completed
The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial [NCT00474851]Phase 253 participants (Actual)Interventional2007-08-31Completed
Effects of One-to-one Service on the Continuation and Satisfaction of Combined Injectable Contraceptive Use. [NCT05362019]400 participants (Anticipated)Interventional2022-05-31Not yet recruiting
Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study [NCT02542410]Phase 210 participants (Actual)Interventional2016-05-31Completed
A Three-Part Phase 1 Study to Evaluate the Potential Drug Interaction Between ACH-0144471 and Warfarin, Bupropion, and Ethinyl Estradiol and Norethindrone (Oral Contraceptive) in Healthy Adult Subjects [NCT04709094]Phase 152 participants (Actual)Interventional2019-07-28Completed
Open-Label Study of Cycle Control With Extended Administration of Norethindrone Acetate 1 mg / Ethinyl Estradiol 20 Mcg Oral Tablets [NCT00338052]Phase 2207 participants (Actual)Interventional2006-06-30Completed
LNG-IUS or Norethisterone Acetate for Treatment of Non-atypical Endometrial Hyperplasia in Perimenopausal Women [NCT01499602]120 participants (Actual)Interventional2009-05-31Completed
[NCT00004763]Phase 245 participants Interventional1993-01-31Completed
Pharmacodynamics of NPC-01( 1mg Norethisterone and 0.02mg Ethinyl Estradiol) and IKH-01( 1mg Norethisterone and 0.035mg Ethinyl Estradiol); Effect of NPC-01 and IKH-01 on Serum Concentrations of Estradiol, Progesterone, FSH and LH. [NCT01253824]Phase 314 participants (Actual)Interventional2011-01-31Completed
Randomized Control Trial Between Norethisterone Acetate and Expectant Management in Treatment of Simple Ovarian Cysts [NCT05293574]Phase 466 participants (Anticipated)Interventional2022-10-01Not yet recruiting
Bleeding Profile With Continuous Hormone Replacement Therapy in Postmenopausal Women: A Prospective, Open, Multicenter Trial of Activelle® Treatment Following Switch From Trisekvens® [NCT01705249]Phase 4191 participants (Actual)Interventional2001-08-14Completed
Treatment of Prolonged Uterine Bleeding of Etonogestrel (ENG)-Releasing Implant Using Norethisterone (NET)-Only Pill: a Randomized Controlled Trial [NCT04047875]Phase 4120 participants (Anticipated)Interventional2020-09-15Recruiting
The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone Contraception [NCT01667978]35 participants (Actual)Interventional2012-06-30Completed
Open Label, Randomized, Comparator-Controlled Study of the Contraceptive Efficacy of Norethindrone Acetate (NA) and Ethinyl Estradiol (EE) [NCT00932321]Phase 3938 participants (Actual)Interventional2004-01-31Completed
An International Phase 3 Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids [NCT03751124]Phase 3229 participants (Actual)Interventional2018-10-16Completed
A Single Dose Pharmacokinetics Study of NPC-01 (1mg Norethisterone and 0.02mg Ethynyl Estradiol) in Healthy Female Volunteers [NCT01246791]Phase 312 participants (Actual)Interventional2010-11-30Completed
SPIRIT 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain [NCT03204318]Phase 3638 participants (Actual)Interventional2017-12-07Completed
A Phase 1, Open Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone [NCT01597986]Phase 124 participants (Actual)Interventional2012-04-30Completed
Ovulation Incidence in Oral Contraceptive Users [NCT03106454]Phase 358 participants (Anticipated)Interventional2014-08-31Suspended(stopped due to Investigator leave of absence)
Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales [NCT02210702]Phase 433 participants (Anticipated)Interventional2014-07-31Recruiting
Efficacy of the Levonorgestrel Intrauterine Device With Norethindrone Acetate for Treatment of Endometriosis in Adolescents and Young Adults [NCT04948489]Phase 280 participants (Anticipated)Interventional2024-01-01Not yet recruiting
Protocol for Randomized Clinical Study Concerning Hormonal Replacement Therapy (HRT) After Previous Radical Breast Cancer Treatment [NCT00003771]Phase 31,300 participants (Anticipated)Interventional1997-09-30Completed
SPIRIT 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain [NCT03204331]Phase 3623 participants (Actual)Interventional2017-11-01Completed
The Effect of BMS-986165 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Subjects [NCT03262727]Phase 149 participants (Actual)Interventional2017-09-01Completed
Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study [NCT05916469]300 participants (Anticipated)Observational [Patient Registry]2024-07-31Not yet recruiting
Phase 2a Proof Of Concept Study to Evaluate the Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids [NCT01441635]Phase 2271 participants (Actual)Interventional2011-09-08Completed
A Single Centre, Open-label, Randomized, Parallel Group, Multiple Dose Comparison of the Effect of TPV 750 mg and RTV 200 mg or TPV 500 mg and RTV 100 mg, Administered Twice Daily, on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol [NCT02245438]Phase 152 participants (Actual)Interventional2002-05-31Terminated
The Effect of BMS-986195 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Subjects [NCT03262740]Phase 158 participants (Actual)Interventional2017-09-11Completed
Open-label, Randomized, Fixed Sequence Cross-over Study With Five Parallel Treatment Arms and Three Treatment Periods to Quantify the Drug-drug Interactions of Two Rifampicin Dose Strengths on Four Progestins and a Fixed Progestin-ethinylestradiol Combina [NCT03353857]Phase 168 participants (Actual)Interventional2017-11-29Completed
The Association of Hormonal Intake and Demographic Factors With Breast Cancer Risk. An Egyptian Case-controlled Study [NCT05135013]200 participants (Anticipated)Observational2021-11-16Not yet recruiting
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids [NCT01817530]Phase 2571 participants (Actual)Interventional2013-04-08Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00391807 (17) [back to overview]Total Number of Bleeding Days Per Cycle, Cycle 6, MITT Population
NCT00391807 (17) [back to overview]Median Duration of Withdrawal Bleeding, Cycle 12, MITT Population
NCT00391807 (17) [back to overview]Percentage of Subjects With Withdrawal Bleeding (%), Cycle 2, MITT Population
NCT00391807 (17) [back to overview]Percentage of Subjects With Amenorrhea, Cycle 2, MITT Population
NCT00391807 (17) [back to overview]Percentage of Subjects With Withdrawal Bleeding (%), Cycle 6, MITT Population
NCT00391807 (17) [back to overview]Percentage of Subjects With Withdrawal Bleeding (%), Cycle 13, MITT Population
NCT00391807 (17) [back to overview]Percentage of Subjects With Amenorrhea, Cycle 6, MITT Population
NCT00391807 (17) [back to overview]Percentage of Subjects With Amenorrhea, Cycle 13, MITT Population
NCT00391807 (17) [back to overview]Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 6, MITT Population
NCT00391807 (17) [back to overview]Median Duration of Withdrawal Bleeding, Cycle 2, MITT Population
NCT00391807 (17) [back to overview]Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 2, MITT Population
NCT00391807 (17) [back to overview]Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 13, MITT Population
NCT00391807 (17) [back to overview]Median Duration of Withdrawal Bleeding, Cycle 6, MITT Population
NCT00391807 (17) [back to overview]Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18 to 35, MITT Population,
NCT00391807 (17) [back to overview]Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18-45, MITT Population
NCT00391807 (17) [back to overview]Total Number of Bleeding Days Per Cycle, Cycle 13, MITT Population
NCT00391807 (17) [back to overview]Total Number of Bleeding Days Per Cycle, Cycle 2, MITT Population
NCT00474851 (2) [back to overview]Bone Mineral Density
NCT00474851 (2) [back to overview]Total Body Bone Mineral Content (BMC)
NCT00477633 (3) [back to overview]Pearl Index, 18-35 Years, MITT Population
NCT00477633 (3) [back to overview]Mean Median Duration (Days) of Intracyclic Bleeding & Spotting, Cycles 2-13, MITT Population
NCT00477633 (3) [back to overview]Mean Number of Days of Intracyclic Bleeding & Spotting, Cycles 2-13, MITT Population
NCT00932321 (2) [back to overview]Mean Number of Intracyclic Bleeding (IB)/Spotting Days in Cycles 2-6, MITT Population
NCT00932321 (2) [back to overview]Pregnancy Rate (Expressed as Pearl Index) for Women 18 to 45 Years Old, MITT Population
NCT01040845 (10) [back to overview]Maximum Plasma Concentration of Ethinyl Estradiol With Colchicine at Steady State (Cmax, ss)
NCT01040845 (10) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] Ethinyl Estradiol With Colchicine
NCT01040845 (10) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Norethindrone With Colchicine
NCT01040845 (10) [back to overview]Maximum Plasma Concentration of Colchicine With Norethindrone/Ethinyl Estradiol at Steady State (Cmax, ss)
NCT01040845 (10) [back to overview]Maximum Plasma Concentration of Norethindrone With Placebo at Steady State (Cmax, ss)
NCT01040845 (10) [back to overview]Maximum Plasma Concentration of Norethindrone With Colchicine at Steady State (Cmax, ss)
NCT01040845 (10) [back to overview]Maximum Plasma Concentration of Ethinyl Estradiol With Placebo at Steady State (Cmax, ss)
NCT01040845 (10) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Norethindrone With Placebo
NCT01040845 (10) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Ethinyl Estradiol With Placebo
NCT01040845 (10) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Colchicine With Norethindrone/Ethinyl Estradiol
NCT01157182 (21) [back to overview]Cmax for Norethindrone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01157182 (21) [back to overview]Cmax for Uncorrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01157182 (21) [back to overview]Cmax for Uncorrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01157182 (21) [back to overview]Cmax for Uncorrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01157182 (21) [back to overview]AUC0-inf for Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01157182 (21) [back to overview]Cmax for Corrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01157182 (21) [back to overview]AUC0-t for Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01157182 (21) [back to overview]AUC0-t for Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01157182 (21) [back to overview]AUC0-t for Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01157182 (21) [back to overview]AUC0-t for Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01157182 (21) [back to overview]AUC0-t for Norethindrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01157182 (21) [back to overview]AUC0-t for Corrected Unconjugated Estradiol.(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01157182 (21) [back to overview]AUC0-t for Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01157182 (21) [back to overview]AUC0-inf for Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01157182 (21) [back to overview]AUC0-inf for Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01157182 (21) [back to overview]AUC0-inf for Norethindrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01157182 (21) [back to overview]AUC0-inf for Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01157182 (21) [back to overview]AUC0-inf for Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01157182 (21) [back to overview]AUC0-inf for Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01157182 (21) [back to overview]Cmax for Corrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01157182 (21) [back to overview]Cmax for Corrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01181726 (21) [back to overview]AUC0-t of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01181726 (21) [back to overview]AUC0-inf of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01181726 (21) [back to overview]AUC0-inf of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01181726 (21) [back to overview]AUC0-inf of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01181726 (21) [back to overview]AUC0-inf of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01181726 (21) [back to overview]Cmax of Corrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01181726 (21) [back to overview]AUC0-t of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01181726 (21) [back to overview]AUC0-t of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01181726 (21) [back to overview]Cmax of Corrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01181726 (21) [back to overview]Cmax of Corrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01181726 (21) [back to overview]Cmax of Norethindrone (Maximum Observed Concentration of Drug Substance in Plasma)
NCT01181726 (21) [back to overview]AUC0-inf of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01181726 (21) [back to overview]Cmax of Uncorrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01181726 (21) [back to overview]Cmax of Uncorrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01181726 (21) [back to overview]AUC0-t of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01181726 (21) [back to overview]Cmax of Uncorrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01181726 (21) [back to overview]AUC0-t of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01181726 (21) [back to overview]AUC0-t of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01181726 (21) [back to overview]AUC0-inf of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01181726 (21) [back to overview]AUC0-t of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01181726 (21) [back to overview]AUC0-inf of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01209143 (4) [back to overview]Geometric Mean Ratio of the Area Under the Plasma Concentration-time Curve From 0 to Infinity (AUC[0-inf]) of Ethinyl Estradiol and Norethindrone
NCT01209143 (4) [back to overview]Geometric Mean Ratio of the Maximum Plasma Concentration (Cmax) of Rosiglitazone
NCT01209143 (4) [back to overview]Geometric Mean Ratio of the Area Under the Plasma Concentration-time Curve From 0 to Infinity (AUC[0-inf]) of Rosiglitazone
NCT01209143 (4) [back to overview]Geometric Mean Ratio of the Maximum Plasma Concentration (Cmax) of Ethinyl Estradiol and Norethindrone
NCT01246791 (12) [back to overview]Area Under the Plasma Concentration Versus Time Curve (AUC) on Norethisterone of NPC-01
NCT01246791 (12) [back to overview]Elimination Rate Constant (Kel) on Ethinyl Estradiol of NPC-01
NCT01246791 (12) [back to overview]Elimination Rate Constant (Kel) on Norethisterone of NPC-01
NCT01246791 (12) [back to overview]Mean Residence Time (MRT) on Ethinyl Estradiol of NPC-01
NCT01246791 (12) [back to overview]Mean Residence Time (MRT) on Norethisterone of NPC-01
NCT01246791 (12) [back to overview]Peak Plasma Concentration (Cmax) on Ethinyl Estradiol of NPC-01
NCT01246791 (12) [back to overview]Peak Plasma Concentration (Cmax) on Norethisterone of NPC-01
NCT01246791 (12) [back to overview]Time to Peak Plasma Concentration (Tmax) on Norethisterone of NPC-01
NCT01246791 (12) [back to overview]Plasma Half Life (t1/2) on Ethinyl Estradiol of NPC-01
NCT01246791 (12) [back to overview]Plasma Half Life (t1/2) on Norethisterone of NPC-01
NCT01246791 (12) [back to overview]Time to Peak Plasma Concentration (Tmax) on Ethinyl Estradiol of NPC-01
NCT01246791 (12) [back to overview]Area Under the Plasma Concentration Versus Time Curve (AUC) on Ethinyl Estradiol of NPC-01
NCT01253824 (4) [back to overview]Comparing Progesterone AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))
NCT01253824 (4) [back to overview]Comparing Estradiol AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))
NCT01253824 (4) [back to overview]Comparing FSH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))
NCT01253824 (4) [back to overview]Comparing LH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))
NCT01340625 (6) [back to overview]Cmax of Norethindrone
NCT01340625 (6) [back to overview]Cmax of Ethinyl Estradiol
NCT01340625 (6) [back to overview]AUC0-t of Norethindrone
NCT01340625 (6) [back to overview]AUC0-t of Ethinyl Estradiol
NCT01340625 (6) [back to overview]AUC0-inf of Norethindrone
NCT01340625 (6) [back to overview]AUC0-inf of Ethinyl Estradiol
NCT01344369 (6) [back to overview]Cmax of Norethindrone
NCT01344369 (6) [back to overview]AUC0-inf of Ethinyl Estradiol
NCT01344369 (6) [back to overview]AUC0-inf of Norethindrone
NCT01344369 (6) [back to overview]AUC0-t of Ethinyl Estradiol
NCT01344369 (6) [back to overview]AUC0-t of Norethindrone
NCT01344369 (6) [back to overview]Cmax of Ethinyl Estradiol
NCT01441635 (20) [back to overview]Percentage of Participants With ≥ 25% Reduction in Uterine Volume at Month 3 / Final Visit
NCT01441635 (20) [back to overview]Percent Change From Baseline to the Last 28 Days of Treatment in Menstrual Blood Loss (MBL)
NCT01441635 (20) [back to overview]Percent Change From Baseline to Month 3 in Volume of the Largest Fibroid
NCT01441635 (20) [back to overview]Percent Change From Baseline to Month 3 in Uterine Volume
NCT01441635 (20) [back to overview]Change in Hemoglobin Concentration From Baseline to Month 3
NCT01441635 (20) [back to overview]Change From Baseline to Month 3 in Uterine Bleeding Score
NCT01441635 (20) [back to overview]Change From Baseline to Month 3 in Percentage of Days With Moderate to Very Heavy Bleeding
NCT01441635 (20) [back to overview]Change From Baseline to Month 3 in Percentage of Days With Any Uterine Bleeding
NCT01441635 (20) [back to overview]Change From Baseline to Month 3 in the Uterine Fibroids Daily Symptom Scale Scores
NCT01441635 (20) [back to overview]Percentage of Participants With MBL < 80 mL During the Last 28 Days of Treatment
NCT01441635 (20) [back to overview]Percentage of Participants With MBL < 80 mL and With a ≥ 50% Reduction From Baseline in MBL During the Last 28 Days of Treatment
NCT01441635 (20) [back to overview]Percentage of Participants With a ≥ 50% Reduction From Baseline in MBL During the Last 28 Days of Treatment
NCT01441635 (20) [back to overview]Percentage of Participants With ≥ 25% Reduction in Volume of Largest Fibroid at Month 3 / Final Visit
NCT01441635 (20) [back to overview]Change From Baseline to Month 3 in the Physician Surgery Intention Questionnaire (PSIQ) Version 2.0
NCT01441635 (20) [back to overview]Change From Baseline to Month 3 in the Subject Surgery Intention Questionnaire (SSIQ) Version 2.0
NCT01441635 (20) [back to overview]Change From Baseline to Month 3 in the Uterine Fibroid Symptom Quality of Life Questionnaire (UFS-QoL)
NCT01441635 (20) [back to overview]Mean Change From Baseline to the Last 28 Days of Treatment in Menstrual Blood Loss (MBL)
NCT01441635 (20) [back to overview]Percentage of Participants With Any Uterine Bleeding or Moderate to Very Heavy Uterine Bleeding at Month 3
NCT01441635 (20) [back to overview]Percentage of Participants With No Change, Decrease From Baseline, or Increase From Baseline in Hemoglobin at Month 3
NCT01441635 (20) [back to overview]Percentage of Participants With Suppression of Bleeding (Spotting Allowed) or Amenorrhea During the Last 56 Days of Treatment
NCT01667978 (1) [back to overview]AUC Norethindrone
NCT01817530 (18) [back to overview]Percentage of Participants With a MBL Volume < 80 mL and a ≥ 50% Reduction in MBL Volume From Baseline During the Last 56 to 29 Days of Treatment
NCT01817530 (18) [back to overview]Percentage of Participants With a ≥ 50% Reduction in MBL Volume From Baseline to the Final Month
NCT01817530 (18) [back to overview]Percentage of Participants Who Achieved Suppression of Bleeding During the Last 56 Days of Treatment
NCT01817530 (18) [back to overview]Percentage of Participants Who Achieved an MBL Volume of < 80 mL at the Final Month
NCT01817530 (18) [back to overview]Percentage of Participants Who Achieved Amenorrhea During the Last 56 Days of Treatment
NCT01817530 (18) [back to overview]Change From Baseline to Each Month in Non-Bleeding Uterine Fibroids Symptom (NBUFSQ) Questionnaire
NCT01817530 (18) [back to overview]Mean Change in the Number of Heavy Bleeding Days From Baseline to Month 6
NCT01817530 (18) [back to overview]Mean Change in the Number of Bleeding Days From Baseline to Month 6
NCT01817530 (18) [back to overview]Mean Change in Hemoglobin Concentration From Baseline to Final Visit
NCT01817530 (18) [back to overview]Change in Bleeding Severity Scores From Baseline at the Final Month
NCT01817530 (18) [back to overview]Percentage of Participants With a MBL Volume < 80 mL and a ≥ 50% Reduction in MBL Volume From Baseline During the Last 84 to 57 Days of Treatment
NCT01817530 (18) [back to overview]Percentage of Participants With a Menstrual Blood Loss (MBL) Volume of < 80 mL at the Final Month and a ≥ 50% Reduction in MBL Volume From Baseline to the Final Month
NCT01817530 (18) [back to overview]Mean Percentage Change From Baseline in Primary Fibroid Volume at Month 3, Month 6, and Final Visit
NCT01817530 (18) [back to overview]Mean Percentage Change From Baseline in Total Fibroid Volume at Month 3, Month 6, and Final Visit
NCT01817530 (18) [back to overview]Mean Percentage Change From Baseline in Uterine Volume at Month 3, Month 6, and Final Visit
NCT01817530 (18) [back to overview]Percentage of Participants With ≥ 25% Reduction From Baseline in Primary Fibroid Volume at Month 3, Month 6, and Final Visit
NCT01817530 (18) [back to overview]Percentage of Participants With ≥ 25% Reduction From Baseline in Total Fibroid Volume at Month 3, Month 6, and Final Visit
NCT01817530 (18) [back to overview]Percentage of Participants With ≥ 25% Reduction From Baseline in Uterine Volume at Month 3, Month 6, and Final Visit
NCT02214550 (6) [back to overview]Differences in EEG Recorded Cortical Activity Among Participants
NCT02214550 (6) [back to overview]Change in Participant Bladder Pain Sensitivity From Baseline.
NCT02214550 (6) [back to overview]Change in Participant Bladder Pain Sensitivity From Baseline.
NCT02214550 (6) [back to overview]Change in Quantitative Sensory Testing (QST) Parameters Regarding Pelvic Hyperalgesia From Baseline
NCT02214550 (6) [back to overview]Change in Quantitative Sensory Testing (QST) Parameters Regarding Pelvic Hyperalgesia From Baseline
NCT02214550 (6) [back to overview]Differences in EEG Recorded Cortical Activity Among Participants
NCT02353247 (1) [back to overview]Impact of Aygestin (and Dose of Aygestin) on the Management of Bothersome Bleeding Associated With the Etonogestrel Contraceptive Implant
NCT02542410 (2) [back to overview]Changes in Pain Interference Scores
NCT02542410 (2) [back to overview]Change in Score in Worst Pain Over the Last Month
NCT02654054 (7) [back to overview]Percentage of Participants Meeting the Criteria for Responder
NCT02654054 (7) [back to overview]Change From Baseline in MBL Volume to the Final Month
NCT02654054 (7) [back to overview]Change From Baseline in MBL Volume to Month 6
NCT02654054 (7) [back to overview]Change From Baseline in MBL Volume to Month 3
NCT02654054 (7) [back to overview]Change From Baseline in MBL Volume to Month 1
NCT02654054 (7) [back to overview]Percentage of Participants With Suppression of Bleeding at the Final Month
NCT02654054 (7) [back to overview]Percentage of Participants With Baseline Hemoglobin <= 10.5 g/dL Who Have an Increase in Hemoglobin > 2 g/dL at Month 6
NCT02691494 (7) [back to overview]Percentage of Participants With Suppression of Bleeding at the Final Month
NCT02691494 (7) [back to overview]Percentage of Participants Meeting the Criteria for Responder
NCT02691494 (7) [back to overview]Change From Baseline in MBL Volume to the Final Month
NCT02691494 (7) [back to overview]Change From Baseline in MBL Volume to Month 6
NCT02691494 (7) [back to overview]Change From Baseline in MBL Volume to Month 3
NCT02691494 (7) [back to overview]Percentage of Participants With Baseline Hemoglobin <= 10.5 g/dL Who Have an Increase in Hemoglobin > 2 g/dL at Month 6
NCT02691494 (7) [back to overview]Change From Baseline in MBL Volume to Month 1
NCT02925494 (5) [back to overview]Percentage of Participants Meeting the Criteria for Responder
NCT02925494 (5) [back to overview]Percentage of Participants With Baseline Hemoglobin Concentration ≤ 10.5 g/dL and an Increase From Baseline > 2 g/dL at Month 6 During the Treatment Period
NCT02925494 (5) [back to overview]Percentage of Participants With Suppression of Bleeding at the Final Month
NCT02925494 (5) [back to overview]Change From Baseline in MBL Volume For Each 28-Day Interval and Final Month of the Treatment Period
NCT02925494 (5) [back to overview]Percent Change From Baseline in MBL Volume For Each 28-Day Interval and Final Month of the Treatment Period
NCT02969590 (5) [back to overview]Median Cervical Mucus Score - 2 Hour
NCT02969590 (5) [back to overview]Median Cervical Mucus Score - 6 Hour
NCT02969590 (5) [back to overview]Median Cervical Mucus Score - 24 Hour
NCT02969590 (5) [back to overview]Median Cervical Mucus Score - Baseline
NCT02969590 (5) [back to overview]Change in PGRMC1 During Menstrual Cycle
NCT03049735 (44) [back to overview]Percent Change From Baseline At Week 24 In Uterine Volume
NCT03049735 (44) [back to overview]Percent Change From Baseline In Hemoglobin For Women With a Hemoglobin ≤ 10.5 g/dL At Baseline
NCT03049735 (44) [back to overview]Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 12
NCT03049735 (44) [back to overview]Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 24
NCT03049735 (44) [back to overview]Percentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A ≥ 50% Reduction From Baseline MBL Volume With Relugolix Plus E2/NETA
NCT03049735 (44) [back to overview]Percentage Of Participants With A Hemoglobin Level ≤ 10.5 g/dL At Baseline Who Achieved An Increase Of > 2 g/dL From Baseline At Week 24
NCT03049735 (44) [back to overview]Percentage Of Participants With A Maximum NRS Score ≤ 1 For Uterine Fibroid-Associated Pain Over The Last 35 Days Of Treatment
NCT03049735 (44) [back to overview]Percentage Of Participants With Amenorrhea Over The Last 35 Days Of Treatment
NCT03049735 (44) [back to overview]Predose Trough Concentrations Of E2 In The Relugolix Plus E2/NETA Group At Week 24
NCT03049735 (44) [back to overview]Sustained Amenorrhea Rate (No Or Negligible Bleeding)
NCT03049735 (44) [back to overview]Time To Achieving Amenorrhea (No Or Negligible Bleeding)
NCT03049735 (44) [back to overview]Time To Achieving Sustained Amenorrhea (No Or Negligible Bleeding)
NCT03049735 (44) [back to overview]Time To MBL Response
NCT03049735 (44) [back to overview]Participants Achieving Improvement From Baseline In The PGA Questionnaire For Symptoms From Baseline At Week 24
NCT03049735 (44) [back to overview]Participants Achieving Improvement From Baseline In The PGA Questionnaire For Uterine Fibroid-related Function From Baseline At Week 24
NCT03049735 (44) [back to overview]Percent Change From Baseline At Week 24 In Bone Mineral Density At The Lumbar Spine (L1 To L4), Total Hip, And Femoral Neck
NCT03049735 (44) [back to overview]Predose Trough Concentrations Of Relugolix And Norethindrone (NET) In The Relugolix Plus E2/NETA Group At Week 24
NCT03049735 (44) [back to overview]Change From Baseline At Week 24 In The Menorrhagia Impact Questionnaire Score For Social Activities
NCT03049735 (44) [back to overview]Change From Baseline At Week 24 In Embarrassment Caused By Uterine Fibroids Based On UFS-QoL Question 29
NCT03049735 (44) [back to overview]Change From Baseline At Week 24 In Function Assessed Using The PGA Questionnaire
NCT03049735 (44) [back to overview]Change From Baseline At Week 24 In Predose Concentrations Of Estradiol In The Relugolix Plus E2/NETA Group
NCT03049735 (44) [back to overview]Change From Baseline At Week 24 In Symptoms Assessed Using The Patient Global Assessment (PGA) Questionnaire
NCT03049735 (44) [back to overview]Change From Baseline At Week 24 In The Interference Of Uterine Fibroids With Physical Activities Based On UFS-QoL Question 11
NCT03049735 (44) [back to overview]Change From Baseline At Week 24 In The Interference Of Uterine Fibroids With Social Activities Based On UFS-QoL Question 20
NCT03049735 (44) [back to overview]Change From Baseline At Week 24 In The Menorrhagia Impact Questionnaire Score For Physical Activities
NCT03049735 (44) [back to overview]Change From Baseline At Week 24 In The UFS-QoL Activities Scale Score
NCT03049735 (44) [back to overview]Change From Baseline At Week 24 In The UFS-QoL Revised Activities Scale Score
NCT03049735 (44) [back to overview]Change From Baseline At Week 24 In The UFS-QoL Symptom Severity Scale Score
NCT03049735 (44) [back to overview]Change From Baseline At Week 24 In UFS-QoL Bleeding And Pelvic Discomfort Scale Score As Measured By The UFS-QoL (Q1, Q2, Q5)
NCT03049735 (44) [back to overview]Change From Baseline In E2 Serum Concentration At Week 24
NCT03049735 (44) [back to overview]Change From Baseline In Follicle Stimulating Serum Concentration At Week 24
NCT03049735 (44) [back to overview]Change From Baseline In Luteinizing Serum Concentration At Week 24
NCT03049735 (44) [back to overview]Change From Baseline In Progesterone Serum Concentration At Week 24
NCT03049735 (44) [back to overview]Change From Baseline In UFS-QoL Bleeding And Pelvic Discomfort Scale Score
NCT03049735 (44) [back to overview]Change From Baseline In UFS-QoL Score By Health-Related Quality Of Life Total Score
NCT03049735 (44) [back to overview]Number Of Participants Who Achieved A Maximum NRS Score ≤ 1 For Uterine Fibroid-associated Pain Over The Last 35 Days Of Treatment Who Had Maximum Pain Scores ≥ 4 During The 35 Days Prior To Randomization
NCT03049735 (44) [back to overview]Number Of Participants With A ≥ 30% Reduction in NRS Score From Baseline to Last 35 Days of Treatment Who Had Maximum Pain Scores ≥ 4 At Baseline
NCT03049735 (44) [back to overview]Number Of Participants With Hemoglobin ≤ 10.5 g/dL At Baseline And Achieved An Increase Of > 2 g/dL At Week 24
NCT03049735 (44) [back to overview]Number Of Participants With Hemoglobin Increase Of ≥ 1 g/dL From Baseline To Week 24 Among Those With Below Lower Limit Of Normal
NCT03049735 (44) [back to overview]Number Of Responders With At Least 20 Points Decrease In UFS-QoL Bleeding And Pelvic Discomfort Scale Score
NCT03049735 (44) [back to overview]Number Of Responders With At Least 20 Points Increase From Baseline At Week 24 In UFS-QoL Revised Activities Scale Score
NCT03049735 (44) [back to overview]Percent Change From Baseline At Week 12 In Bone Mineral Density At The Lumbar Spine (L1 To L4), As Assessed By DXA
NCT03049735 (44) [back to overview]Percent Change From Baseline At Week 24 In MBL Volume
NCT03049735 (44) [back to overview]Percent Change From Baseline At Week 24 In Primary Uterine Fibroid Volume
NCT03103087 (44) [back to overview]Sustained Amenorrhea Rate (No Or Negligible Bleeding)
NCT03103087 (44) [back to overview]Change From Baseline In Luteinizing Serum Concentration At Week 24
NCT03103087 (44) [back to overview]Change From Baseline In Follicle Stimulating Serum Concentration At Week 24
NCT03103087 (44) [back to overview]Change From Baseline In E2 Serum Concentration At Week 24
NCT03103087 (44) [back to overview]Change From Baseline At Week 24 In UFS-QoL Bleeding And Pelvic Discomfort Scale Score As Measured By The UFS-QoL (Q1, Q2, Q5)
NCT03103087 (44) [back to overview]Change From Baseline At Week 24 In The UFS-QoL Symptom Severity Scale Score
NCT03103087 (44) [back to overview]Change From Baseline At Week 24 In The UFS-QoL Revised Activities Scale Score
NCT03103087 (44) [back to overview]Change From Baseline At Week 24 In The UFS-QoL Activities Scale Score
NCT03103087 (44) [back to overview]Change From Baseline At Week 24 In The Menorrhagia Impact Questionnaire Score For Social Activities
NCT03103087 (44) [back to overview]Change From Baseline At Week 24 In The Menorrhagia Impact Questionnaire Score For Physical Activities
NCT03103087 (44) [back to overview]Change From Baseline At Week 24 In The Interference Of Uterine Fibroids With Social Activities Based On UFS-QoL Question 20
NCT03103087 (44) [back to overview]Change From Baseline At Week 24 In The Interference Of Uterine Fibroids With Physical Activities Based On UFS-QoL Question 11
NCT03103087 (44) [back to overview]Change From Baseline At Week 24 In Symptoms Assessed Using The Patient Global Assessment (PGA) Questionnaire
NCT03103087 (44) [back to overview]Change From Baseline At Week 24 In Predose Concentrations Of E2 In The Relugolix Plus E2/NETA Group
NCT03103087 (44) [back to overview]Predose Trough Concentrations Of Relugolix And NET In The Relugolix Plus E2/NETA Group At Week 24
NCT03103087 (44) [back to overview]Percent Change From Baseline At Week 24 In Bone Mineral Density At The Lumbar Spine (L1 To L4), Total Hip, And Femoral Neck As Assessed By DXA
NCT03103087 (44) [back to overview]Participants Achieving Improvement From Baseline In PGA Questionnaire For Symptoms From Baseline At Week 24
NCT03103087 (44) [back to overview]Participants Achieving Improvement From Baseline In PGA For Uterine Fibroid-related Function From Baseline At Week 24
NCT03103087 (44) [back to overview]Time To MBL Response
NCT03103087 (44) [back to overview]Time To Achieving Sustained Amenorrhea (No Or Negligible Bleeding)
NCT03103087 (44) [back to overview]Time To Achieving Amenorrhea (No Or Negligible Bleeding)
NCT03103087 (44) [back to overview]Change From Baseline in UFS-QoL Bleeding and Pelvic Discomfort Scale Score
NCT03103087 (44) [back to overview]Change From Baseline At Week 24 In Function Assessed Using The PGA Questionnaire
NCT03103087 (44) [back to overview]Predose Trough Concentrations Of E2 In The Relugolix Plus E2/NETA Group At Week 24
NCT03103087 (44) [back to overview]Percentage Of Participants With Amenorrhea Over The Last 35 Days Of Treatment
NCT03103087 (44) [back to overview]Percentage Of Participants With A Maximum Numerical Rating Scale (NRS) Score ≤ 1 For Uterine Fibroid-Associated Pain Over The Last 35 Days Of Treatment
NCT03103087 (44) [back to overview]Percentage Of Participants With A Hemoglobin Level ≤ 10.5 g/dL At Baseline Who Achieved An Increase Of > 2 g/dL From Baseline At Week 24
NCT03103087 (44) [back to overview]Percentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A ≥ 50% Reduction From Baseline MBL Volume With Relugolix Plus E2/NETA
NCT03103087 (44) [back to overview]Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 24
NCT03103087 (44) [back to overview]Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 12
NCT03103087 (44) [back to overview]Percent Change From Baseline At Week 24 In Uterine Volume
NCT03103087 (44) [back to overview]Percent Change From Baseline At Week 24 In Primary Uterine Fibroid Volume
NCT03103087 (44) [back to overview]Change From Baseline At Week 24 In Embarrassment Caused By Uterine Fibroids Based On UFS-QoL Question 29
NCT03103087 (44) [back to overview]Percent Change From Baseline At Week 24 In Hemoglobin For Women With A Hemoglobin Concentration ≤ 10.5 g/dL At Baseline
NCT03103087 (44) [back to overview]Percent Change From Baseline At Week 12 In Bone Mineral Density At The Lumbar Spine (L1 to L4) As Assessed By DXA
NCT03103087 (44) [back to overview]Number Of Responders With At Least 20 Points Increase From Baseline At Week 24 In UFS-QoL Revised Activities Scale Score
NCT03103087 (44) [back to overview]Number Of Responders With At Least 20 Points Decrease in UFS-QoL Bleeding And Pelvic Discomfort Scale Score
NCT03103087 (44) [back to overview]Number Of Participants With Hemoglobin Increase Of ≥ 1 g/dL From Baseline To Week 24 Among Those With Below Lower Limit Of Normal
NCT03103087 (44) [back to overview]Number Of Participants With Hemoglobin ≤ 10.5 g/dL At Baseline And Achieved An Increase Of > 2 g/dL At Week 24
NCT03103087 (44) [back to overview]Number Of Participants With A ≥ 30% Reduction in NRS Score From Baseline to Last 35 Days of Treatment Who Had Maximum Pain Scores ≥ 4 At Baseline
NCT03103087 (44) [back to overview]Percent Change From Baseline At Week 24 In MBL Volume
NCT03103087 (44) [back to overview]Change From Baseline In Progesterone Serum Concentration At Week 24
NCT03103087 (44) [back to overview]Number Of Participants Who Achieved A Maximum NRS Score ≤ 1 For Uterine Fibroid-associated Pain Over The Last 35 Days Of Treatment Who Had Maximum Pain Scores ≥ 4 During The 35 Days Prior To Randomization
NCT03103087 (44) [back to overview]Change From Baseline In UFS-QoL Score by Health-Related Quality of Life Total Score
NCT03213457 (16) [back to overview]Change From Baseline in DYS at Month 6 Based on Daily Assessment
NCT03213457 (16) [back to overview]Change From Baseline in DYS at Month 3 Based on Daily Assessment
NCT03213457 (16) [back to overview]Change From Baseline in Endometriosis-Associated Pain Score at Month 12 Assessed With Numeric Rating Scale (NRS)
NCT03213457 (16) [back to overview]Change From Baseline in Endometriosis-Associated Pain Score at Month 3 Assessed With NRS
NCT03213457 (16) [back to overview]Change From Baseline in Endometriosis-Associated Pain Score at Month 6 Assessed With NRS
NCT03213457 (16) [back to overview]Change From Baseline in NMPP at Month 3 Based on Daily Assessment
NCT03213457 (16) [back to overview]Change From Baseline in NMPP at Month 6 Based on Daily Assessment
NCT03213457 (16) [back to overview]Change From Baseline in Non-menstrual Pelvic Pain (NMPP) at Month 12 Based on Daily Assessment
NCT03213457 (16) [back to overview]Change From Baseline in Dyspareunia (DYSP) at Month 12 Based on Daily Assessment
NCT03213457 (16) [back to overview]Change From Baseline to Month 6 in Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue Short Form 6a T-Score
NCT03213457 (16) [back to overview]Co-Primary Endpoint: Percentage of Participants With a Response for Dysmenorrhea (DYS) at Months 6 and 12 Based on Daily Assessment
NCT03213457 (16) [back to overview]Co-Primary Endpoint: Percentage of Participants With a Response for Non-menstrual Pelvic Pain (NMPP) at Months 6 and 12 Based on Daily Assessment
NCT03213457 (16) [back to overview]Change From Baseline in DYS at Month 12 Based on Daily Assessment
NCT03213457 (16) [back to overview]Change From Baseline in DYSP at Month 3 Based on Daily Assessment
NCT03213457 (16) [back to overview]Change From Baseline in DYSP at Month 6 Based on Daily Assessment
NCT03213457 (16) [back to overview]Change From Baseline to Month 12 in Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue Short Form 6a T-Score
NCT03343067 (62) [back to overview]Change From Baseline Over Time in Monthly Average Dyspareunia Pain Score
NCT03343067 (62) [back to overview]Change From Baseline Over Time in Monthly Average Dyspareunia Pain Score
NCT03343067 (62) [back to overview]Change From Baseline Over Time in Monthly Average DYS Pain Score
NCT03343067 (62) [back to overview]Change From Baseline Over Time in Monthly Average DYS Pain Score
NCT03343067 (62) [back to overview]Change From Baseline Over Time in Monthly Average Daily Diary Endometriosis-Associated Pain Score Via NRS
NCT03343067 (62) [back to overview]Change From Baseline Over Time in Monthly Average Daily Diary Endometriosis-Associated Pain Score Via NRS
NCT03343067 (62) [back to overview]Change From Baseline Over Time in Daily Rescue Analgesic Use Across Both Classes of Rescue Analgesics
NCT03343067 (62) [back to overview]Change From Baseline Over Time in Daily Rescue Analgesic Use Across Both Classes of Rescue Analgesics
NCT03343067 (62) [back to overview]Change From Baseline in Rescue Analgesic Use Across Both Classes of Rescue Analgesics (NSAIDs/Opioids) at Month 6
NCT03343067 (62) [back to overview]Percentage of Participants With 30% or More Reduction From Baseline Based on the 35 Day Mean of the Daily Diary Endometriosis-Associated Pain Score Via NRS at Month 6
NCT03343067 (62) [back to overview]Change From Baseline in NMPP at Month 6
NCT03343067 (62) [back to overview]Change From Baseline in Dyspareunia at Month 6
NCT03343067 (62) [back to overview]Change From Baseline in DYS at Month 6
NCT03343067 (62) [back to overview]Change From Baseline in Daily Diary Endometriosis-Associated Pain Score Via Numeric Rating Scale (NRS) at Month 6
NCT03343067 (62) [back to overview]EuroQol-5D 5 Level (EQ-5D-5L) Scores Over Time: Mobility
NCT03343067 (62) [back to overview]WPAI:SHP Scores Over Time: Percent Overall Work Impairment Due to Problem
NCT03343067 (62) [back to overview]WPAI:SHP Scores Over Time: Percent Impairment While Working Due to Problem
NCT03343067 (62) [back to overview]WPAI:SHP Scores Over Time: Percent Activity Impairment Due to Problem
NCT03343067 (62) [back to overview]Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) Scores Over Time: Percent Work Missed Due to Problem
NCT03343067 (62) [back to overview]PROMIS Fatigue Short Form 6a Scores Over Time
NCT03343067 (62) [back to overview]Percent Change From Baseline to Each Month During the Treatment Period for NMPP
NCT03343067 (62) [back to overview]Percent Change From Baseline to Each Month During the Treatment Period for NMPP
NCT03343067 (62) [back to overview]Percent Change From Baseline to Each Month During the Treatment Period for Dyspareunia
NCT03343067 (62) [back to overview]Percent Change From Baseline to Each Month During the Treatment Period for Dyspareunia
NCT03343067 (62) [back to overview]Percent Change From Baseline to Each Month During the Treatment Period for DYS
NCT03343067 (62) [back to overview]Percent Change From Baseline to Each Month During the Treatment Period for DYS
NCT03343067 (62) [back to overview]Percent Change From Baseline to Each Month During the Treatment Period for Daily Diary Endometriosis-Associated Pain Score Via NRS
NCT03343067 (62) [back to overview]Percent Change From Baseline to Each Month During the Treatment Period for Daily Diary Endometriosis-Associated Pain Score Via NRS
NCT03343067 (62) [back to overview]Patient Global Impression of Change (PGIC) Scores Over Time
NCT03343067 (62) [back to overview]Patient Global Impression of Change (PGIC) Scores Over Time
NCT03343067 (62) [back to overview]Patient Global Impression of Change (PGIC) Scores Over Time
NCT03343067 (62) [back to overview]Overall Endometriosis-Associated Pain Via NRS (7-Day Recall) Scores Over Time
NCT03343067 (62) [back to overview]Overall Endometriosis-Associated Pain Via NRS (7-Day Recall) Scores Over Time
NCT03343067 (62) [back to overview]Overall Endometriosis-Associated Pain Via NRS (7-Day Recall) Scores Over Time
NCT03343067 (62) [back to overview]Number of Analgesic Use Responders and Non-Responders Over Time
NCT03343067 (62) [back to overview]Health Endometriosis Treatment Satisfaction Questionnaire (ETSQ) Scores Over Time
NCT03343067 (62) [back to overview]Health Endometriosis Treatment Satisfaction Questionnaire (ETSQ) Scores Over Time
NCT03343067 (62) [back to overview]EuroQol-5D 5 Level (EQ-5D-5L) Scores Over Time: Mobility
NCT03343067 (62) [back to overview]EQ-5D-5L VAS Scores Over Time: Health Today
NCT03343067 (62) [back to overview]EQ-5D-5L VAS Scores Over Time: Health Today
NCT03343067 (62) [back to overview]EQ-5D-5L Scores Over Time: Usual Activities
NCT03343067 (62) [back to overview]EQ-5D-5L Scores Over Time: Usual Activities
NCT03343067 (62) [back to overview]EQ-5D-5L Scores Over Time: Self-Care
NCT03343067 (62) [back to overview]EQ-5D-5L Scores Over Time: Self-Care
NCT03343067 (62) [back to overview]EQ-5D-5L Scores Over Time: Pain/Discomfort
NCT03343067 (62) [back to overview]EQ-5D-5L Scores Over Time: Pain/Discomfort
NCT03343067 (62) [back to overview]EQ-5D-5L Scores Over Time: Anxiety/Depression
NCT03343067 (62) [back to overview]EQ-5D-5L Scores Over Time: Anxiety/Depression
NCT03343067 (62) [back to overview]Endometriosis Health Profile-30 (EHP-30) Scores Over Time: Pain
NCT03343067 (62) [back to overview]Endometriosis Health Profile-30 (EHP-30) Scores Over Time: Pain
NCT03343067 (62) [back to overview]EHP-30 Scores Over Time: Social Support
NCT03343067 (62) [back to overview]EHP-30 Scores Over Time: Social Support
NCT03343067 (62) [back to overview]EHP-30 Scores Over Time: Sexual Intercourse
NCT03343067 (62) [back to overview]EHP-30 Scores Over Time: Sexual Intercourse
NCT03343067 (62) [back to overview]EHP-30 Scores Over Time: Self-Image
NCT03343067 (62) [back to overview]EHP-30 Scores Over Time: Self-Image
NCT03343067 (62) [back to overview]EHP-30 Scores Over Time: Emotional Well-Being
NCT03343067 (62) [back to overview]EHP-30 Scores Over Time: Emotional Well-Being
NCT03343067 (62) [back to overview]EHP-30 Scores Over Time: Control and Powerlessness
NCT03343067 (62) [back to overview]EHP-30 Scores Over Time: Control and Powerlessness
NCT03343067 (62) [back to overview]Change From Baseline Over Time in Monthly Average NMPP Pain Score
NCT03343067 (62) [back to overview]Change From Baseline Over Time in Monthly Average NMPP Pain Score
NCT03654274 (41) [back to overview]Change From The Pivotal Phase 3 Study Baseline In Each Of The Non-Pain EHP-30 Domains At Week 52
NCT03654274 (41) [back to overview]Percent Change From The Pivotal Phase 3 Study Baseline In BMD At Lumbar Spine (L1-L4), Femoral Neck, And Total Hip At Week 104
NCT03654274 (41) [back to overview]Percent Change From The Pivotal Phase 3 Study Baseline In BMD At Lumbar Spine (L1-L4), Femoral Neck, And Total Hip At Week 52
NCT03654274 (41) [back to overview]Percentage Of Participants With Improvement, No Change, Or Worsening From Baseline In PGA Score For Function At Week 104
NCT03654274 (41) [back to overview]Percentage Of Participants With Improvement, No Change, Or Worsening From Baseline In PGA Score For Function At Week 52
NCT03654274 (41) [back to overview]Percentage Of Participants With Improvement, No Change, Or Worsening From Baseline In PGA Score For Overall Pelvic Pain At Week 104
NCT03654274 (41) [back to overview]Percentage Of Participants With Improvement, No Change, Or Worsening From Baseline In PGA Score For Overall Pelvic Pain At Week 52
NCT03654274 (41) [back to overview]Change From Pivotal Phase 3 Study Baseline In Predose Serum Concentrations Of Estradiol At Week 104
NCT03654274 (41) [back to overview]Change From Pivotal Phase 3 Study Baseline In NMPP Functional Impairment Score At Week 52
NCT03654274 (41) [back to overview]Change From Pivotal Phase 3 Study Baseline In NMPP Functional Impairment Score At Week 104
NCT03654274 (41) [back to overview]"Percentage Of Participants Who Are Better Or Much Better On The PGIC For NMPP At Week 52"
NCT03654274 (41) [back to overview]"Percentage Of Participants Who Are Better Or Much Better On The PGIC For Dyspareunia At Week 52"
NCT03654274 (41) [back to overview]"Percentage Of Participants Who Are Better Or Much Better On The Patient Global Impression Of Change (PGIC) For Dysmenorrhea At Week 52"
NCT03654274 (41) [back to overview]Change From Pivotal Phase 3 Study Baseline In Predose Serum Concentrations Of Estradiol At Week 52
NCT03654274 (41) [back to overview]Change From The Pivotal Phase 3 Study Baseline In Each Of The Non-Pain EHP-30 Domains At Week 104
NCT03654274 (41) [back to overview]Percentage Of Participants Who Have A Reduction Of At Least 20 Points In The EHP-30 Pain Domain Scores From The Pivotal Phase 3 Study Baseline At Week 104
NCT03654274 (41) [back to overview]Percentage Of Participants Who Have A Reduction Of At Least 20 Points In The EHP-30 Pain Domain Scores From The Pivotal Phase 3 Study Baseline At Week 52
NCT03654274 (41) [back to overview]Percentage Of Participants Who Meet The Dysmenorrhea Responder Criteria At Week 104
NCT03654274 (41) [back to overview]Change From The Pivotal Phase 3 Study Baseline In Function Impairment On The PGA For Function At Week 104
NCT03654274 (41) [back to overview]Percentage Of Participants Who Meet The Dysmenorrhea Responder Criteria At Week 52
NCT03654274 (41) [back to overview]Percentage Of Participants Who Meet The NMPP Responder Criteria At Week 104
NCT03654274 (41) [back to overview]Percentage Of Participants Who Meet The NMPP Responder Criteria At Week 52
NCT03654274 (41) [back to overview]Change From The Pivotal Phase 3 Study Baseline In Dysmenorrhea Functional Impairment Score At Week 104
NCT03654274 (41) [back to overview]Change From The Pivotal Phase 3 Study Baseline In Dysmenorrhea Functional Impairment Score At Week 52
NCT03654274 (41) [back to overview]Change From The Pivotal Phase 3 Study Baseline In The Mean Dysmenorrhea NRS Score At Week 104
NCT03654274 (41) [back to overview]Change From The Pivotal Phase 3 Study Baseline In Function Impairment On The PGA For Function At Week 52
NCT03654274 (41) [back to overview]Change From The Pivotal Phase 3 Study Baseline In Severity Scores On The Patient Global Assessment (PGA) For Overall Pelvic Pain At Week 104
NCT03654274 (41) [back to overview]Change From The Pivotal Phase 3 Study Baseline In Severity Scores On The Patient Global Assessment (PGA) For Overall Pelvic Pain At Week 52
NCT03654274 (41) [back to overview]Change From The Pivotal Phase 3 Study Baseline In The Endometriosis Health Profile (EHP)-30 Pain Domain Scores At Week 104
NCT03654274 (41) [back to overview]Change From The Pivotal Phase 3 Study Baseline In The Endometriosis Health Profile (EHP)-30 Pain Domain Scores At Week 52
NCT03654274 (41) [back to overview]Change From The Pivotal Phase 3 Study Baseline In The Mean Dysmenorrhea NRS Score At Week 52
NCT03654274 (41) [back to overview]Change From The Pivotal Phase 3 Study Baseline In The Mean Dyspareunia Functional Impairment At Week 104
NCT03654274 (41) [back to overview]Change From The Pivotal Phase 3 Study Baseline In The Mean Dyspareunia Functional Impairment At Week 52
NCT03654274 (41) [back to overview]Change From The Pivotal Phase 3 Study Baseline In The Mean Dyspareunia NRS Scores At Week 104
NCT03654274 (41) [back to overview]Change From The Pivotal Phase 3 Study Baseline In The Mean Dyspareunia NRS Scores At Week 52
NCT03654274 (41) [back to overview]Change From The Pivotal Phase 3 Study Baseline In The Mean NMPP NRS Score At Week 104
NCT03654274 (41) [back to overview]Change From The Pivotal Phase 3 Study Baseline In The Mean NMPP NRS Score At Week 52
NCT03654274 (41) [back to overview]Change From The Pivotal Phase 3 Study Baseline In The Mean Overall Pelvic Pain NRS Score At Week 104
NCT03654274 (41) [back to overview]Change From The Pivotal Phase 3 Study Baseline In The Mean Overall Pelvic Pain NRS Score At Week 52
NCT03654274 (41) [back to overview]Percentage Of Participants Not Using Analgesics For Endometriosis-associated Pain At Week 104
NCT03654274 (41) [back to overview]Percentage Of Participants Not Using Opioids For Endometriosis-associated Pain At Week 104
NCT03970330 (7) [back to overview]PGIC Score (Painful Periods)
NCT03970330 (7) [back to overview]Ibuprofen Use
NCT03970330 (7) [back to overview]Oxycodone Use
NCT03970330 (7) [back to overview]EHP-30 Score
NCT03970330 (7) [back to overview]PGIC Score (Dyspareunia)
NCT03970330 (7) [back to overview]PGIC Score (Nonmenstrual Pelvic Pain)
NCT03970330 (7) [back to overview]Pain Score Area Under the Curve (AUC)

Total Number of Bleeding Days Per Cycle, Cycle 6, MITT Population

(NCT00391807)
Timeframe: 6 cycles, 28 days each (168 days)

InterventionDays (Mean)
Norethindrone/Ethinyl Estradiol3.00

[back to top]

Median Duration of Withdrawal Bleeding, Cycle 12, MITT Population

(NCT00391807)
Timeframe: 12 cycles, 28 days each (336 days)

InterventionDays (Median)
Norethindrone/Ethinyl Estradiol3.85

[back to top]

Percentage of Subjects With Withdrawal Bleeding (%), Cycle 2, MITT Population

(NCT00391807)
Timeframe: 2 cycles, 28 days each (56 days)

InterventionPercentage of Participants (Number)
Norethindrone/Ethinyl Estradiol34.8

[back to top]

Percentage of Subjects With Amenorrhea, Cycle 2, MITT Population

(NCT00391807)
Timeframe: 2 cycles, 28 days each (56 days)

InterventionPercentage of Participants (Number)
Norethindrone/Ethinyl Estradiol30.7

[back to top]

Percentage of Subjects With Withdrawal Bleeding (%), Cycle 6, MITT Population

(NCT00391807)
Timeframe: 6 cycles, 28 days each (168 days)

InterventionPercentage of Participants (Number)
Norethindrone/Ethinyl Estradiol25.0

[back to top]

Percentage of Subjects With Withdrawal Bleeding (%), Cycle 13, MITT Population

(NCT00391807)
Timeframe: 13 cycles, 28 days each (1 year)

InterventionPercentage of Participants (Number)
Norethindrone/Ethinyl Estradiol22.4

[back to top]

Percentage of Subjects With Amenorrhea, Cycle 6, MITT Population

(NCT00391807)
Timeframe: 6 cycles, 28 days each (168 days)

InterventionPercentage of Participants (Number)
Norethindrone/Ethinyl Estradiol42.9

[back to top]

Percentage of Subjects With Amenorrhea, Cycle 13, MITT Population

(NCT00391807)
Timeframe: 13 cycles, 28 days each (1 year)

InterventionPercentage of Participants (Number)
Norethindrone/Ethinyl Estradiol49.1

[back to top]

Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 6, MITT Population

MITT Population (NCT00391807)
Timeframe: 6 cycles, 28 days each (168 days)

InterventionBleeding/Spotting Days (Mean)
Norethindrone/Ethinyl Estradiol2.00

[back to top]

Median Duration of Withdrawal Bleeding, Cycle 2, MITT Population

(NCT00391807)
Timeframe: 2 cycles, 28 days each (56 days)

InterventionDays (Median)
Norethindrone/Ethinyl Estradiol3.93

[back to top]

Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 2, MITT Population

MITT Population (NCT00391807)
Timeframe: 2 Cycles, 28 days each (56 days)

InterventionBleeding/Spotting Days (Mean)
Norethindrone/Ethinyl Estradiol3.21

[back to top]

Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 13, MITT Population

MITT Population (NCT00391807)
Timeframe: 13 cycles, 28 days each (1 year)

InterventionBleeding/Spotting Days (Mean)
Norethindrone/Ethinyl Estradiol1.81

[back to top]

Median Duration of Withdrawal Bleeding, Cycle 6, MITT Population

(NCT00391807)
Timeframe: 6 cycles, 28 days each (168 days)

InterventionDays (Median)
Norethindrone/Ethinyl Estradiol3.99

[back to top]

Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18 to 35, MITT Population,

(NCT00391807)
Timeframe: 13 cycles, 28 days each (1 year)

InterventionPregnancy Rate (Number)
Norethindrone/Ethinyl Estradiol2.554

[back to top]

Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18-45, MITT Population

(NCT00391807)
Timeframe: 13 Cycles, 28 days each (1 year)

InterventionPregnancy Rate (Number)
Norethindrone/Ethinyl Estradiol2.167

[back to top]

Total Number of Bleeding Days Per Cycle, Cycle 13, MITT Population

(NCT00391807)
Timeframe: 13 cycles, 28 days each (1 year)

InterventionDays (Mean)
Norethindrone/Ethinyl Estradiol3.36

[back to top]

Total Number of Bleeding Days Per Cycle, Cycle 2, MITT Population

(NCT00391807)
Timeframe: 2 cycles, 28 days each (56 days)

InterventionDays (Mean)
Norethindrone/Ethinyl Estradiol4.57

[back to top]

Bone Mineral Density

Adjusted mean change in total body areal bone mineral density (aBMD) over the 12 month trial (NCT00474851)
Timeframe: Baseline to 12 months

Interventiong/cm^2 (Mean)
Intervention Group0.01
Placebo Group-0.11

[back to top]

Total Body Bone Mineral Content (BMC)

(NCT00474851)
Timeframe: Baseline to 12 months

Interventiong (Mean)
Intervention Group37
Placebo Group15

[back to top]

Pearl Index, 18-35 Years, MITT Population

Pregnancy rate in women 18-35 years old, Pearl Index - number of pregnancies per 100 women-years of treatment (NCT00477633)
Timeframe: 13 cycles (28 days each), approximately 364 days

InterventionPearl Index (Number)
Norethindrone/Ethinyl Estradiol Tablets1.903

[back to top]

Mean Median Duration (Days) of Intracyclic Bleeding & Spotting, Cycles 2-13, MITT Population

"Each IB episode has a unique duration, with 0, 1, 2, 3 or more episodes per cycle. To obtain mean median duration of episodes during a cycle, take the median duration of all episodes in each cycle. If there are no episodes in the cycle, then median duration is undefined/missing for that cycle. 1 episode - median duration = duration of that episode, 2 episodes - median duration = average of 2 durations, more than 2 episodes, calculated in usual way for median of an ordered set of numbers. Once median determined for each cycle/subject, the mean & SD of those quantities calculated." (NCT00477633)
Timeframe: 12 cycles (28 days each), approximately 336 days

InterventionDays (Mean)
Norethindrone/Ethinyl Estradiol Tablets3.52

[back to top]

Mean Number of Days of Intracyclic Bleeding & Spotting, Cycles 2-13, MITT Population

(NCT00477633)
Timeframe: 12 cycles (28 days each), approximately 336 days

InterventionDays (Mean)
Norethindrone/Ethinyl Estradiol Tablets1.19

[back to top]

Mean Number of Intracyclic Bleeding (IB)/Spotting Days in Cycles 2-6, MITT Population

Self-reported via patient completed diary (none - no vaginal bleeding, light - less than normal menstruation, normal - like normal menstruation, heavy - more than normal menstruation) along with daily use of sanitary protection (other than panty liners). Light bleeding requiring no more than single pad or tampon will be spotting. (NCT00932321)
Timeframe: 5.6 months (6 - 28 day cycles)

InterventionDays (Mean)
24 Day NA/EE6.31
21 Day NA/EE7.31

[back to top]

Pregnancy Rate (Expressed as Pearl Index) for Women 18 to 45 Years Old, MITT Population

Pearl Index = 1300 * number of pregnancies/number of women-cycles of treatment (NCT00932321)
Timeframe: 5.6 months (6 - 28 day cycles)

InterventionPearl Index (Number)
24 Day NA/EE1.823
21 Day NA/EE2.978

[back to top]

Maximum Plasma Concentration of Ethinyl Estradiol With Colchicine at Steady State (Cmax, ss)

The maximum or peak concentration that Ethinyl Estradiol with Colchicine reaches in the plasma at steady state. Steady state refers to the point that constant concentration of drug is achieved subsequent to administration of constant doses of that drug given at constant intervals. (NCT01040845)
Timeframe: Day 21 of each cycle - plasma concentrations were drawn prior to the morning dose (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 (prior to pm colchicine/placebo dose), and 24 hours post-dose.

Interventionng/mL (Mean)
Ethinyl Estradiol With Colchicine0.14

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] Ethinyl Estradiol With Colchicine

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule. (NCT01040845)
Timeframe: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.33, 3.67, 4, 4.5, 5, 5.5, 6, 7, 8, 10, 14, 18, 24, 36, and 48 hours after drug administration.

Interventionng/mL (Mean)
Ethinyl Estradiol With Colchicine1.24

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Norethindrone With Colchicine

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule. (NCT01040845)
Timeframe: Day 21 of each cycle - plasma concentrations were drawn prior to the morning dose (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 (prior to pm colchicine/placebo dose), and 24 hours post-dose.

Interventionng-hr/mL (Mean)
Norethindrone With Colchicine175.57

[back to top]

Maximum Plasma Concentration of Colchicine With Norethindrone/Ethinyl Estradiol at Steady State (Cmax, ss)

The maximum or peak concentration that Colchicine with Norethindrone/Ethinyl Estradiol reaches in the plasma at steady state. Steady state refers to the point that constant concentration of drug is achieved subsequent to administration of constant doses of that drug given at constant intervals (NCT01040845)
Timeframe: Day 21 of each cycle - plasma concentrations were drawn prior to the morning dose (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 (prior to pm colchicine/placebo dose), and 24 hours post-dose

Interventionng/mL (Mean)
Colchicine With Norethindrone/Ethinyl Estradiol3.11

[back to top]

Maximum Plasma Concentration of Norethindrone With Placebo at Steady State (Cmax, ss)

The maximum or peak concentration that Norethindrone with Placebo reaches in the plasma at steady state. Steady state refers to the point that constant concentration of drug is achieved subsequent to administration of constant doses of that drug given at constant intervals. (NCT01040845)
Timeframe: Day 21 of each cycle - plasma concentrations were drawn prior to the morning dose (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 (prior to pm colchicine/placebo dose), and 24 hours post-dose.

Interventionng/mL (Mean)
Norethindrone With Placebo24.42

[back to top]

Maximum Plasma Concentration of Norethindrone With Colchicine at Steady State (Cmax, ss)

The maximum or peak concentration that Norethindrone with Colchicine reaches in the plasma at steady state. Steady state refers to the point that constant concentration of drug is achieved subsequent to administration of constant doses of that drug given at constant intervals. (NCT01040845)
Timeframe: Day 21 of each cycle - plasma concentrations were drawn prior to the morning dose (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 (prior to pm colchicine/placebo dose), and 24 hours post-dose.

Interventionng/mL (Mean)
Norethindrone With Colchicine24.17

[back to top]

Maximum Plasma Concentration of Ethinyl Estradiol With Placebo at Steady State (Cmax, ss)

The maximum or peak concentration that Ethinyl Estradiol with Placebo reaches in the plasma at steady state. Steady state refers to the point that constant concentration of drug is achieved subsequent to administration of constant doses of that drug given at constant intervals. (NCT01040845)
Timeframe: Day 21 of each cycle - plasma concentrations were drawn prior to the morning dose (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 (prior to pm colchicine/placebo dose), and 24 hours post-dose.

Interventionng/mL (Mean)
Ethinyl Estradiol With Placebo0.15

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Norethindrone With Placebo

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule. (NCT01040845)
Timeframe: Day 21 of each cycle - plasma concentrations were drawn prior to the morning dose (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 (prior to pm colchicine/placebo dose), and 24 hours post-dose.

Interventionng/mL (Mean)
Norethindrone With Placebo178.08

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Ethinyl Estradiol With Placebo

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule. (NCT01040845)
Timeframe: Day 21 of each cycle - plasma concentrations were drawn prior to the morning dose (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 (prior to pm colchicine/placebo dose), and 24 hours post-dose.

Interventionng/mL (Mean)
Ethinyl Estradiol With Placebo1.29

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Colchicine With Norethindrone/Ethinyl Estradiol

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule. (NCT01040845)
Timeframe: Day 21 of each cycle - plasma concentrations were drawn prior to the morning dose (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 (prior to pm colchicine/placebo dose), and 24 hours post-dose

Interventionng/mL (Mean)
Colchicine With Norethindrone/Ethinyl Estradiol18.40

[back to top]

Cmax for Norethindrone(Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Norethindrone Cmax. (NCT01157182)
Timeframe: Blood samples collected over a 36 hour period.

Interventionng/mL (Mean)
Estradiol/Norethindrone Acetate (Test)10.08
Activella® (Reference)9.90

[back to top]

Cmax for Uncorrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)

Informational comparison of Cmax values for Uncorrected Total Estrone. (NCT01157182)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg/mL (Mean)
Estradiol/Norethindrone Acetate (Test)43723.53
Activella® (Reference)47170.59

[back to top]

Cmax for Uncorrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)

Informational comparison of Cmax values for Uncorrected Unconjugated Estradiol. (NCT01157182)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg/mL (Mean)
Estradiol/Norethindrone Acetate (Test)52.09
Activella® (Reference)56.26

[back to top]

Cmax for Uncorrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)

Informational comparison of Cmax values for Uncorrected Unconjugated Estrone. (NCT01157182)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg/mL (Mean)
Estradiol/Norethindrone Acetate (Test)475.44
Activella® (Reference)502.24

[back to top]

AUC0-inf for Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

Informational comparison of AUC0-inf values for Uncorrected Total Estrone. (NCT01157182)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)387085.29
Activella® (Reference)400726.94

[back to top]

Cmax for Corrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Corrected Total Estrone Cmax. (NCT01157182)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg/mL (Mean)
Estradiol/Norethindrone Acetate (Test)43997.17
Activella® (Reference)47015.47

[back to top]

AUC0-t for Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Informational comparison of AUC0-t values for Uncorrected Unconjugated Estrone. (NCT01157182)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)10870.03
Activella® (Reference)11252.64

[back to top]

AUC0-t for Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Informational comparison of AUC0-t values for Corrected Unconjugated Estrone. (NCT01157182)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)9409.59
Activella® (Reference)9762.49

[back to top]

AUC0-t for Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Informational comparison of AUC0-t values for Uncorrected Unconjugated Estradiol. (NCT01157182)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)1575.01
Activella® (Reference)1656.16

[back to top]

AUC0-t for Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Informational comparison of AUC0-t values for Uncorrected Total Estrone. (NCT01157182)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)372088.37
Activella® (Reference)385829.05

[back to top]

AUC0-t for Norethindrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on Norethindrone AUC0-t. (NCT01157182)
Timeframe: Blood samples collected over a 36 hour period.

Interventionng*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)36.59
Activella® (Reference)37.05

[back to top]

AUC0-t for Corrected Unconjugated Estradiol.(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Informational comparison of AUC0-t values for Corrected Unconjugated Estradiol. (NCT01157182)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)1267.50
Activella® (Reference)1323.70

[back to top]

AUC0-t for Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on Corrected Total Estrone AUC0-t. (NCT01157182)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)365242.88
Activella® (Reference)374730.12

[back to top]

AUC0-inf for Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

Informational comparison of AUC0-inf values for Uncorrected Unconjugated Estrone. (NCT01157182)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)12387.14
Activella® (Reference)12646.49

[back to top]

AUC0-inf for Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)

Informational comparison of AUC0-inf values for Uncorrected Unconjugated Estradiol. (NCT01157182)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)1739.31
Activella® (Reference)1905.28

[back to top]

AUC0-inf for Norethindrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on Norethindrone AUC0-inf. (NCT01157182)
Timeframe: Blood samples collected over a 36 hour period.

Interventionng*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)39.94
Activella® (Reference)40.40

[back to top]

AUC0-inf for Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

Informational comparison of AUC0-inf values for Corrected Unconjugated Estrone. (NCT01157182)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)10267.03
Activella® (Reference)10214.23

[back to top]

AUC0-inf for Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)

Informational comparison of AUC0-inf values for Corrected Unconjugated Estradiol. (NCT01157182)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)1359.50
Activella® (Reference)1410.51

[back to top]

AUC0-inf for Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on Corrected Total Estrone AUC0-inf. (NCT01157182)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)375439.71
Activella® (Reference)384535.16

[back to top]

Cmax for Corrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)

Informational comparison of Cmax values for Corrected Unconjugated Estradiol. (NCT01157182)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg/mL (Mean)
Estradiol/Norethindrone Acetate (Test)47.80
Activella® (Reference)51.59

[back to top]

Cmax for Corrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)

Informational comparison of Cmax values for Corrected Unconjugated Estrone. (NCT01157182)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg/mL (Mean)
Estradiol/Norethindrone Acetate (Test)455.16
Activella® (Reference)481.46

[back to top]

AUC0-t of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Informational comparison of AUC0-t values for Uncorrected Unconjugated Estrone. (NCT01181726)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)12444.22
Activella® (Reference)12977.00

[back to top]

AUC0-inf of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)

Informational comparison of AUC0-inf values for Corrected Unconjugated Estradiol. (NCT01181726)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)1823.43
Activella® (Reference)1871.56

[back to top]

AUC0-inf of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)

Informational comparison of AUC0-inf values for Uncorrected Unconjugated Estradiol. (NCT01181726)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)2301.59
Activella® (Reference)2274.04

[back to top]

AUC0-inf of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

Informational comparison of AUC0-inf values for Uncorrected Total Estrone. (NCT01181726)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)398139.63
Activella® (Reference)425739.45

[back to top]

AUC0-inf of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

Informational comparison of AUC0-inf values for Corrected Unconjugated Estrone. (NCT01181726)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)11293.21
Activella® (Reference)11747.97

[back to top]

Cmax of Corrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Corrected Total Estrone Cmax. (NCT01181726)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg/mL (Mean)
Estradiol/Norethindrone Acetate (Test)27076.08
Activella® (Reference)27240.03

[back to top]

AUC0-t of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Informational comparison of AUC0-t values for Uncorrected Total Estrone. (NCT01181726)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)397537.88
Activella® (Reference)420763.02

[back to top]

AUC0-t of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on Norethindrone AUC0-t. (NCT01181726)
Timeframe: Blood samples collected over a 36 hour period.

Interventionng*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)45.03
Activella® (Reference)46.13

[back to top]

Cmax of Corrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)

Informational comparison of Cmax values for Corrected Unconjugated Estradiol. (NCT01181726)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg/mL (Mean)
Estradiol/Norethindrone Acetate (Test)55.18
Activella® (Reference)56.24

[back to top]

Cmax of Corrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)

Informational comparison of Cmax values for Corrected Unconjugated Estrone. (NCT01181726)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg/mL (Mean)
Estradiol/Norethindrone Acetate (Test)492.81
Activella® (Reference)509.81

[back to top]

Cmax of Norethindrone (Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Norethindrone Cmax. (NCT01181726)
Timeframe: Blood samples collected over a 36 hour period.

Interventionng/mL (Mean)
Estradiol/Norethindrone Acetate (Test)6.54
Activella® (Reference)6.06

[back to top]

AUC0-inf of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on Corrected Total Estrone AUC0-inf. (NCT01181726)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)380131.12
Activella® (Reference)424801.99

[back to top]

Cmax of Uncorrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)

Informational comparison of Cmax values for Uncorrected Total Estrone. (NCT01181726)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg/mL (Mean)
Estradiol/Norethindrone Acetate (Test)27256.41
Activella® (Reference)27430.77

[back to top]

Cmax of Uncorrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)

Informational comparison of Cmax values for Uncorrected Unconjugated Estradiol. (NCT01181726)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg/mL (Mean)
Estradiol/Norethindrone Acetate (Test)59.24
Activella® (Reference)60.33

[back to top]

AUC0-t of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Informational comparison of AUC0-t values for Corrected Unconjugated Estrone. (NCT01181726)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)10952.25
Activella® (Reference)11369.60

[back to top]

Cmax of Uncorrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)

Informational comparison of Cmax values for Uncorrected Unconjugated Estrone. (NCT01181726)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg/mL (Mean)
Estradiol/Norethindrone Acetate (Test)513.56
Activella® (Reference)529.23

[back to top]

AUC0-t of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Informational comparison of AUC0-t values for Corrected Unconjugated Estradiol. (NCT01181726)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)1723.44
Activella® (Reference)1793.04

[back to top]

AUC0-t of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on Corrected Total Estrone AUC0-t. (NCT01181726)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)384547.68
Activella® (Reference)407028.98

[back to top]

AUC0-inf of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

Informational comparison of AUC0-inf values for Uncorrected Unconjugated Estrone. (NCT01181726)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)13592.44
Activella® (Reference)14155.46

[back to top]

AUC0-t of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Informational comparison of AUC0-t values for Uncorrected Unconjugated Estradiol. (NCT01181726)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)2016.26
Activella® (Reference)2086.39

[back to top]

AUC0-inf of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on Norethindrone AUC0-inf. (NCT01181726)
Timeframe: Blood samples collected over a 36 hour period.

Interventionng*h/mL (Mean)
Estradiol/Norethindrone Acetate (Test)49.55
Activella® (Reference)50.68

[back to top]

Geometric Mean Ratio of the Area Under the Plasma Concentration-time Curve From 0 to Infinity (AUC[0-inf]) of Ethinyl Estradiol and Norethindrone

On Days 1 and 8, blood samples were taken prior to the administration of the contraceptive norethindrone 1 mg/ethinyl estradiol 35 µg (Ortho-Novum 1/35®) and 30 minutes, and 1, 2, 3, 4, and 6 hours, between 8 and 12 hours, and 24 hours post-dose. Plasma concentrations of ethinyl estradiol and norethindrone were determined using a validated liquid chromatography mass spectrometry/mass spectrometry (LC MS/MS) assay. Individual and mean plasma ethinyl estradiol and norethindrone concentration versus time data were tabulated and plotted by analyte. The pharmacokinetic parameters of each analyte were calculated using standard non-compartmental methods (WinNonlin version 5.2.1, Pharsight Corp., Mountain View, CA). The geometric mean ratios of AUC(0-inf) of ethinyl estradiol and norethindrone were defined as the ratios of AUC(0-inf) of ethinyl estradiol and norethindrone on Day 8 divided by AUC(0-inf) of ethinyl estradiol and norethindrone on Day 1, respectively. (NCT01209143)
Timeframe: Pre-dose and 30 minutes, and 1, 2, 3, 4, and 6 hours, between 8 and 12 hours, and 24 hours post-dose

Interventionng/mL*hr (Number)
Ethinyl estradiolNorethindrone
Vismodegib + Oral Contraceptive99.6123

[back to top]

Geometric Mean Ratio of the Maximum Plasma Concentration (Cmax) of Rosiglitazone

On Days 1 and 8, blood samples were taken prior to the administration of rosiglitazone and 30 minutes, and 1, 2, 3, 4, and 6 hours, between 8 and 12 hours, and 24 hours post-dose. Plasma concentrations of rosiglitazone were determined using a validated liquid chromatography mass spectrometry/mass spectrometry (LC MS/MS) assay. Individual and mean plasma rosiglitazone concentration versus time data were tabulated and plotted by analyte. The pharmacokinetic parameters of each analyte were calculated using standard non-compartmental methods (WinNonlin version 5.2.1, Pharsight Corp., Mountain View, CA). The geometric mean ratio of Cmax of rosiglitazone was defined as the Cmax of rosiglitazone on Day 8/ Cmax of rosiglitazone on Day 1. (NCT01209143)
Timeframe: Pre-dose and 30 minutes, and 1, 2, 3, 4, and 6 hours, between 8 and 12 hours, and 24 hours post-dose

Interventionng/mL (Number)
Vismodegib + Rosiglitazone93.1

[back to top]

Geometric Mean Ratio of the Area Under the Plasma Concentration-time Curve From 0 to Infinity (AUC[0-inf]) of Rosiglitazone

On Days 1 and 8, blood samples were taken prior to the administration of rosiglitazone and 30 minutes, and 1, 2, 3, 4, and 6 hours, between 8 and 12 hours, and 24 hours post-dose. Plasma concentrations of rosiglitazone were determined using a validated liquid chromatography mass spectrometry/mass spectrometry (LC MS/MS) assay. Individual and mean plasma rosiglitazone concentration versus time data were tabulated and plotted by analyte. The pharmacokinetic parameters of each analyte were calculated using standard non-compartmental methods (WinNonlin version 5.2.1, Pharsight Corp., Mountain View, CA). The geometric mean ratio of AUC(0-inf) of rosiglitazone was defined as the AUC(0-inf) of rosiglitazone on Day 8/AUC(0-inf) of rosiglitazone on Day 1. (NCT01209143)
Timeframe: Pre-dose and 30 minutes, and 1, 2, 3, 4, and 6 hours, between 8 and 12 hours, and 24 hours post-dose

Interventionng/mL*hr (Number)
Vismodegib + Rosiglitazone92.0

[back to top]

Geometric Mean Ratio of the Maximum Plasma Concentration (Cmax) of Ethinyl Estradiol and Norethindrone

On Days 1 and 8, blood samples were taken prior to the administration of the contraceptive norethindrone 1 mg/ethinyl estradiol 35 µg (Ortho-Novum 1/35®) and 30 minutes, and 1, 2, 3, 4, and 6 hours, between 8 and 12 hours, and 24 hours post-dose. Plasma concentrations of ethinyl estradiol and norethindrone were determined using a validated liquid chromatography mass spectrometry/mass spectrometry (LC MS/MS) assay. Individual and mean plasma ethinyl estradiol and norethindrone concentration versus time data were tabulated and plotted by analyte. The pharmacokinetic parameters of each analyte were calculated using standard non-compartmental methods (WinNonlin version 5.2.1, Pharsight Corp., Mountain View, CA). The geometric mean ratios of Cmax of ethinyl estradiol and norethindrone were defined as the ratios of Cmax of ethinyl estradiol and norethindrone on Day 8 divided by Cmax of ethinyl estradiol and norethindrone on Day 1, respectively. (NCT01209143)
Timeframe: Pre-dose and 30 minutes, and 1, 2, 3, 4, and 6 hours, between 8 and 12 hours, and 24 hours post-dose

Interventionng/mL (Number)
Ethinyl estradiolNorethindrone
Vismodegib + Oral Contraceptive105112

[back to top]

Area Under the Plasma Concentration Versus Time Curve (AUC) on Norethisterone of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of area under the plasma concentration versus time curve (AUC) of norethisterone that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionng・hr/mL (Mean)
NPC-0169.183

[back to top]

Elimination Rate Constant (Kel) on Ethinyl Estradiol of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of elimination rate constant (kel) of ethinyl estradiol that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionhr^-1 (Mean)
NPC-010.141

[back to top]

Elimination Rate Constant (Kel) on Norethisterone of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of elimination rate constant (kel) of norethisterone that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionhr^-1 (Mean)
NPC-010.101

[back to top]

Mean Residence Time (MRT) on Ethinyl Estradiol of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of mean residence time (MRT) of ethinyl estradiol that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionhours (Mean)
NPC-015.161

[back to top]

Mean Residence Time (MRT) on Norethisterone of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of mean residence time (MRT) of norethisterone that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionhours (Mean)
NPC-016.340

[back to top]

Peak Plasma Concentration (Cmax) on Ethinyl Estradiol of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of peak plasma concentration (Cmax) of ethinyl estradiol that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionpg/mL (Mean)
NPC-0155.783

[back to top]

Peak Plasma Concentration (Cmax) on Norethisterone of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of peak plasma concentration (Cmax) of norethisterone that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionng/mL (Mean)
NPC-0112.481

[back to top]

Time to Peak Plasma Concentration (Tmax) on Norethisterone of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of time to peak plasma concentration (Tmax) of norethisterone that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionhours (Mean)
NPC-011.81

[back to top]

Plasma Half Life (t1/2) on Ethinyl Estradiol of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of plasma Half life (t1/2) of ethinyl estradiol that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionhours (Mean)
NPC-015.499

[back to top]

Plasma Half Life (t1/2) on Norethisterone of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of plasma Half life (t1/2) of norethisterone that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionhours (Mean)
NPC-017.357

[back to top]

Time to Peak Plasma Concentration (Tmax) on Ethinyl Estradiol of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of time to peak plasma concentration (Tmax) of ethinyl estradiol that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionhours (Mean)
NPC-011.50

[back to top]

Area Under the Plasma Concentration Versus Time Curve (AUC) on Ethinyl Estradiol of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of area under the plasma concentration versus time curve (AUC) of ethinyl estradiol that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionpg・hr/mL (Mean)
NPC-01368.123

[back to top]

Comparing Progesterone AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))

Progesterone was measured on day 3, 6, 9, 12, 15, 18, 21, 24 on 3 consecutive menstrual period (pre administration/Baseline(BL), study drug administration(SDA), post administration/follow up(FU)) and calculated AUC from these data (NCT01253824)
Timeframe: Day 3, 6, 9, 12, 15, 18, 21, 24 of menstrual cycles

,
Interventionng・day/mL (Mean)
Difference of progesterone(BL-SDA)Difference of progesterone(FU-SDA)
IKH-0193.14859.344
NPC-0154.17189.711

[back to top]

Comparing Estradiol AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))

Estradiol was measured on day 3, 6, 9, 12, 15, 18, 21, 24 on 3 consecutive menstrual period (pre administration/Baseline(BL), study drug administration(SDA), post administration/follow up(FU)) and calculated AUC from these data (NCT01253824)
Timeframe: Day 3, 6, 9, 12, 15, 18, 21, 24 of menstrual cycles

,
Interventionpg・day/mL, (Mean)
Difference of estradiol AUC (BL-SDA)Difference of estradiol AUC(FU-SDA)
IKH-012478.02434.9
NPC-011654.71872.6

[back to top]

Comparing FSH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))

FSH was measured on day 3, 6, 9, 12, 15, 18, 21, 24 on 3 consecutive menstrual period (pre administration/Baseline(BL), study drug administration(SDA), post administration/follow up(FU)) and calculated AUC from these data (NCT01253824)
Timeframe: Day 3, 6, 9, 12, 15, 18, 21, 24 of menstrual cycles

,
InterventionmIU・day/mL (Mean)
Differnce of FSH (BL-SDA)Difference of FSH(FP-SDA)
IKH-01-4.3800.538
NPC-01-9.609-4.404

[back to top]

Comparing LH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))

LH was measured on day 3, 6, 9, 12, 15, 18, 21, 24 on 3 consecutive menstrual period (pre administration/Baseline(BL), study drug administration(SDA), post administration/follow up(FU)) and calculated AUC from these data (NCT01253824)
Timeframe: Day 3, 6, 9, 12, 15, 18, 21, 24 of menstrual cycles

,
InterventionmIU・day/mL (Mean)
Difference of LH(BL-SDA)Difference of LH(FU-SDA)
IKH-0157.12459.837
NPC-0160.87461.571

[back to top]

Cmax of Norethindrone

Bioequivalence based on Norethindrone Cmax (maximum observed concentration of drug substance in plasma). (NCT01340625)
Timeframe: Blood samples collected over a 60 hour period.

Interventionng/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)10.94
Ovcon® 35 Fe (Reference)10.00

[back to top]

Cmax of Ethinyl Estradiol

Bioequivalence based on Ethinyl Estradiol Cmax (maximum observed concentration of drug substance in plasma). (NCT01340625)
Timeframe: Blood samples collected over a 60 hour period.

Interventionpg/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)230.56
Ovcon® 35 Fe (Reference)237.00

[back to top]

AUC0-t of Norethindrone

Bioequivalence based on Norethindrone AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration). (NCT01340625)
Timeframe: Blood samples collected over a 60 hour period.

Interventionng*h/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)43.83
Ovcon® 35 Fe (Reference)40.73

[back to top]

AUC0-t of Ethinyl Estradiol

Bioequivalence based on Ethinyl Estradiol AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration). (NCT01340625)
Timeframe: Blood samples collected over a 60 hour period.

Interventionpg*h/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)1976.72
Ovcon® 35 Fe (Reference)1989.82

[back to top]

AUC0-inf of Norethindrone

Bioequivalence based on Norethindrone AUC0-inf (area under the concentration-time curve from time zero to infinity). (NCT01340625)
Timeframe: Blood samples collected over a 60 hour period.

Interventionng*h/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)48.67
Ovcon® 35 Fe (Reference)45.43

[back to top]

AUC0-inf of Ethinyl Estradiol

Bioequivalence based on Ethinyl Estradiol AUC0-inf (area under the concentration-time curve from time zero to infinity). (NCT01340625)
Timeframe: Blood samples collected over a 60 hour period.

Interventionpg*h/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)2129.43
Ovcon® 35 Fe (Reference)2131.84

[back to top]

Cmax of Norethindrone

Bioequivalence based on Norethindrone Cmax (maximum observed concentration of drug substance in plasma). (NCT01344369)
Timeframe: Blood samples collected over a 60 hour period.

Interventionng/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)4.3306
FEMCON® Fe (Reference)4.2282

[back to top]

AUC0-inf of Ethinyl Estradiol

Bioequivalence based on Ethinyl Estradiol AUC0-inf (area under the concentration-time curve from time zero to infinity). (NCT01344369)
Timeframe: Blood samples collected over a 60 hour period.

Interventionpg*h/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)2072.5423
FEMCON® Fe (Reference)2152.3775

[back to top]

AUC0-inf of Norethindrone

Bioequivalence based on Norethindrone AUC0-inf (area under the concentration-time curve from time zero to infinity). (NCT01344369)
Timeframe: Blood samples collected over a 60 hour period.

Interventionng*h/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)43.9982
FEMCON® Fe (Reference)43.8819

[back to top]

AUC0-t of Ethinyl Estradiol

Bioequivalence based on Ethinyl Estradiol AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration). (NCT01344369)
Timeframe: Blood samples collected over a 60 hour period.

Interventionpg*h/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)1916.2311
FEMCON® Fe (Reference)1987.6311

[back to top]

AUC0-t of Norethindrone

Bioequivalence based on Norethindrone AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration). (NCT01344369)
Timeframe: Blood samples collected over a 60 hour period.

Interventionng*h/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)37.8065
FEMCON® Fe (Reference)37.3991

[back to top]

Cmax of Ethinyl Estradiol

Bioequivalence based on Ethinyl Estradiol Cmax (maximum observed concentration of drug substance in plasma). (NCT01344369)
Timeframe: Blood samples collected over a 60 hour period.

Interventionpg/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)137.6758
FEMCON® Fe (Reference)137.8485

[back to top]

Percentage of Participants With ≥ 25% Reduction in Uterine Volume at Month 3 / Final Visit

Uterine volume was determined using transabdominal ultrasound. The images were analyzed by a central imaging center. (NCT01441635)
Timeframe: Baseline and month 3 or the final visit during the treatment period for participants who prematurely discontinued.

Interventionpercentage of participants (Number)
Cohort 4 Elagolix 400 mg QD53
Cohort 4 Elagolix 100 mg BID43
Cohort 4 Placebo7
Cohort 1 Elagolix 200 mg BID48
Cohort 1 Placebo11
Cohort 3 Elagolix 200 mg BID + LD E2/NETA42
Cohort 5 Elagolix 600 mg QD56
Cohort 2 Elagolix 300 mg BID69
Cohort 2 Placebo7
Cohort 6 Elagolix 300 mg BID + CEP25

[back to top]

Percent Change From Baseline to the Last 28 Days of Treatment in Menstrual Blood Loss (MBL)

"The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.~Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero." (NCT01441635)
Timeframe: Baseline (last menstrual cycle during the screening period) and the last 28 days of treatment (approximately days 61 to 90)

Interventionpercent change (Mean)
Cohort 4 Elagolix 400 mg QD-83.83
Cohort 4 Elagolix 100 mg BID-71.85
Cohort 4 Placebo-6.98
Cohort 1 Elagolix 200 mg BID-81.03
Cohort 1 Placebo-11.12
Cohort 3 Elagolix 200 mg BID + LD E2/NETA-79.60
Cohort 5 Elagolix 600 mg QD-88.58
Cohort 2 Elagolix 300 mg BID-97.31
Cohort 2 Placebo-42.64
Cohort 6 Elagolix 300 mg BID + CEP-85.39

[back to top]

Percent Change From Baseline to Month 3 in Volume of the Largest Fibroid

The volume of the largest fibroid was determined using transabdominal ultrasound. The images were analyzed by a central imaging center. (NCT01441635)
Timeframe: Baseline and month 3

Interventionpercent change (Mean)
Cohort 4 Elagolix 400 mg QD14.23
Cohort 4 Elagolix 100 mg BID-22.19
Cohort 4 Placebo-7.26
Cohort 1 Elagolix 200 mg BID-38.52
Cohort 1 Placebo-2.05
Cohort 3 Elagolix 200 mg BID + LD E2/NETA-25.77
Cohort 5 Elagolix 600 mg QD-16.60
Cohort 2 Elagolix 300 mg BID-35.79
Cohort 2 Placebo6.70
Cohort 6 Elagolix 300 mg BID + CEP-4.94

[back to top]

Percent Change From Baseline to Month 3 in Uterine Volume

Uterine volume was determined using transabdominal ultrasound. The images were analyzed by a central imaging center. (NCT01441635)
Timeframe: Baseline and month 3

Interventionpercent change (Mean)
Cohort 4 Elagolix 400 mg QD-21.01
Cohort 4 Elagolix 100 mg BID-21.37
Cohort 4 Placebo18.72
Cohort 1 Elagolix 200 mg BID-21.68
Cohort 1 Placebo-8.62
Cohort 3 Elagolix 200 mg BID + LD E2/NETA-17.43
Cohort 5 Elagolix 600 mg QD-27.99
Cohort 2 Elagolix 300 mg BID-33.25
Cohort 2 Placebo-1.92
Cohort 6 Elagolix 300 mg BID + CEP-10.06

[back to top]

Change in Hemoglobin Concentration From Baseline to Month 3

(NCT01441635)
Timeframe: Baseline and Month 3

Interventiong/dL (Mean)
Cohort 4 Elagolix 400 mg QD1.18
Cohort 4 Elagolix 100 mg BID1.30
Cohort 4 Placebo-0.43
Cohort 1 Elagolix 200 mg BID1.13
Cohort 1 Placebo0.28
Cohort 3 Elagolix 200 mg BID + LD E2/NETA0.92
Cohort 5 Elagolix 600 mg QD1.40
Cohort 2 Elagolix 300 mg BID1.19
Cohort 2 Placebo0.31
Cohort 6 Elagolix 300 mg BID + CEP1.54

[back to top]

Change From Baseline to Month 3 in Uterine Bleeding Score

"Participants recorded the previous days' presence and severity of bleeding every morning in an electronic diary (eDiary) according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:~1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.~2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.~3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.~4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.~5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.~6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2." (NCT01441635)
Timeframe: Baseline (average bleeding score over the 30 days prior to first dose) and month 3 (average bleeding score over days 61 to 90)

Interventionunits on a scale (Mean)
Cohort 4 Elagolix 400 mg QD-0.50
Cohort 4 Elagolix 100 mg BID-0.37
Cohort 4 Placebo-0.19
Cohort 1 Elagolix 200 mg BID-0.52
Cohort 1 Placebo-0.22
Cohort 3 Elagolix 200 mg BID + LD E2/NETA-0.24
Cohort 5 Elagolix 600 mg QD-0.44
Cohort 2 Elagolix 300 mg BID-0.53
Cohort 2 Placebo-0.38
Cohort 6 Elagolix 300 mg BID + CEP-0.25

[back to top]

Change From Baseline to Month 3 in Percentage of Days With Moderate to Very Heavy Bleeding

"Participants recorded the previous days' presence and severity of bleeding every morning in an electronic diary (eDiary) according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:~1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.~2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.~3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.~4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.~5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.~6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.~A day with moderate to very heavy bleeding is defined as a days with a bleeding score ≥ 3." (NCT01441635)
Timeframe: Baseline (average bleeding score over the 30 days prior to first dose) and month 3 (average bleeding score over days 61 to 90)

Interventionpercentage of days (Mean)
Cohort 4 Elagolix 400 mg QD-7.22
Cohort 4 Elagolix 100 mg BID-5.00
Cohort 4 Placebo-4.00
Cohort 1 Elagolix 200 mg BID-7.03
Cohort 1 Placebo-3.08
Cohort 3 Elagolix 200 mg BID + LD E2/NETA-7.92
Cohort 5 Elagolix 600 mg QD-6.15
Cohort 2 Elagolix 300 mg BID-8.02
Cohort 2 Placebo-3.31
Cohort 6 Elagolix 300 mg BID + CEP-6.80

[back to top]

Change From Baseline to Month 3 in Percentage of Days With Any Uterine Bleeding

"Participants recorded the previous days' presence and severity of bleeding every morning in an electronic diary (eDiary) according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:~1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.~2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.~3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.~4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.~5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.~6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.~A day with any uterine bleeding is defined as a days with a bleeding score ≥ 1." (NCT01441635)
Timeframe: Baseline (average bleeding score over the 30 days prior to first dose) and month 3 (average bleeding score over days 61 to 90)

Interventionpercentage of days (Mean)
Cohort 4 Elagolix 400 mg QD-15.22
Cohort 4 Elagolix 100 mg BID-11.00
Cohort 4 Placebo-5.78
Cohort 1 Elagolix 200 mg BID-15.82
Cohort 1 Placebo-6.99
Cohort 3 Elagolix 200 mg BID + LD E2/NETA3.63
Cohort 5 Elagolix 600 mg QD-15.38
Cohort 2 Elagolix 300 mg BID-16.91
Cohort 2 Placebo-13.95
Cohort 6 Elagolix 300 mg BID + CEP1.73

[back to top]

Change From Baseline to Month 3 in the Uterine Fibroids Daily Symptom Scale Scores

The uterine fibroid daily symptom scale is self-administered questionnaire, with a scale that ranges from 0 to 10 for the symptoms of pelvic pain, fatigue, and cramping and the impact of uterine fibroids on the subject's daily life, with 0 being the absence of the symptom and 10 being the worst severity of the symptoms or completely preventing the subjects from performing daily activities. Participants self-reported values daily in the e-Diary. (NCT01441635)
Timeframe: Baseline (average score over the 30 days prior to first dose) and month 3 (average score over days 61 to 90)

,,,,,,,,,
Interventionunits on a scale (Mean)
Pelvic painFatigueMenstrual crampingImpact of uterine fibroids
Cohort 1 Elagolix 200 mg BID-0.6-0.6-0.9-1.0
Cohort 1 Placebo-1.4-0.5-1.2-1.0
Cohort 2 Elagolix 300 mg BID-1.0-1.5-1.2-1.3
Cohort 2 Placebo-1.2-0.5-1.0-1.0
Cohort 3 Elagolix 200 mg BID + LD E2/NETA-1.1-1.2-0.9-0.9
Cohort 4 Elagolix 100 mg BID-0.2-0.0-0.7-0.4
Cohort 4 Elagolix 400 mg QD-1.0-0.5-1.2-1.1
Cohort 4 Placebo-0.3-0.6-0.5-0.8
Cohort 5 Elagolix 600 mg QD-0.9-1.0-1.1-1.7
Cohort 6 Elagolix 300 mg BID + CEP-2.4-2.1-1.3-3.1

[back to top]

Percentage of Participants With MBL < 80 mL During the Last 28 Days of Treatment

"The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.~Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero." (NCT01441635)
Timeframe: The last 28 days of treatment (approximately days 61 to 90)

Interventionpercentage of participants (Number)
Cohort 4 Elagolix 400 mg QD84
Cohort 4 Elagolix 100 mg BID74
Cohort 4 Placebo13
Cohort 1 Elagolix 200 mg BID85
Cohort 1 Placebo22
Cohort 3 Elagolix 200 mg BID + LD E2/NETA88
Cohort 5 Elagolix 600 mg QD93
Cohort 2 Elagolix 300 mg BID97
Cohort 2 Placebo47
Cohort 6 Elagolix 300 mg BID + CEP88

[back to top]

Percentage of Participants With MBL < 80 mL and With a ≥ 50% Reduction From Baseline in MBL During the Last 28 Days of Treatment

"The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.~Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero." (NCT01441635)
Timeframe: Baseline (last menstrual cycle during the screening period) and the last 28 days of treatment (approximately days 61 to 90)

Interventionpercentage of participants (Number)
Cohort 4 Elagolix 400 mg QD84
Cohort 4 Elagolix 100 mg BID74
Cohort 4 Placebo13
Cohort 1 Elagolix 200 mg BID85
Cohort 1 Placebo17
Cohort 3 Elagolix 200 mg BID + LD E2/NETA85
Cohort 5 Elagolix 600 mg QD93
Cohort 2 Elagolix 300 mg BID97
Cohort 2 Placebo33
Cohort 6 Elagolix 300 mg BID + CEP85

[back to top]

Percentage of Participants With a ≥ 50% Reduction From Baseline in MBL During the Last 28 Days of Treatment

"The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.~Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero." (NCT01441635)
Timeframe: Baseline (last menstrual cycle during the screening period) and the last 28 days of treatment (approximately days 61 to 90)

Interventionpercentage of participants (Number)
Cohort 4 Elagolix 400 mg QD84
Cohort 4 Elagolix 100 mg BID74
Cohort 4 Placebo13
Cohort 1 Elagolix 200 mg BID91
Cohort 1 Placebo28
Cohort 3 Elagolix 200 mg BID + LD E2/NETA85
Cohort 5 Elagolix 600 mg QD93
Cohort 2 Elagolix 300 mg BID97
Cohort 2 Placebo40
Cohort 6 Elagolix 300 mg BID + CEP88

[back to top]

Percentage of Participants With ≥ 25% Reduction in Volume of Largest Fibroid at Month 3 / Final Visit

The volume of the largest fibroid was determined using transabdominal ultrasound. The images were analyzed by a central imaging center. (NCT01441635)
Timeframe: Baseline and month 3 or the final visit during the treatment period for participants who prematurely discontinued.

Interventionpercentage of participants (Number)
Cohort 4 Elagolix 400 mg QD57
Cohort 4 Elagolix 100 mg BID52
Cohort 4 Placebo33
Cohort 1 Elagolix 200 mg BID68
Cohort 1 Placebo35
Cohort 3 Elagolix 200 mg BID + LD E2/NETA58
Cohort 5 Elagolix 600 mg QD60
Cohort 2 Elagolix 300 mg BID55
Cohort 2 Placebo27
Cohort 6 Elagolix 300 mg BID + CEP48

[back to top]

Change From Baseline to Month 3 in the Physician Surgery Intention Questionnaire (PSIQ) Version 2.0

"The Physician Intention Questionnaire (PSIQ) is a non-validated, exploratory questionnaire intended to evaluate the investigator's intent to recommend surgical procedures if current endometriosis-associated symptoms continued. The scoring scale ranged from 0 (not at all likely to recommend surgery) to 10 (very likely to recommend surgery).~The PSIQ included the 2 following questions:~How likely are you to recommend myomectomy to treat this patient's uterine fibroid if her symptoms continue as they are now?~How likely are you to recommend definitive surgery hysterectomy for this patient if her uterine fibroid symptoms continue as they are now?" (NCT01441635)
Timeframe: Baseline and month 3

,,,,,,,,,
Interventionunits on a scale (Mean)
Likelihood to recommend myomectomyLikelihood to recommend hysterectomy
Cohort 1 Elagolix 200 mg BID-0.8-2.2
Cohort 1 Placebo0.70.4
Cohort 2 Elagolix 300 mg BID-1.2-1.5
Cohort 2 Placebo0.0-0.6
Cohort 3 Elagolix 200 mg BID + LD E2/NETA-0.6-1.4
Cohort 4 Elagolix 100 mg BID-1.3-1.8
Cohort 4 Elagolix 400 mg QD-0.9-0.8
Cohort 4 Placebo-2.7-0.2
Cohort 5 Elagolix 600 mg QD-1.3-2.3
Cohort 6 Elagolix 300 mg BID + CEP0.0-2.8

[back to top]

Change From Baseline to Month 3 in the Subject Surgery Intention Questionnaire (SSIQ) Version 2.0

"The Subject Intention Questionnaire (SSIQ) is a non-validated, exploratory questionnaires intended to evaluate the subject's intent to undergo surgical procedures if current endometriosis-associated symptoms continued. The scoring scale ranged from 0 (not at all likely to consider surgery) to 10 (very likely to consider surgery).~SSIQ included the 2 following questions:~How likely are you to consider having myomectomy surgery to treat your uterine fibroid if your symptoms continue as they are now?~How likely are you to consider hysterectomy surgery if your uterine fibroid symptoms continue as they are now?" (NCT01441635)
Timeframe: Baseline and month 3

,,,,,,,,,
Interventionunits on a scale (Mean)
Likelihood of having myomectomyLikelihood of having hysterectomy
Cohort 1 Elagolix 200 mg BID-1.8-0.8
Cohort 1 Placebo2.3-0.3
Cohort 2 Elagolix 300 mg BID-0.60.2
Cohort 2 Placebo0.40.0
Cohort 3 Elagolix 200 mg BID + LD E2/NETA-1.4-0.7
Cohort 4 Elagolix 100 mg BID-3.1-1.9
Cohort 4 Elagolix 400 mg QD-1.20.0
Cohort 4 Placebo1.02.0
Cohort 5 Elagolix 600 mg QD-1.7-0.8
Cohort 6 Elagolix 300 mg BID + CEP0.1-1.5

[back to top]

Change From Baseline to Month 3 in the Uterine Fibroid Symptom Quality of Life Questionnaire (UFS-QoL)

"The UFS-QoL is a disease-specific, self-administered, validated questionnaire developed to evaluate the symptoms associated with uterine fibroids and their impact on health-related quality of life (HRQL) in women with symptomatic uterine fibroids. The questionnaire consists of 37 questions, divided into 2 parts: 1) an 8-item symptom severity scale and 2) a 29-item HRQL subscale comprising 6 domains (concern, activities, energy/mood, control, self-consiousness, and sexual function), with a 4-week recall. All items are scored on a 5-point scale, ranging from not at all to a very great deal for symptom severity items and none of the time to all of the time for the HRQL items. Symptom severity and HRQL subscale scores were summed and transformed into a 0 to 100 point scale to provide a total score for each of the 2 components.~Lower symptom severity scores indicate better quality of life and higher total HRQL scores indicate better quality of life." (NCT01441635)
Timeframe: Baseline and month 3

,,,,,,,,,
Interventionunits on a scale (Mean)
Symptom severityHRQL total
Cohort 1 Elagolix 200 mg BID-31.636.0
Cohort 1 Placebo-21.418.3
Cohort 2 Elagolix 300 mg BID-44.133.5
Cohort 2 Placebo-12.011.0
Cohort 3 Elagolix 200 mg BID + LD E2/NETA-20.328.6
Cohort 4 Elagolix 100 mg BID-33.229.1
Cohort 4 Elagolix 400 mg QD-39.035.3
Cohort 4 Placebo-19.616.3
Cohort 5 Elagolix 600 mg QD-36.429.9
Cohort 6 Elagolix 300 mg BID + CEP-39.133.1

[back to top]

Mean Change From Baseline to the Last 28 Days of Treatment in Menstrual Blood Loss (MBL)

"The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.~Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero." (NCT01441635)
Timeframe: Baseline (last menstrual cycle during the screening period) and the last 28 days of treatment (approximately days 61 to 90)

,,,,,,,,,
InterventionmL (Mean)
BaselineChange from Baseline
Cohort 1 Elagolix 200 mg BID335.11-272.97
Cohort 1 Placebo251.72-79.00
Cohort 2 Elagolix 300 mg BID206.27-202.57
Cohort 2 Placebo349.17-175.31
Cohort 3 Elagolix 200 mg BID + LD E2/NETA247.70-192.33
Cohort 4 Elagolix 100 mg BID269.36-184.69
Cohort 4 Elagolix 400 mg QD213.70-183.97
Cohort 4 Placebo321.73-10.46
Cohort 5 Elagolix 600 mg QD215.62-189.05
Cohort 6 Elagolix 300 mg BID + CEP257.99-216.15

[back to top]

Percentage of Participants With Any Uterine Bleeding or Moderate to Very Heavy Uterine Bleeding at Month 3

"Participants recorded the previous days' presence and severity of bleeding every morning in an eDiary according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:~1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.~2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.~3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.~4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.~5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.~6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.~Any bleeding is defined as a score ≥ 1 and moderate to very heavy bleeding is defined as a score ≥ 3." (NCT01441635)
Timeframe: Month 3 (average bleeding score over days 61 to 90)

,,,,,,,,,
Interventionpercentage of participants (Number)
Any bleedingModerate to Very Heavy Bleeding
Cohort 1 Elagolix 200 mg BID4728
Cohort 1 Placebo9482
Cohort 2 Elagolix 300 mg BID267
Cohort 2 Placebo8073
Cohort 3 Elagolix 200 mg BID + LD E2/NETA7831
Cohort 4 Elagolix 100 mg BID5740
Cohort 4 Elagolix 400 mg QD3727
Cohort 4 Placebo9387
Cohort 5 Elagolix 600 mg QD2715
Cohort 6 Elagolix 300 mg BID + CEP6935

[back to top]

Percentage of Participants With No Change, Decrease From Baseline, or Increase From Baseline in Hemoglobin at Month 3

"The percentage of subjects with changes in hemoglobin concentration from Baseline to Month 3 in each of the following categories:~No change from baseline in hemoglobin~Decrease from baseline in hemoglobin ≥ -0.5 g/dL~Decrease from baseline in hemoglobin ≥ -1.0 g/dL~Increase from baseline in hemoglobin ≥ 0.5 g/dL~Increase from baseline in hemoglobin ≥ 1.0 g/dL~The above categories are not all mutually exclusive or exhaustive." (NCT01441635)
Timeframe: Baseline and Month 3

,,,,,,,,,
Interventionpercentage of participants (Number)
No ChangeDecreases from -0.5 to 0 g/dLDecreases from -1.0 to -0.5 g/dLIncrease ≥ 0.5 g/dLIncrease ≥ 1.0 g/dL
Cohort 1 Elagolix 200 mg BID04116759
Cohort 1 Placebo021142929
Cohort 2 Elagolix 300 mg BID0007652
Cohort 2 Placebo02172929
Cohort 3 Elagolix 200 mg BID + LD E2/NETA01407543
Cohort 4 Elagolix 100 mg BID01747171
Cohort 4 Elagolix 400 mg QD0947861
Cohort 4 Placebo9027189
Cohort 5 Elagolix 600 mg QD4448357
Cohort 6 Elagolix 300 mg BID + CEP55107162

[back to top]

Percentage of Participants With Suppression of Bleeding (Spotting Allowed) or Amenorrhea During the Last 56 Days of Treatment

"Suppression of bleeding is defined as no record of bleeding (spotting allowed) in the e-diary and no record of bleeding Indicated in the alkaline hematin data during the last 56 days of treatment.~Amenorrhea is defined as no record of bleeding or spotting indicated in the e-diary and no record of bleeding or spotting Indicated in the alkaline hematin data during the last 56 days of treatment." (NCT01441635)
Timeframe: The last 56 days of treatment (approximately days 33 to 90)

,,,,,,,,,
Interventionpercentage of participants (Number)
Suppression of bleedingAmenorrhea
Cohort 1 Elagolix 200 mg BID6644
Cohort 1 Placebo00
Cohort 2 Elagolix 300 mg BID7966
Cohort 2 Placebo00
Cohort 3 Elagolix 200 mg BID + LD E2/NETA3119
Cohort 4 Elagolix 100 mg BID4531
Cohort 4 Elagolix 400 mg QD6660
Cohort 4 Placebo00
Cohort 5 Elagolix 600 mg QD7773
Cohort 6 Elagolix 300 mg BID + CEP3219

[back to top]

AUC Norethindrone

0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Day 21 (NCT01667978)
Timeframe: following 21 days of continuous ingestion

Interventionng*h/mL (Mean)
Protease Inhibitor37.81
Control25.21

[back to top]

Percentage of Participants With a MBL Volume < 80 mL and a ≥ 50% Reduction in MBL Volume From Baseline During the Last 56 to 29 Days of Treatment

The percentage of participants meeting a composite endpoint consisting of these 2 bleeding assessments: a MBL volume < 80 mL and a ≥ 50% reduction in MBL volume from baseline during the last 56 to 29 days of last treatment. Baseline is defined as the last qualified menstrual cycle during the screening period. (NCT01817530)
Timeframe: Baseline, second last 28 days of treatment (last 56 to 29 days of treatment)

Interventionpercentage of participants (Number)
Cohort 1: Placebo11.29
Cohort 1: Elagolix 300 mg BID94.83
Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD88.14
Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD85.00
Cohort 2: Placebo18.42
Cohort 2: Elagolix 600 mg QD85.29
Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD67.19
Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD77.14

[back to top]

Percentage of Participants With a ≥ 50% Reduction in MBL Volume From Baseline to the Final Month

Percentage of participants with a >= 50% reduction from baseline in MBL to the Final Month (last 28 days of treatment). Baseline is defined as the last qualified menstrual cycle during the screening period. (NCT01817530)
Timeframe: Baseline, Final Month (last 28 days of treatment)

Interventionpercentage of participants (Number)
Cohort 1: Placebo31.25
Cohort 1: Elagolix 300 mg BID93.55
Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD86.89
Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD82.26
Cohort 2: Placebo35.53
Cohort 2: Elagolix 600 mg QD90.14
Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD79.45
Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD85.53

[back to top]

Percentage of Participants Who Achieved Suppression of Bleeding During the Last 56 Days of Treatment

Suppression of bleeding is defined as having 0 days of bleeding based on observed validated and nonvalidated alkaline hematin data and having 0 days of bleeding (spotting is allowed) based on imputed electronic diary data during the last 56 days of treatment. (NCT01817530)
Timeframe: Last 56 days of treatment (after 10 days from first dose date)

Interventionpercentage of participants (Number)
Cohort 1: Placebo1.6
Cohort 1: Elagolix 300 mg BID75.4
Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD52.6
Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD43.3
Cohort 2: Placebo2.7
Cohort 2: Elagolix 600 mg QD67.2
Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD31.7
Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD34.8

[back to top]

Percentage of Participants Who Achieved an MBL Volume of < 80 mL at the Final Month

Percentage of participants who achieved an MBL volume of < 80 mL at the Final Month (last 28 days of treatment). Baseline is defined as the last qualified menstrual cycle during the screening period. (NCT01817530)
Timeframe: Final Month (last 28 days of treatment)

Interventionpercentage of participants (Number)
Cohort 1: Placebo32.81
Cohort 1: Elagolix 300 mg BID91.94
Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD88.52
Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD79.03
Cohort 2: Placebo36.84
Cohort 2: Elagolix 600 mg QD91.55
Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD72.6
Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD85.53

[back to top]

Percentage of Participants Who Achieved Amenorrhea During the Last 56 Days of Treatment

Amenorrhea is defined as having 0 days of bleeding or spotting based on observed validated and nonvalidated alkaline hematin data and having 0 days of bleeding or spotting, based on imputed electronic diary data during the last 56 days of treatment. Participants needed to have at least 66 days on treatment. (NCT01817530)
Timeframe: Last 56 days of treatment (after 10 days from first dose date)

Interventionpercentage of participants (Number)
Cohort 1: Placebo1.6
Cohort 1: Elagolix 300 mg BID56.1
Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD33.3
Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD28.3
Cohort 2: Placebo1.3
Cohort 2: Elagolix 600 mg QD50.7
Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD17.5
Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD22.7

[back to top]

Change From Baseline to Each Month in Non-Bleeding Uterine Fibroids Symptom (NBUFSQ) Questionnaire

The NBUFSQ (8 items) is a brief patient-reported daily diary that assesses non-bleeding symptoms experienced by women with uterine fibroids. It includes 6 items, asking women to rate their symptoms (abdominal/pelvic pain, pressure, and cramping, back pain, bloating, and urinary problems) in the past 24 hours using an 11-point numeric response scale that ranges from 0 (i.e., no symptom) to 10 (i.e., worst possible symptom) and 2 items to address urinary frequency during the daytime and at night. Data presented in the sum of scores to the 6 symptom questions, ranging from 0 (no symptoms) to 60 (worst possible symptoms). Baseline is defined as the last 28 days prior to the first day of study drug. Final Month is defined as the last 28 days prior to and including the last dose date of study drug. (NCT01817530)
Timeframe: Baseline, Days 1-28, Days 29-56, Days 57-84, Days 85-112, Days 113-140, Days 141-168, Final Month of treatment, Post-treatment (PT) Days 1-28, PT Days 29-56, PT Days 57-84, PT Days 85-112, PT Days 113-140, PT Days 141-168

,,,,,,,
Interventionunits on a scale (Least Squares Mean)
Days 1-28Days 29-56Days 57-84Days 85-112Days 113-140Days 141-168Final MonthPT Days 1-28PT Days 29-56PT Days 57-84PT Days 85-112PT Days 113-140PT Days 141-168
Cohort 1: Elagolix 300 mg BID-3.4-5.8-7.2-7.8-7.6-8.0-6.7-5.2-4.1-4.0-6.4-3.1-8.0
Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD-3.1-4.4-4.1-5.2-5.3-5.1-4.1-3.8-1.0-2.1-4.81.34.1
Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD-1.4-2.9-3.2-3.7-3.4-3.3-3.5-3.00.0-1.10.71.4-3.3
Cohort 1: Placebo-3.3-4.5-5.6-7.0-4.1-6.8-5.3-5.6-5.7-5.4-4.43.47.5
Cohort 2: Elagolix 600 mg QD-2.7-4.2-4.5-5.1-5.5-5.9-4.0-3.8-2.8-2.0-2.4-17.3-3.1
Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD-2.1-2.2-2.2-3.6-4.0-4.4-3.3-2.0-2.7-1.6-3.0-5.6-3.3
Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD0.0-2.3-3.8-4.1-5.3-4.8-2.3-2.3-2.5-3.9-5.0-7.0-6.4
Cohort 2: Placebo0.4-0.30.1-0.20.1-0.4-0.8-0.8-0.2-0.5-2.7-6.2-10.5

[back to top]

Mean Change in the Number of Heavy Bleeding Days From Baseline to Month 6

The number of days with heavy bleeding (either heavy or very heavy/gushing bleeding) was calculated using data collected on daily bleeding diary. Baseline is defined as the last 28 days prior to the first dose day of study drug. (NCT01817530)
Timeframe: Baseline, Month 6

Interventiondays (Least Squares Mean)
Cohort 1: Placebo-1.0
Cohort 1: Elagolix 300 mg BID-2.0
Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD-1.9
Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD-1.7
Cohort 2: Placebo-0.7
Cohort 2: Elagolix 600 mg QD-1.2
Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD-1.4
Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD-1.8

[back to top]

Mean Change in the Number of Bleeding Days From Baseline to Month 6

The number of days with any bleeding including spotting was calculated using data collected on daily bleeding diary. Baseline is defined as the last 28 days prior to the first dose day of study drug. (NCT01817530)
Timeframe: Baseline, Month 6

Interventiondays (Least Squares Mean)
Cohort 1: Placebo-1.2
Cohort 1: Elagolix 300 mg BID-4.9
Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD-2.7
Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD-1.1
Cohort 2: Placebo-1.4
Cohort 2: Elagolix 600 mg QD-3.3
Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD-1.3
Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD-1.8

[back to top]

Mean Change in Hemoglobin Concentration From Baseline to Final Visit

Baseline is defined as the last measurement prior to the first dose of study drug. (NCT01817530)
Timeframe: Baseline, Final Visit during treatment period (Month 6 or early termination)

Interventiong/dL (Least Squares Mean)
Cohort 1: Placebo0.6
Cohort 1: Elagolix 300 mg BID1.9
Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD1.9
Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD1.4
Cohort 2: Placebo0.3
Cohort 2: Elagolix 600 mg QD1.4
Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD1.1
Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD1.2

[back to top]

Change in Bleeding Severity Scores From Baseline at the Final Month

The average bleeding score was calculated for each 28-day interval starting on Day 29 using data collected on daily bleeding diary using the Mansfield-Voda-Jorgenson (MVJ) Menstrual Bleeding Scale (1=spotting, 2 = very light bleeding, 3 = light bleeding, 4 = moderate bleeding, 5 = heavy bleeding, 6 = very heavy/gushing bleeding). Baseline is defined as the last 28 days prior to the first day of study drug. (NCT01817530)
Timeframe: Baseline, Final Month (last 28 days of treatment)

Interventionunits on a scale (Least Squares Mean)
Cohort 1: Placebo-0.3
Cohort 1: Elagolix 300 mg BID-0.7
Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD-0.4
Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD-0.1
Cohort 2: Placebo-0.2
Cohort 2: Elagolix 600 mg QD-0.4
Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD-0.3
Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD-0.1

[back to top]

Percentage of Participants With a MBL Volume < 80 mL and a ≥ 50% Reduction in MBL Volume From Baseline During the Last 84 to 57 Days of Treatment

The percentage of participants meeting a composite endpoint consisting of these 2 bleeding assessments: a MBL volume < 80 mL and a ≥ 50% reduction in MBL volume from baseline during the last 84 to 57 days of last treatment. Baseline is defined as the last qualified menstrual cycle during the screening period. (NCT01817530)
Timeframe: Baseline, third last 28 days of treatment (last 84 to 57 days of treatment)

Interventionpercentage of participants (Number)
Cohort 1: Placebo19.67
Cohort 1: Elagolix 300 mg BID96.43
Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD89.47
Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD79.31
Cohort 2: Placebo21.62
Cohort 2: Elagolix 600 mg QD86.36
Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD74.19
Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD72.31

[back to top]

Percentage of Participants With a Menstrual Blood Loss (MBL) Volume of < 80 mL at the Final Month and a ≥ 50% Reduction in MBL Volume From Baseline to the Final Month

The percentage of participants meeting a composite endpoint consisting of these 2 bleeding assessments: a MBL Volume of < 80 mL at the Final Month and a ≥50% Reduction in MBL Volume from Baseline to the Final Month (last 28 days of treatment). Baseline is defined as the last qualified menstrual cycle during the screening period. (NCT01817530)
Timeframe: Baseline, Final Month (last 28 days of treatment)

Interventionpercentage of participants (Number)
Cohort 1: Placebo26.56
Cohort 1: Elagolix 300 mg BID91.94
Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD85.25
Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD79.03
Cohort 2: Placebo31.58
Cohort 2: Elagolix 600 mg QD90.14
Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD72.6
Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD81.58

[back to top]

Mean Percentage Change From Baseline in Primary Fibroid Volume at Month 3, Month 6, and Final Visit

Volume of the largest fibroid (primary fibroid), as measured by transvaginal ultrasound, or transabdominal ultrasound. (NCT01817530)
Timeframe: Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)

,,,,,,,
Interventionpercentage change (Mean)
Month 3Month 6Final Visit
Cohort 1: Elagolix 300 mg BID-35.5-36.1-35.6
Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD-20.3-19.620.0
Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD-3.70.0-2.7
Cohort 1: Placebo6.913.29.0
Cohort 2: Elagolix 600 mg QD-33.6-33.5-34.8
Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD-17.2-12.2-12.8
Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD-1.9-0.70.0
Cohort 2: Placebo6.71.43.0

[back to top]

Mean Percentage Change From Baseline in Total Fibroid Volume at Month 3, Month 6, and Final Visit

Volume of the total fibroid volume (3 largest fibroids), as measured by transvaginal ultrasound, or transabdominal ultrasound. (NCT01817530)
Timeframe: Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)

,,,,,,,
Interventionpercentage change (Mean)
Month 3Month 6Final Visit
Cohort 1: Elagolix 300 mg BID-41.9-40.2-39.6
Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD-24.6-23.3-24.0
Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD-9.8-8.8-12.9
Cohort 1: Placebo1.78.34.6
Cohort 2: Elagolix 600 mg QD-34.4-34.2-36.4
Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD-17.5-17.8-16.6
Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD-4.6-1.1-1.6
Cohort 2: Placebo5.4-1.80.1

[back to top]

Mean Percentage Change From Baseline in Uterine Volume at Month 3, Month 6, and Final Visit

Uterine volume, as measured by transvaginal ultrasound or transabdominal ultrasound. (NCT01817530)
Timeframe: Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)

,,,,,,,
Interventionpercentage change (Mean)
Month 3Month 6Final Visit
Cohort 1: Elagolix 300 mg BID-30.9-35.6-31.5
Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD-19.4-21.9-22.0
Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD-7.3-13.2-11.8
Cohort 1: Placebo7.317.515.9
Cohort 2: Elagolix 600 mg QD-24.7-26.00-26.6
Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD-15.7-13.5-11.5
Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD-6.1-9.0-6.7
Cohort 2: Placebo8.410.711.6

[back to top]

Percentage of Participants With ≥ 25% Reduction From Baseline in Primary Fibroid Volume at Month 3, Month 6, and Final Visit

Volume of the largest fibroid (primary fibroid) was measured by transvaginal ultrasound or transabdominal ultrasound. (NCT01817530)
Timeframe: Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)

,,,,,,,
Interventionpercentage of participants (Number)
Month 3Month 6Final Visit
Cohort 1: Elagolix 300 mg BID67.370.569.8
Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD46.247.950.0
Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD23.426.227.5
Cohort 1: Placebo13.224.424.5
Cohort 2: Elagolix 600 mg QD63.264.066.1
Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD37.738.640.0
Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD22.434.830.0
Cohort 2: Placebo10.914.513.6

[back to top]

Percentage of Participants With ≥ 25% Reduction From Baseline in Total Fibroid Volume at Month 3, Month 6, and Final Visit

Total fibroid volume (3 largest fibroids) was measured by transvaginal ultrasound, or transabdominal ultrasound. (NCT01817530)
Timeframe: Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)

,,,,,,,
Interventionpercentage of participants (Number)
Month 3Month 6Final Visit
Cohort 1: Elagolix 300 mg BID79.675.073.6
Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD50.054.257.4
Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD31.940.541.2
Cohort 1: Placebo13.224.424.5
Cohort 2: Elagolix 600 mg QD66.762.064.4
Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD34.040.940.0
Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD22.434.830.0
Cohort 2: Placebo9.418.216.7

[back to top]

Percentage of Participants With ≥ 25% Reduction From Baseline in Uterine Volume at Month 3, Month 6, and Final Visit

Uterine volume was measured by transvaginal ultrasound or transabdominal ultrasound. (NCT01817530)
Timeframe: Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)

,,,,,,,
Interventionpercentage of participants (Number)
Month 3Month 6Final Visit
Cohort 1: Elagolix 300 mg BID73.178.773.2
Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD42.958.058.9
Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD18.531.926.8
Cohort 1: Placebo5.22.03.4
Cohort 2: Elagolix 600 mg QD57.162.563.1
Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD36.832.729.3
Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD17.526.023.4
Cohort 2: Placebo1.41.61.4

[back to top]

Differences in EEG Recorded Cortical Activity Among Participants

We obtained the peak alpha frequency at the right and left parietal occipital electrodes and averages of the two sides were assessed at Baseline, 6 month, and 12 Month to determine whether differences in resting state brain activity at parieto-occipital electrode sites are affected by oral contraceptives (NCT02214550)
Timeframe: Baseline, 6 months and 12 months

,,,,
InterventionHertz (Mean)
Baseline
No Intervention Chronic Pain (Positive Controls)10.15
No Intervention: Dysmenorrhea (D)10.12
No Intervention: Dysmenorrhea With Cross Organ Sensitization (D+COS)9.96
No Intervention: Healthy Controls10.03
No Intervention: Painful Bladder Syndrome (PBS)/Interstitial Cystitis (IC)10.0

[back to top]

Change in Participant Bladder Pain Sensitivity From Baseline.

Score on a scale. Specifically, we used a Visual Analog Scale- 0 through 100 scale with 0 being no pain and 100 worst pain imaginable. Results from the visual analog scale (VAS) of the bladder filling test at the initial, 6 month and 12 month visits will be compared to determine if participants in each of the treatment groups had a reduction in pain. Bladder pain ratings at first urge will be used at the outcome measure. (NCT02214550)
Timeframe: 0 (baseline), 6 month, and 12 month visits

,,,,
Interventionscore on a scale (Mean)
Baseline
No Intervention Chronic Pain (Positive Controls)17.3
No Intervention: Dysmenorrhea (D)4.1
No Intervention: Dysmenorrhea With Cross Organ Sensitization (D+COS)33
No Intervention: Healthy Controls2.2
No Intervention: Painful Bladder Syndrome (PBS)/Interstitial Cystitis (IC)49.0

[back to top]

Change in Participant Bladder Pain Sensitivity From Baseline.

Score on a scale. Specifically, we used a Visual Analog Scale- 0 through 100 scale with 0 being no pain and 100 worst pain imaginable. Results from the visual analog scale (VAS) of the bladder filling test at the initial, 6 month and 12 month visits will be compared to determine if participants in each of the treatment groups had a reduction in pain. Bladder pain ratings at first urge will be used at the outcome measure. (NCT02214550)
Timeframe: 0 (baseline), 6 month, and 12 month visits

,,,
Interventionscore on a scale (Mean)
BaselineMonth 6Month 12
D+COS-continuous Microgestin 1/2041.218.68.6
D+COS-cyclic Microgestin 1/2037.032.034.0
D+COS-no OC38.244.547.0
PBS-continuous Microgestin 1/2047.941.438.8

[back to top]

Change in Quantitative Sensory Testing (QST) Parameters Regarding Pelvic Hyperalgesia From Baseline

Results from the QST testing performed at initial, 6 month and 12 month visits will be compared to determine if participants in each of the treatment groups had a reduction in sensitivity from baseline. Specifically, measure reported is the pressure pain threshold in newtons observed at the transition from pressure to pain transvaginally at the 12 o'clock position (anteriorly against the bladder). Lower values (pressure) indicate greater sensitivity. (NCT02214550)
Timeframe: 0 (baseline), 6 months and 12 months

,,,,
InterventionNewtons (Mean)
Baseline
No Intervention Chronic Pain (Positive Controls)6.9
No Intervention: Dysmenorrhea (D)8.9
No Intervention: Dysmenorrhea With Cross Organ Sensitization (D+COS)7.2
No Intervention: Healthy Controls11.6
No Intervention: Painful Bladder Syndrome (PBS)/Interstitial Cystitis (IC)6.9

[back to top]

Change in Quantitative Sensory Testing (QST) Parameters Regarding Pelvic Hyperalgesia From Baseline

Results from the QST testing performed at initial, 6 month and 12 month visits will be compared to determine if participants in each of the treatment groups had a reduction in sensitivity from baseline. Specifically, measure reported is the pressure pain threshold in newtons observed at the transition from pressure to pain transvaginally at the 12 o'clock position (anteriorly against the bladder). Lower values (pressure) indicate greater sensitivity. (NCT02214550)
Timeframe: 0 (baseline), 6 months and 12 months

,,,
InterventionNewtons (Mean)
BaselineMonth 6Month 12
D+COS-no OC5.955.407.36
D+COS-continuous Microgestin 1/2013.812.39.94
D+COS-cyclic Microgestin 1/209.3813.97.74
PBS-continuous Microgestin 1/208.213.395.59

[back to top]

Differences in EEG Recorded Cortical Activity Among Participants

We obtained the peak alpha frequency at the right and left parietal occipital electrodes and averages of the two sides were assessed at Baseline, 6 month, and 12 Month to determine whether differences in resting state brain activity at parieto-occipital electrode sites are affected by oral contraceptives (NCT02214550)
Timeframe: Baseline, 6 months and 12 months

,,,
InterventionHertz (Mean)
BaselineMonth 6Month 12
D+COS-continuous Microgestin 1/2010.0510.199.75
D+COS-cyclic Microgestin 1/2010.010.019.97
D+COS-no OC10.0310.109.88
PBS-continuous Microgestin 1/2010.1310.1610.48

[back to top]

Impact of Aygestin (and Dose of Aygestin) on the Management of Bothersome Bleeding Associated With the Etonogestrel Contraceptive Implant

"Bothersome bleeding was defined per WHO classification as either frequent bleeding (greater than 5 bleeding-spotting episodes in a 90-day reference period) or prolonged bleeding (any bleeding-spotting episode, uninterrupted, lasting greater than 14 days in a 90-day reference period)~The scale used was derived from the WHO classification system:~Bleeding Day (assigned value = 1) Spotting Day (assigned value = .5) Bleeding Free Day (assigned value = 0) Prefer not to answer today (assigned value = missing)~Higher scores (average of the time period) indicate more bothersome bleeding; low scores indicate less bothersome bleeding. Less bothersome bleeding is the desired outcome.~Note, the scale is not a published scale but rather was constructed for this study." (NCT02353247)
Timeframe: Initial 3 months of baseline collection (medicine free); For intervention group, 3 months of medicine, followed by 3 months of medicine free; For control group, 6 months of medicine free.

Interventionunits on a scale (Mean)
Control Group T12.73
Control Group T22.77
Control Group T32.76
Intervention Group T12.27
Intervention Group T22.65
Intervention Group T32.67

[back to top]

Changes in Pain Interference Scores

"Brief Pain Inventory Interference subscale is a 7-item self-report measure, designed to assess the extent to which pain interferes with various components of functioning, including physical and emotional functioning and sleep.The items in this scale can be grouped into those that assess physical functioning (general activity; walking ability; normal work, including both work outside the home and housework), those that assess emotional functioning (mood; relations with people; enjoyment of life), and a single item that assess the extent to which pain interferes with sleep. The arithmetic mean of the seven interference items is used as a measure of pain interference (i.e., how much a participant's pain interferes with her ability to complete activities of daily living and functioning). The score on the pain interference subscale ranges from 0-70. Higher scores are worse outcomes.~Outcome measure calculated as the value at 6 months minus the value at baseline" (NCT02542410)
Timeframe: Baseline, 6 months

Interventionunits on a scale (Mean)
Norethindrone Acetate 5 mg0.85
Cabergoline 0.5 mg0

[back to top]

Change in Score in Worst Pain Over the Last Month

"visual analog scale, minimum=0 and maximum=10 Higher numbers are a worse outcome~Outcome measures is calculated as the value at 6 months minus value at baseline." (NCT02542410)
Timeframe: Baseline, 6 months

Interventionscore on a scale (Median)
Norethindrone Acetate 5 mg-0.5
Cabergoline 0.5 mg-5

[back to top]

Percentage of Participants Meeting the Criteria for Responder

"Percentage of responders, defined as participants who met the following conditions:~Menstrual blood loss (MBL) volume < 80 mL during the Final Month (the last 28 days prior to and including the Reference Day, which is defined as the last visit date during the Treatment Period [last treatment visit date] or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date), and~≥ 50% reduction in MBL volume from Baseline to the Final Month.~Participants who prematurely discontinued study drug due to lack of efficacy, requires surgery or invasive intervention for treatment of uterine fibroids, or adverse events were considered non-responders regardless of whether she meets the two aforementioned responder criteria or not." (NCT02654054)
Timeframe: Final Month (the last 28 days prior to and including the Reference Day), up to Month 6

Interventionpercentage of participants (Number)
Placebo8.7
Elagolix84.1
Elagolix + E2/NETA68.5

[back to top]

Change From Baseline in MBL Volume to the Final Month

"Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL.~The Reference Day is defined as the last visit date during the Treatment Period (last treatment visit date) or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date." (NCT02654054)
Timeframe: Month 0 (Baseline), Final Month (the last 28 days prior to and including the Reference Day), up to Month 6

InterventionmL (Least Squares Mean)
Placebo0.8
Elagolix-221.5
Elagolix + E2/NETA-176.7

[back to top]

Change From Baseline in MBL Volume to Month 6

(NCT02654054)
Timeframe: Month 0 (Baseline), Month 6

InterventionmL (Least Squares Mean)
Placebo-2.3
Elagolix-236.2
Elagolix + E2/NETA-194.7

[back to top]

Change From Baseline in MBL Volume to Month 3

(NCT02654054)
Timeframe: Month 0 (Baseline), Month 3

InterventionmL (Least Squares Mean)
Placebo6.1
Elagolix-234.7
Elagolix + E2/NETA-192.2

[back to top]

Change From Baseline in MBL Volume to Month 1

(NCT02654054)
Timeframe: Month 0 (Baseline), Month 1

InterventionmL (Least Squares Mean)
Placebo-19.0
Elagolix-209.0
Elagolix + Estradiol/Norethindrone Acetate-135.2

[back to top]

Percentage of Participants With Suppression of Bleeding at the Final Month

"Suppression of bleeding is defined as having 0 days of bleeding (spotting is allowed) during the Final Month with the interval starting from Study Day 11.~The Reference Day is defined as the last visit date during the Treatment Period (last treatment visit date) or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date." (NCT02654054)
Timeframe: Final Month (the last 28 days prior to and including the Reference Day), up to Month 6

Interventionpercentage of participants (Number)
Placebo4.4
Elagolix84.0
Elagolix + E2/NETA56.8

[back to top]

Percentage of Participants With Baseline Hemoglobin <= 10.5 g/dL Who Have an Increase in Hemoglobin > 2 g/dL at Month 6

(NCT02654054)
Timeframe: Month 0 (Baseline), Month 6

Interventionpercentage of participants (Number)
Placebo16.1
Elagolix65.9
Elagolix + E2/NETA61.5

[back to top]

Percentage of Participants With Suppression of Bleeding at the Final Month

"Suppression of bleeding is defined as having 0 days of bleeding (spotting is allowed) during the Final Month with the interval starting from Study Day 11.~The Reference Day is defined as the last visit date during the Treatment Period (last treatment visit date) or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date." (NCT02691494)
Timeframe: Final Month (the last 28 days prior to and including the Reference Day), up to Month 6

Interventionpercentage of participants (Number)
Placebo4.7
Elagolix88.9
Elagolix + E2/NETA61.0

[back to top]

Percentage of Participants Meeting the Criteria for Responder

"Percentage of responders, defined as participants who met the following conditions:~Menstrual blood loss (MBL) volume < 80 mL during the Final Month (the last 28 days prior to and including the Reference Day, which is defined as the last visit date during the Treatment Period (last treatment visit date) or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date), and~≥ 50% reduction in MBL volume from Baseline to the Final Month.~Participants who prematurely discontinued study drug due to lack of efficacy, requires surgery or invasive intervention for treatment of uterine fibroids, or adverse events were considered non-responders regardless of whether she meets the two aforementioned responder criteria or not." (NCT02691494)
Timeframe: Final Month (the last 28 days prior to and including the Reference Day), up to Month 6

Interventionpercentage of participants (Number)
Placebo10.5
Elagolix76.9
Elagolix + E2/NETA76.5

[back to top]

Change From Baseline in MBL Volume to the Final Month

"Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL.~The Reference Day is defined as the last visit date during the Treatment Period (last treatment visit date) or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date." (NCT02691494)
Timeframe: Baseline and Final Month (the last 28 days prior to and including the Reference Day), up to Month 6

InterventionmL (Least Squares Mean)
Placebo-4.3
Elagolix-198.8
Elagolix + E2/NETA-168.8

[back to top]

Change From Baseline in MBL Volume to Month 6

Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL. (NCT02691494)
Timeframe: Month 0 (Baseline), Month 6

InterventionmL (Least Squares Mean)
Placebo28.5
Elagolix-223.7
Elagolix + E2/NETA-198.1

[back to top]

Change From Baseline in MBL Volume to Month 3

Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL. (NCT02691494)
Timeframe: Month 0 (Baseline), Month 3

InterventionmL (Least Squares Mean)
Placebo-14.2
Elagolix-211.1
Elagolix + E2/NETA-200.3

[back to top]

Percentage of Participants With Baseline Hemoglobin <= 10.5 g/dL Who Have an Increase in Hemoglobin > 2 g/dL at Month 6

(NCT02691494)
Timeframe: Month 0 (Baseline), Month 6

Interventionpercentage of participants (Number)
Placebo20.8
Elagolix40.0
Elagolix + E2/NETA50.0

[back to top]

Change From Baseline in MBL Volume to Month 1

Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL. (NCT02691494)
Timeframe: Month 0 (Baseline), Month 1

InterventionmL (Least Squares Mean)
Placebo-2.1
Elagolix-196.6
Elagolix + E2/NETA-127.0

[back to top]

Percentage of Participants Meeting the Criteria for Responder

"Percentage of responders, defined as participants who met the following conditions:~Menstrual blood loss (MBL) volume < 80 mL during the Final Month (the last 28 days prior to and including the last dose date), and~≥ 50% reduction in MBL volume from Baseline to the Final Month.~Participants who prematurely discontinued study drug due to lack of efficacy, requires surgery or invasive intervention for treatment of uterine fibroids, or adverse events were considered non-responders regardless of whether she meets the two aforementioned responder criteria or not." (NCT02925494)
Timeframe: From Month 0 (Baseline in Pivotal Study) to Final Month of Treatment Period (up through Month 6 in Extension Study)

Interventionpercentage of participants (Number)
Placebo->Elagolix85.7
Placebo->Elagolix + E2/NETA66.7
Elagolix->Elagolix89.4
Elagolix + E2/NETA->Elagolix + E2/NETA87.9

[back to top]

Percentage of Participants With Baseline Hemoglobin Concentration ≤ 10.5 g/dL and an Increase From Baseline > 2 g/dL at Month 6 During the Treatment Period

(NCT02925494)
Timeframe: Month 6

Interventionpercentage of participants (Number)
Placebo->Elagolix70.6
Placebo->Elagolix + E2/NETA36.4
Elagolix->Elagolix71.4
Elagolix + E2/NETA->Elagolix + E2/NETA72.5

[back to top]

Percentage of Participants With Suppression of Bleeding at the Final Month

Suppression of bleeding is defined as having 0 days of bleeding (spotting is allowed) during the Final Month with the interval starting from Study Day 11. (NCT02925494)
Timeframe: Final Month of Treatment Period (up through Month 6)

Interventionpercentage of participants (Number)
Placebo->Elagolix88.7
Placebo->Elagolix + E2/NETA56.0
Elagolix->Elagolix89.2
Elagolix->Elagolix + E2/NETA74.8

[back to top]

Change From Baseline in MBL Volume For Each 28-Day Interval and Final Month of the Treatment Period

Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period of the pivotal study, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL. (NCT02925494)
Timeframe: Month 0 (Baseline in Pivotal Study), Extension Study: Day 1 to 28, Day 29 to 56, Day 57 to 84, Day 85 to 112, Day 113 to 140, Day 141 to 168, Final Month of Treatment Period (up through Month 6)

,,,
InterventionmL (Mean)
Study Day 1 to 28Study Day 29 to 56Study Day 57 to 84Study Day 85 to 112Study Day 113 to 140Study Day 141 to 168Final Month
Elagolix + E2/NETA->Elagolix + E2/NETA-186.5-191.9-200.6-200.5-192.9-211.4-205.6
Elagolix->Elagolix-253.4-249.7-255.9-252.0-253.9-279.1-250.3
Placebo->Elagolix-151.7-210.9-236.9-235.1-237.3-263.8-256.6
Placebo->Elagolix + E2/NETA-61.7-203.1-209.0-204.5-194.5-175.4-186.4

[back to top]

Percent Change From Baseline in MBL Volume For Each 28-Day Interval and Final Month of the Treatment Period

Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period of the pivotal study, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL. (NCT02925494)
Timeframe: Month 0 (Baseline in Pivotal Study), Extension Study: Day 1 to 28, Day 29 to 56, Day 57 to 84, Day 85 to 112, Day 113 to 140, Day 141 to 168, Final Month of Treatment Period (up through Month 6)

,,,
Interventionpercentage change (Mean)
Study Day 1 to 28Study Day 29 to 56Study Day 57 to 84Study Day 85 to 112Study Day 113 to 140Study Day 141 to 168Final Month
Elagolix + E2/NETA->Elagolix + E2/NETA-87.7-87.8-90.6-91.2-87.5-89.7-90.8
Elagolix->Elagolix-94.0-93.3-96.9-95.2-97.7-99.2-96.6
Placebo->Elagolix-46.5-87.2-89.9-90.3-90.0-91.8-91.0
Placebo->Elagolix + E2/NETA-28.2-79.4-82.9-82.7-75.0-79.3-78.5

[back to top]

Median Cervical Mucus Score - 2 Hour

"Measurement of median cervical mucus scores 2 hours following norethindrone administration. The current clinical standard for appraising cervical mucus is the cervical mucus score (ie. Insler score) that examines mucus based on 5 metrics including volume, spinnbarkeit (stretch), ferning, viscosity and cellularity on a 15-point scale. Per WHO guidelines, scores above 10 are considered mucus favoring penetration and scores below 10 are considered to be unfavorable to penetration." (NCT02969590)
Timeframe: 2 hours

Interventionscore on a scale (Median)
Norethindrone8.5
Estradiol10.5

[back to top]

Median Cervical Mucus Score - 6 Hour

"Measurement of median cervical mucus scores 6 hours following norethindrone administration. The current clinical standard for appraising cervical mucus is the cervical mucus score (ie. Insler score) that examines mucus based on 5 metrics including volume, spinnbarkeit (stretch), ferning, viscosity and cellularity on a 15-point scale. Per WHO guidelines, scores above 10 are considered mucus favoring penetration and scores below 10 are considered to be unfavorable to penetration." (NCT02969590)
Timeframe: 6 hours

Interventionscore on a scale (Median)
Norethindrone6.5
Estradiol8.5

[back to top]

Median Cervical Mucus Score - 24 Hour

"Measurement of median cervical mucus scores 24 hours following norethindrone administration. The current clinical standard for appraising cervical mucus is the cervical mucus score (ie. Insler score) that examines mucus based on 5 metrics including volume, spinnbarkeit (stretch), ferning, viscosity and cellularity on a 15-point scale. Per WHO guidelines, scores above 10 are considered mucus favoring penetration and scores below 10 are considered to be unfavorable to penetration." (NCT02969590)
Timeframe: 24 hours

Interventionscore on a scale (Median)
Norethindrone8
Estradiol10.5

[back to top]

Median Cervical Mucus Score - Baseline

"Measurement of median cervical mucus scores at baseline. The current clinical standard for appraising cervical mucus is the cervical mucus score (ie. Insler score) that examines mucus based on 5 metrics including volume, spinnbarkeit (stretch), ferning, viscosity and cellularity on a 15-point scale. Per WHO guidelines, scores above 10 are considered mucus favoring penetration and scores below 10 are considered to be unfavorable to penetration." (NCT02969590)
Timeframe: Baseline

Interventionscore on a scale (Median)
Norethindrone11
Estradiol13

[back to top]

Change in PGRMC1 During Menstrual Cycle

"Measuring the mean transcript change of membrane bound progestin receptors (PGRMC1) from follicular phase to ovulation to luteal phase of spontaneous menstrual cycle.~Total RNA (ribonucleic acid) was isolated from endocervical cell samples and analyzed for expression of PGRMC1 using real-time PCR (polymerase chain reaction) relative to levels of ribosomal (S10) RNA. An endocervical brush will be inserted into the os and then immediately rinsed into a special RNA preserving reagent. After total RNA is isolated and purified, it will be reverse transcribed into cDNA using primers.~Ratio of PGRMC1 to 18s RNA~Gene expression of membrane bound progesterone receptors in endocervical cells" (NCT02969590)
Timeframe: 1 month

Interventionratio (Mean)
Follicular PhaseOvulation PhaseLuteal Phase
Spontaneous Cycle1.24.01.02

[back to top]

Percent Change From Baseline At Week 24 In Uterine Volume

"The volume of the uterus was measured by transvaginal or transabdominal ultrasound.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: Baseline, Week 24

Interventionpercent change (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-12.9
Placebo (Group C)2.2

[back to top]

Percent Change From Baseline In Hemoglobin For Women With a Hemoglobin ≤ 10.5 g/dL At Baseline

"LS means and p-value for test of difference is relugolix plus E2/NETA minus Placebo based on mixed-effect model with treatment, visit, region, Baseline MBL and treatment by visit interaction included as fixed effects.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: Week 24

Interventionpercent change (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)20.8
Placebo (Group C)10.0

[back to top]

Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 12

"An adverse event was defined as an unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or not related to the medicinal product. The preferred terms of hyperhidrosis, feeling hot, hot flush, night sweats, and flushing were combined to describe vasomotor symptoms. Participants with multiple events for a given preferred term were counted only once for each preferred term.~Reported CI based on exact binomial 95% CI (Clopper-Pearson).~As per the objective of the study, this secondary analysis compared relugolix plus E2/NETA with relugolix plus delayed E2/NETA at Week 12 and are presented below." (NCT03049735)
Timeframe: Baseline through Week 12

Interventionpercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)10.94
Relugolix Plus Delayed E2/NETA (Group B)36.36

[back to top]

Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 24

"An adverse event was defined as an unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or not related to the medicinal product. The preferred terms of hyperhidrosis, feeling hot, hot flush, night sweats, and flushing were combined to describe vasomotor symptoms. Participants with multiple events for a given preferred term were counted only once for each preferred term.~Reported percentages based on the total number of participants in each treatment group.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: Baseline through Week 24

Interventionpercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)14.8
Placebo (Group C)9.4

[back to top]

Percentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A ≥ 50% Reduction From Baseline MBL Volume With Relugolix Plus E2/NETA

"A responder was a participant who had MBL volume of < 80 mL and at least a 50% reduction from baseline MBL volume over the last 35 days of treatment (up to Week 24). All returned feminine products collected at each clinical visit were analyzed by the alkaline hematin method to obtain the MBL volume. MBL volume was measured over the Week 24/early termination feminine product collection interval (up to 35 days prior to the last dose of treatment). The percentage of participants who were responders are presented.~As per the objective of the study, the pre-specified primary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: From Baseline up to last 35 days of treatment (up to Week 24)

InterventionPercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)73.4
Placebo (Group C)18.9

[back to top]

Percentage Of Participants With A Hemoglobin Level ≤ 10.5 g/dL At Baseline Who Achieved An Increase Of > 2 g/dL From Baseline At Week 24

"Blood samples were collected from participants for hemoglobin measurements. Percentages are based on number of participants with hemoglobin ≤ 10.5 gram (g)/deciliter (dL) at Baseline and reported at Week 24.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA with placebo arms are presented." (NCT03049735)
Timeframe: From Baseline up to Week 24

InterventionPercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)50.0
Placebo (Group C)21.74

[back to top]

Percentage Of Participants With A Maximum NRS Score ≤ 1 For Uterine Fibroid-Associated Pain Over The Last 35 Days Of Treatment

"Uterine fibroid-associated pain was assessed by a pain numerical rating scale (NRS). The pain NRS is a validated, single-item, self-reported measure, which asks respondents to rank their pain on an 11-point scale as follows: 0 (no pain), 1 to 3 (mild pain), 4 to 6 (moderate pain), and 7 to 10 (severe pain).~Participants were asked to document, in an e-Diary, the worst pain associated with their uterine fibroids that they experienced during the last 24 hours, every day until the end of study drug administration. Pain evaluable participants, defined as those who had maximum NRS score ≥ 4 at Baseline and had at least 28 days (80% of the last 35 days of treatment) of pain scores recorded in the e-Diary, were analyzed.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: From Baseline up to Week 24

InterventionPercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)43.10
Placebo (Group C)10.14

[back to top]

Percentage Of Participants With Amenorrhea Over The Last 35 Days Of Treatment

"Amenorrhea was defined as meeting 1 of the following criteria for 2 consecutive visits:~No feminine product returned due to reported amenorrhea;~No feminine product returned due to reports of spotting/negligible bleeding coupled with electronic diary (eDiary) data indicating infrequent non-cyclic bleeding/spotting;~Feminine product collection with a negligible observed MBL volume coupled with eDiary data indicating infrequent non-cyclic bleeding/spotting.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: From Baseline up to last 35 days of treatment (up to Week 24)

Interventionpercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)52.34
Placebo (Group C)5.51

[back to top]

Predose Trough Concentrations Of E2 In The Relugolix Plus E2/NETA Group At Week 24

"Blood samples for determination of E2 serum concentrations were collected predose at Week 24. Relugolix and NET plasma concentrations were determined using validated bioanalytical methodology.~Concentrations below the quantification limit (BQL) were set to 0 for analysis of summary statistics. As per the objective of the study, only relugolix plus E2/NETA concentration is presented." (NCT03049735)
Timeframe: Week 24

Interventionpg/mL (Mean)
Relugolix Plus E2/NETA (Group A)48.34

[back to top]

Sustained Amenorrhea Rate (No Or Negligible Bleeding)

"Sustained amenorrhea is defined as participants time to achieve and maintain amenorrhea until the date of last study drug.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: Week 24

InterventionParticipants (Count of Participants)
Relugolix Plus E2/NETA (Group A)67
Placebo (Group C)7

[back to top]

Time To Achieving Amenorrhea (No Or Negligible Bleeding)

"Time to amenorrhea was defined as the weeks from date of first dose of study drug to the start of amenorrhea.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: From Baseline through Week 24

Interventionweeks (Median)
Relugolix Plus E2/NETA (Group A)5.3
Placebo (Group C)NA

[back to top]

Time To Achieving Sustained Amenorrhea (No Or Negligible Bleeding)

"Sustained amenorrhea status as determined based on time to achieve and maintain amenorrhea status.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: From Baseline through Week 24

Interventionweeks (Median)
Relugolix Plus E2/NETA (Group A)11.3
Placebo (Group C)NA

[back to top]

Time To MBL Response

"Defined as the time to achieve an MBL volume of < 80 mL and a ≥ 50% reduction from Baseline MBL volume as measured by the alkaline hematin method. MBL volume was measured using the alkaline hematin method.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: From Baseline through Week 24

Interventionweeks (Median)
Relugolix Plus E2/NETA (Group A)8.3
Placebo (Group C)25.1

[back to top]

Participants Achieving Improvement From Baseline In The PGA Questionnaire For Symptoms From Baseline At Week 24

"The PGAs assessed participants' limitation in activities and the severity of symptoms due to uterine fibroids over the previous 4 weeks, as perceived by the participant. The PGA for function and symptoms was evaluated using a 5-point response scale (no limitation at all [1], mild limitation [2], moderate limitation [3], quite a bit of limitation [4], and extreme limitation [5]). Category improvements for symptoms are presented. A 1-category improvement would be severe at baseline to moderate.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: From Baseline through Week 24

,
InterventionParticipants (Count of Participants)
1 Category improvement (-1)2 Category improvement (-2)3 Category improvement (-3)4 Category improvement (-4)
Placebo (Group C)281415
Relugolix Plus E2/NETA (Group A)1429228

[back to top] [back to top]

Percent Change From Baseline At Week 24 In Bone Mineral Density At The Lumbar Spine (L1 To L4), Total Hip, And Femoral Neck

"BMD was assessed by DXA at the lumbar spine (L1, L2, L3, and L4), total hip, and femoral neck at Baseline and at Week 24. The scans were read by the central radiology laboratory in accordance with the imaging charter. The same DXA machine was used at the local imaging center at each site and operated in the same scan mode for all images procured for an individual participant. All images were submitted for central reading. The central radiology laboratory collected and evaluated all DXA scans for acceptability and measured BMD.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: Baseline, Week 24

,
Interventionpercent change (Least Squares Mean)
Lumbar Spine (L1 to L4)Total HipFemoral Neck
Placebo (Group C)0.0520.5490.307
Relugolix Plus E2/NETA (Group A)-0.3560.023-0.262

[back to top]

Predose Trough Concentrations Of Relugolix And Norethindrone (NET) In The Relugolix Plus E2/NETA Group At Week 24

"Blood samples for determination of relugolix and NET plasma concentrations were collected predose at Week 24. Relugolix and NET plasma concentrations were determined using validated bioanalytical methodology.~Concentrations below the quantification limit (BQL) were set to 0 for analysis of summary statistics.~As per the objective of the study, only relugolix plus E2/NETA concentration is presented." (NCT03049735)
Timeframe: Week 24

Interventionng/mL (Mean)
RelugolixNET
Relugolix Plus E2/NETA (Group A)2.130.33

[back to top]

Change From Baseline At Week 24 In The Menorrhagia Impact Questionnaire Score For Social Activities

"The Menorrhagia Impact was evaluated using a 5-point response scale to assess level of improvement from Baseline to Week 24. Response scale: Not at all, 2. Slightly, 3.Moderately, 4. Quite a bit and 5. Extremely.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-1.9
Placebo (Group C)-0.8

[back to top]

Change From Baseline At Week 24 In Embarrassment Caused By Uterine Fibroids Based On UFS-QoL Question 29

"Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity. A negative change from baseline indicates improvement.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-1.5
Placebo (Group C)-0.4

[back to top]

Change From Baseline At Week 24 In Function Assessed Using The PGA Questionnaire

"The PGAs assessed participants' limitation in activities and the severity of symptoms due to uterine fibroids over the previous 4 weeks, as perceived by the participant. The PGA for symptoms is a 1-item questionnaire designed to assess participant's impression of the severity of their symptoms related to uterine fibroids. The PGA for function and symptoms was evaluated using a 5-point response scale (no limitation at all [1], mild limitation [2], moderate limitation [3], quite a bit of limitation [4], and extreme limitation [5]).~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-1.6
Placebo (Group C)-0.5

[back to top]

Change From Baseline At Week 24 In Predose Concentrations Of Estradiol In The Relugolix Plus E2/NETA Group

"Blood samples for determination of serum concentrations were collected predose at Week 24. Relugolix and NET plasma concentrations were determined using validated bioanalytical methodology.~Concentrations below the quantification limit (BQL) were set to 0 for analysis of summary statistics. As per the objective of the study, only relugolix plus E2/NETA concentration is presented." (NCT03049735)
Timeframe: Baseline, Week 24

Interventionpg/mL (Mean)
Relugolix Plus E2/NETA (Group A)-22.95

[back to top]

Change From Baseline At Week 24 In Symptoms Assessed Using The Patient Global Assessment (PGA) Questionnaire

"The PGAs assessed participants' limitation in activities and the severity of symptoms due to uterine fibroids over the previous 4 weeks, as perceived by the participant. The PGA for symptoms is a 1-item questionnaire designed to assess participant's impression of the severity of their symptoms related to uterine fibroids. The PGA for function and symptoms was evaluated using a 5-point response scale (no limitation at all [1], mild limitation [2], moderate limitation [3], quite a bit of limitation [4], and extreme limitation [5]).~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-2.1
Placebo (Group C)-0.8

[back to top]

Change From Baseline At Week 24 In The Interference Of Uterine Fibroids With Physical Activities Based On UFS-QoL Question 11

"Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity. A negative change from baseline indicates improvement.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-2.1
Placebo (Group C)-0.6

[back to top]

Change From Baseline At Week 24 In The Interference Of Uterine Fibroids With Social Activities Based On UFS-QoL Question 20

"Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity. A negative change from baseline indicates improvement.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-1.7
Placebo (Group C)-0.7

[back to top]

Change From Baseline At Week 24 In The Menorrhagia Impact Questionnaire Score For Physical Activities

"The Menorrhagia Impact was evaluated using a 5-point response scale to assess level of improvement from Baseline to Week 24. Response scale: Not at all, 2. Slightly, 3.Moderately, 4. Quite a bit and 5. Extremely.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-2.0
Placebo (Group C)-0.9

[back to top]

Change From Baseline At Week 24 In The UFS-QoL Activities Scale Score

"Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)44.4
Placebo (Group C)14.6

[back to top]

Change From Baseline At Week 24 In The UFS-QoL Revised Activities Scale Score

"Transformed score ranges from 0 to 100 based on Likert scale (none of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: Baseline, Week 24

Interventionunits on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)45.8
Placebo (Group C)15.1

[back to top]

Change From Baseline At Week 24 In The UFS-QoL Symptom Severity Scale Score

"Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity. A negative change from baseline indicates improvement.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-30.9
Placebo (Group C)-10.5

[back to top]

Change From Baseline At Week 24 In UFS-QoL Bleeding And Pelvic Discomfort Scale Score As Measured By The UFS-QoL (Q1, Q2, Q5)

"The Uterine Fibroid Symptom and Health-Related Quality of Life (UFS-QoL) Bleeding and Pelvic Discomfort (BPD) Scale has been derived from the UFS-QoL Symptoms Scale. The scale consists of the following 3 symptoms proximal to uterine fibroids: Heavy bleeding during your menstrual period (Question [Q] 1), passing blood clots during your menstrual period (Q2), and feeling tightness or pressure in your pelvic area (Q5). raw scores were transformed to a normalized score: Transformed Score = [(Actual raw score - lowest possible raw score)/(Possible raw score range)] * 100 Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity.~As per the study objective, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only these two arms are presented." (NCT03049735)
Timeframe: Baseline, Week 24

Interventionunits on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-45.0
Placebo (Group C)-16.1

[back to top]

Change From Baseline In E2 Serum Concentration At Week 24

As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. (NCT03049735)
Timeframe: Baseline, Week 24

Interventionpg/mL (Mean)
Relugolix Plus E2/NETA (Group A)-22.95
Placebo (Group C)51.72

[back to top]

Change From Baseline In Follicle Stimulating Serum Concentration At Week 24

As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. (NCT03049735)
Timeframe: Baseline, Week 24

InterventionIU/L (Mean)
Relugolix Plus E2/NETA (Group A)-6.25
Placebo (Group C)0.10

[back to top]

Change From Baseline In Luteinizing Serum Concentration At Week 24

As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. (NCT03049735)
Timeframe: Baseline, Week 24

InterventionIU/L (Mean)
Relugolix Plus E2/NETA (Group A)-1.90
Placebo (Group C)3.62

[back to top]

Change From Baseline In Progesterone Serum Concentration At Week 24

As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. (NCT03049735)
Timeframe: Baseline, Week 24

Interventionng/mL (Mean)
Relugolix Plus E2/NETA (Group A)-0.05
Placebo (Group C)3.00

[back to top]

Change From Baseline In UFS-QoL Bleeding And Pelvic Discomfort Scale Score

"The Bleeding and Pelvic Discomfort Scale consists of 3 items proximal to uterine fibroids that are experienced by most patients (heavy bleeding during the menstrual period [Question 1], passing blood clots during the menstrual period [Question 2], and feeling tightness or pressure in the pelvic area [Question 5]).Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity. A negative change from baseline indicates improvement.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-45.0
Placebo (Group C)-16.1

[back to top] [back to top]

Number Of Participants Who Achieved A Maximum NRS Score ≤ 1 For Uterine Fibroid-associated Pain Over The Last 35 Days Of Treatment Who Had Maximum Pain Scores ≥ 4 During The 35 Days Prior To Randomization

"Uterine fibroid-associated pain was assessed by a pain NRS. The pain NRS is a validated, single-item, self-reported measure, which asks respondents to rank their pain on an 11-point scale as follows: 0 (no pain), 1 to 3 (mild pain), 4 to 6 (moderate pain), and 7 to 10 (severe pain).~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: From Baseline up to the last 35 days of treatment (up to 24 weeks)

InterventionParticipants (Count of Participants)
Relugolix Plus E2/NETA (Group A)33
Placebo (Group C)11

[back to top]

Number Of Participants With A ≥ 30% Reduction in NRS Score From Baseline to Last 35 Days of Treatment Who Had Maximum Pain Scores ≥ 4 At Baseline

"Uterine fibroid-associated pain was assessed by a pain NRS. The pain NRS is a validated, single-item, self-reported measure, which asks respondents to rank their pain on an 11-point scale as follows: 0 (no pain), 1 to 3 (mild pain), 4 to 6 (moderate pain), and 7 to 10 (severe pain).~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: Baseline, Week 24

InterventionParticipants (Count of Participants)
Relugolix Plus E2/NETA (Group A)42
Placebo (Group C)27

[back to top]

Number Of Participants With Hemoglobin ≤ 10.5 g/dL At Baseline And Achieved An Increase Of > 2 g/dL At Week 24

As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. (NCT03049735)
Timeframe: From Baseline through Week 24

InterventionParticipants (Count of Participants)
Relugolix Plus E2/NETA (Group A)15
Placebo (Group C)5

[back to top]

Number Of Participants With Hemoglobin Increase Of ≥ 1 g/dL From Baseline To Week 24 Among Those With Below Lower Limit Of Normal

As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. (NCT03049735)
Timeframe: Week 24

InterventionParticipants (Count of Participants)
Relugolix Plus E2/NETA (Group A)34
Placebo (Group C)17

[back to top]

Number Of Responders With At Least 20 Points Decrease In UFS-QoL Bleeding And Pelvic Discomfort Scale Score

"A Responder was defined as meeting a meaningful change threshold, set as a 20-point change from Baseline, in the Bleeding And Pelvic Discomfort Scale at Week 24 on the transformed score.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: Baseline, Week 24

InterventionParticipants (Count of Participants)
Relugolix Plus E2/NETA (Group A)79
Placebo (Group C)35

[back to top]

Number Of Responders With At Least 20 Points Increase From Baseline At Week 24 In UFS-QoL Revised Activities Scale Score

As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. (NCT03049735)
Timeframe: From Baseline through Week 24

InterventionParticipants (Count of Participants)
Relugolix Plus E2/NETA (Group A)78
Placebo (Group C)45

[back to top]

Percent Change From Baseline At Week 12 In Bone Mineral Density At The Lumbar Spine (L1 To L4), As Assessed By DXA

"Bone mineral density (BMD) was assessed by dual-energy x-ray absorptiometry (DXA) at the lumbar spine (L1, L2, L3, and L4) at Baseline and at Week 12. The scans were read by the central radiology laboratory in accordance with the imaging charter. The same DXA machine was used at the local imaging center at each site and operated in the same scan mode for all images procured for an individual participant. All images were submitted for central reading. The central radiology laboratory collected and evaluated all DXA scans for acceptability and measured BMD.~As per the objective of the study, the pre-specified secondary analyses compared relugolix plus E2/NETA with relugolix plus delayed E2/NETA at Week 12 and are presented below." (NCT03049735)
Timeframe: Baseline, Week 12

Interventionpercent change (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-0.470
Relugolix Plus Delayed E2/NETA (Group B)-1.995

[back to top]

Percent Change From Baseline At Week 24 In MBL Volume

MBL volume was measured using the alkaline hematin method. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. (NCT03049735)
Timeframe: Baseline, Week 24

Interventionpercent change (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-84.3
Placebo (Group C)-23.2

[back to top]

Percent Change From Baseline At Week 24 In Primary Uterine Fibroid Volume

"The volume of the primary uterine fibroid was measured by transvaginal or transabdominal ultrasound.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03049735)
Timeframe: Baseline, Week 24

InterventionPercent change (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-12.4
Placebo (Group C)-0.3

[back to top]

Sustained Amenorrhea Rate (No Or Negligible Bleeding)

"Sustained amenorrhea is defined as participants time to achieve and maintain amenorrhea until the date of last study drug.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: Week 24

InterventionParticipants (Count of Participants)
Relugolix Plus E2/NETA (Group A)63
Placebo (Group C)4

[back to top]

Change From Baseline In Luteinizing Serum Concentration At Week 24

As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. (NCT03103087)
Timeframe: Baseline, Week 24

InterventionIU/L (Mean)
Relugolix Plus E2/NETA (Group A)-3.10
Placebo (Group C)3.04

[back to top]

Change From Baseline In Follicle Stimulating Serum Concentration At Week 24

As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. (NCT03103087)
Timeframe: Baseline, Week 24

InterventionIU/L (Mean)
Relugolix Plus E2/NETA (Group A)-5.47
Placebo (Group C)-0.67

[back to top]

Change From Baseline In E2 Serum Concentration At Week 24

As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. (NCT03103087)
Timeframe: Baseline, Week 24

Interventionpg/mL (Mean)
Relugolix Plus E2/NETA (Group A)-22.30
Placebo (Group C)39.85

[back to top]

Change From Baseline At Week 24 In UFS-QoL Bleeding And Pelvic Discomfort Scale Score As Measured By The UFS-QoL (Q1, Q2, Q5)

"The Uterine Fibroid Symptom and Health-Related Quality of Life (UFS-QoL) Bleeding and Pelvic Discomfort (BPD) Scale has been derived from the UFS-QoL Symptoms Scale. The scale consists of the following 3 symptoms proximal to uterine fibroids: Heavy bleeding during your menstrual period (Question [Q] 1), passing blood clots during your menstrual period (Q2), and feeling tightness or pressure in your pelvic area (Q5), raw scores were transformed to a normalized score: Transformed Score = [(Actual raw score - lowest possible raw score)/(Possible raw score range)]*100 Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates symptom severity.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms" (NCT03103087)
Timeframe: Baseline Week 24

Interventionunits on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-51.7
Placebo (Group C)-18.3

[back to top]

Change From Baseline At Week 24 In The UFS-QoL Symptom Severity Scale Score

"Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of time, most of the time and all of the time.) Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity. A negative change from baseline indicates improvement.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-36.1
Placebo (Group C)-13.7

[back to top]

Change From Baseline At Week 24 In The UFS-QoL Revised Activities Scale Score

"Transformed score ranges from 0 to 100 based on Likert scale (none of time, a little of time, some of the time, most of the time and all of the time). Higher scores are indicative of better health-related quality of life (high score = good). LS means and p-value for test of difference was relugolix plus E2/NETA minus placebo based on mixed-effect model with treatment, visit, region, Baseline MBL and treatment by visit interaction included as fixed effects.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: Baseline, Week 24

Interventionunits on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)44.4
Placebo (Group C)16.5

[back to top]

Change From Baseline At Week 24 In The UFS-QoL Activities Scale Score

"Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Higher scores are indicative of better health-related quality of life (high score = good).~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)43.6
Placebo (Group C)17.1

[back to top]

Change From Baseline At Week 24 In The Menorrhagia Impact Questionnaire Score For Social Activities

"The Menorrhagia Impact was evaluated using a 5-point response scale to assess level of improvement from Baseline to Week 24. Response scale: Not at all, 2. Slightly, 3.Moderately, 4. Quite a bit and 5. Extremely.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-1.8
Placebo (Group C)-1.0

[back to top]

Change From Baseline At Week 24 In The Menorrhagia Impact Questionnaire Score For Physical Activities

"The Menorrhagia Impact was evaluated using a 5-point response scale to assess level of improvement from Baseline to Week 24. Response scale: Not at all, 2. Slightly, 3.Moderately, 4. Quite a bit and 5. Extremely.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-1.8
Placebo (Group C)-0.9

[back to top]

Change From Baseline At Week 24 In The Interference Of Uterine Fibroids With Social Activities Based On UFS-QoL Question 20

"Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity. A negative change from baseline indicates improvement.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-1.8
Placebo (Group C)-0.6

[back to top]

Change From Baseline At Week 24 In The Interference Of Uterine Fibroids With Physical Activities Based On UFS-QoL Question 11

"Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity. A negative change from baseline indicates improvement.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-2.0
Placebo (Group C)-0.7

[back to top]

Change From Baseline At Week 24 In Symptoms Assessed Using The Patient Global Assessment (PGA) Questionnaire

"PGAs assessed participants' limitation in activities and the severity of symptoms due to uterine fibroids over the previous 4 weeks, as perceived by the participant. The PGA for symptoms is a 1-item questionnaire designed to assess participant's impression of the severity of their symptoms related to uterine fibroids. The PGA for function and symptoms was evaluated using a 5-point response scale (no limitation at all [1], mild limitation [2], moderate limitation [3], quite a bit of limitation [4], and extreme limitation [5]).~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-2.0
Placebo (Group C)-0.8

[back to top]

Change From Baseline At Week 24 In Predose Concentrations Of E2 In The Relugolix Plus E2/NETA Group

"Blood samples for determination of E2 serum concentrations were collected predose at Week 24. Relugolix and NET plasma concentrations were determined using validated bioanalytical methodology.~Concentrations below the quantification limit (BQL) were set to 0 for analysis of summary statistics. As per the objective of the study, only relugolix plus E2/NETA concentration is presented." (NCT03103087)
Timeframe: Baseline, Week 24

Interventionpg/mL (Mean)
Relugolix Plus E2/NETA (Group A)-22.30

[back to top]

Predose Trough Concentrations Of Relugolix And NET In The Relugolix Plus E2/NETA Group At Week 24

"Blood samples for determination of relugolix and NET plasma concentrations were collected predose at Week 24. Relugolix and NET plasma concentrations were determined using validated bioanalytical methodology.~Concentrations below the quantification limit (BQL) were set to 0 for analysis of summary statistics. As per the objective of the study, only relugolix plus E2/NETA concentration is presented." (NCT03103087)
Timeframe: Week 24

Interventionng/mL (Mean)
RelugolixNET
Relugolix Plus E2/NETA (Group A)1.960.28

[back to top]

Percent Change From Baseline At Week 24 In Bone Mineral Density At The Lumbar Spine (L1 To L4), Total Hip, And Femoral Neck As Assessed By DXA

"BMD was assessed by DXA at the lumbar spine (L1, L2, L3, and L4), total hip, and femoral neck (same leg across participants) at Baseline and at Week 24. The scans were read by the central radiology laboratory in accordance with the imaging charter. The same DXA machine was used at the local imaging center at each site and operated in the same scan mode for all images procured for an individual participant. All images were submitted for central reading. The central radiology laboratory collected and evaluated all DXA scans for acceptability and measured BMD. The LS means were based on a mixed-effect model with visit, region, Baseline MBL volume, age at Baseline, body mass index at Baseline, BMD at Baseline, race, and treatment by visit interaction included as fixed effects. For Relugolix plus E2/NETA Lumbar Spine (L1 to L4), number (n)=95.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only rel" (NCT03103087)
Timeframe: Baseline through Week 24

,
Interventionpercent change (Least Squares Mean)
Lumbar Spine (L1-L4)Total HipFemoral Neck
Placebo (Group C)0.315-0.0440.019
Relugolix Plus E2/NETA (Group A)-0.126-0.173-0.684

[back to top]

Participants Achieving Improvement From Baseline In PGA Questionnaire For Symptoms From Baseline At Week 24

"The PGAs assessed participants' limitation in activities and the severity of symptoms due to uterine fibroids over the previous 4 weeks, as perceived by the participant. The PGA for function and symptoms was evaluated using a 5-point response scale (no limitation at all [1], mild limitation [2], moderate limitation [3], quite a bit of limitation [4], and extreme limitation [5]). Category improvements for symptoms are presented. A 1-category improvement would be severe at baseline to moderate.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: From Baseline through Week 24

,
InterventionParticipants (Count of Participants)
1 Category improvement (-1)3 Category improvement (-3)2 Category improvement (-2)4 Category improvement (-4)
Placebo (Group C)218182
Relugolix Plus E2/NETA (Group A)7222910

[back to top] [back to top]

Time To MBL Response

"Defined as the time to achieve an MBL volume of < 80 mL and a ≥ 50% reduction from Baseline MBL volume as measured by the alkaline hematin method.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: From Baseline through Week 24

Interventionweeks (Median)
Relugolix Plus E2/NETA (Group A)8.4
Placebo (Group C)27.1

[back to top]

Time To Achieving Sustained Amenorrhea (No Or Negligible Bleeding)

"Sustained amenorrhea status as determined based on time to achieve and maintain amenorrhea status.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: From Baseline through Week 24

Interventionweeks (Median)
Relugolix Plus E2/NETA (Group A)16.3
Placebo (Group C)NA

[back to top]

Time To Achieving Amenorrhea (No Or Negligible Bleeding)

"Time to amenorrhea was defined as the weeks from date of first dose of study drug to the start of amenorrhea.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: From Baseline through Week 24

Interventionweeks (Median)
Relugolix Plus E2/NETA (Group A)8.9
Placebo (Group C)NA

[back to top]

Change From Baseline in UFS-QoL Bleeding and Pelvic Discomfort Scale Score

"The Bleeding and Pelvic Discomfort Scale consists of 3 items proximal to uterine fibroids that are experienced by most participants (heavy bleeding during the menstrual period [Question 1], passing blood clots during the menstrual period [Question 2], and feeling tightness or pressure in the pelvic area [Question 5]).Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity. A negative change from baseline indicates improvement.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-51.7
Placebo (Group C)-18.3

[back to top]

Change From Baseline At Week 24 In Function Assessed Using The PGA Questionnaire

"PGAs assessed participants' limitation in activities and the severity of symptoms due to uterine fibroids over the previous 4 weeks, as perceived by the participant. The PGA for symptoms is a 1-item questionnaire designed to assess participant's impression of the severity of their symptoms related to uterine fibroids. The PGA for function and symptoms was evaluated using a 5-point response scale (no limitation at all [1], mild limitation [2], moderate limitation [3], quite a bit of limitation [4], and extreme limitation [5]).~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-1.7
Placebo (Group C)-0.8

[back to top]

Predose Trough Concentrations Of E2 In The Relugolix Plus E2/NETA Group At Week 24

"Blood samples for determination of relugolix and NET plasma concentrations were collected predose at Week 24. Relugolix and NET plasma concentrations were determined using validated bioanalytical methodology.~Concentrations below the quantification limit (BQL) were set to 0 for analysis of summary statistics. As per the objective of the study, only relugolix plus E2/NETA concentration is presented." (NCT03103087)
Timeframe: Week 24

Interventionpg/mL (Mean)
Relugolix Plus E2/NETA (Group A)45.34

[back to top]

Percentage Of Participants With Amenorrhea Over The Last 35 Days Of Treatment

"Amenorrhea was defined as meeting 1 of the following criteria for 2 consecutive visits:~No feminine product returned due to reported amenorrhea;~No feminine product returned due to reports of spotting/negligible bleeding coupled with electronic diary (e-Diary) data indicating infrequent non-cyclic bleeding/spotting;~Feminine product collection with a negligible observed MBL volume coupled with e-Diary data indicating infrequent non-cyclic bleeding/spotting.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: From Baseline up to last 35 days of treatment (up to Week 24)

InterventionPercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)50.40
Placebo (Group C)3.10

[back to top]

Percentage Of Participants With A Maximum Numerical Rating Scale (NRS) Score ≤ 1 For Uterine Fibroid-Associated Pain Over The Last 35 Days Of Treatment

"Uterine fibroid-associated pain was assessed by a pain numerical rating scale (NRS). The pain NRS is a validated, single-item, self-reported measure, which asks respondents to rank their pain on an 11-point scale as follows: 0 (no pain), 1 to 3 (mild pain), 4 to 6 (moderate pain), and 7 to 10 (severe pain).~Participants were asked to document, in an e-Diary, the worst pain associated with their uterine fibroids that they experienced during the last 24 hours, every day until the end of study drug administration. Pain evaluable participants, defined as those who had maximum NRS score ≥ 4 at baseline and had at least 28 days (80% of the last 35 days of treatment) of pain scores recorded in the e-Diary, were analyzed.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: From Baseline up to Week 24

Interventionpercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)47.06
Placebo (Group C)17.07

[back to top]

Percentage Of Participants With A Hemoglobin Level ≤ 10.5 g/dL At Baseline Who Achieved An Increase Of > 2 g/dL From Baseline At Week 24

"Blood samples were collected from participants for hemoglobin measurements. Percentages are based on number of participants with hemoglobin ≤ 10.5 gram (g)/deciliter (dL) at Baseline and reported at Week 24.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA with placebo arms are presented." (NCT03103087)
Timeframe: From Baseline up to Week 24

InterventionPercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)61.29
Placebo (Group C)5.41

[back to top]

Percentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A ≥ 50% Reduction From Baseline MBL Volume With Relugolix Plus E2/NETA

"A responder was a participant who had MBL volume of < 80 mL and at least a 50% reduction from baseline MBL volume over the last 35 days of treatment (up to Week 24). All returned feminine products collected at each clinical visit were analyzed by the alkaline hematin method to obtain the MBL volume. MBL volume was measured over the Week 24/early termination feminine product collection interval (up to 35 days prior to the last dose of treatment). The percentage of participants who were responders are presented.~As per the objective of the study, the pre-specified primary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: From Baseline up to the last 35 days of treatment (up to Week 24)

InterventionPercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)71.2
Placebo (Group C)14.73

[back to top]

Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 24

"An adverse event was defined as an unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or not related to the medicinal product. The preferred terms of hyperhidrosis, feeling hot, hot flush, night sweats, and flushing were combined to describe vasomotor symptoms. Participants with multiple events for a given preferred term were counted only once for each preferred term.~Reported percentages based on the total number of participants in each treatment group.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: Baseline through Week 24

Interventionpercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)6.3
Placebo (Group C)3.9

[back to top]

Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 12

An adverse event was defined as an unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or not related to the medicinal product. The preferred terms of hyperhidrosis, feeling hot, hot flush, night sweats, and flushing were combined to describe vasomotor symptoms. Participants with multiple events for a given preferred term were counted only once for each preferred term. Reported confidence interval (CI) based on exact binomial 95% CI (Clopper-Pearson). As per the objective of the study, the secondary analysis compared relugolix plus E2/NETA with relugolix plus delayed E2/NETA at Week 12 and are presented below. (NCT03103087)
Timeframe: Baseline through Week 12

Interventionpercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)5.56
Relugolix Plus Delayed E2/NETA (Group B)35.71

[back to top]

Percent Change From Baseline At Week 24 In Uterine Volume

"The volume of the uterus was measured by transvaginal or transabdominal ultrasound.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: From Baseline up to Week 24

Interventionpercent change (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-13.8
Placebo (Group C)-1.5

[back to top]

Percent Change From Baseline At Week 24 In Primary Uterine Fibroid Volume

"The volume of the primary uterine fibroid was measured by transvaginal or transabdominal ultrasound.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: Baseline Week 24

Interventionpercent change (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-17.4
Placebo (Group C)-7.4

[back to top]

Change From Baseline At Week 24 In Embarrassment Caused By Uterine Fibroids Based On UFS-QoL Question 29

"Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity. A negative change from baseline indicates improvement.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-1.4
Placebo (Group C)-0.7

[back to top]

Percent Change From Baseline At Week 24 In Hemoglobin For Women With A Hemoglobin Concentration ≤ 10.5 g/dL At Baseline

As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. (NCT03103087)
Timeframe: Baseline, Week 24

Interventionpercent change (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)24.3
Placebo (Group C)4.3

[back to top]

Percent Change From Baseline At Week 12 In Bone Mineral Density At The Lumbar Spine (L1 to L4) As Assessed By DXA

"Bone mineral density (BMD) was assessed by dual-energy x-ray absorptiometry (DXA) at the lumbar spine (L1, L2, L3, and L4) at Baseline and at Week 12. The scans were read by the central radiology laboratory in accordance with the imaging charter. The same DXA machine was used at the local imaging center at each site and operated in the same scan mode for all images procured for an individual participant. All images were submitted for central reading. The central radiology laboratory collected and evaluated all DXA scans for acceptability and measured BMD. The LS means were based on a mixed-effect model with visit, region, Baseline MBL volume, age at Baseline, body mass index at Baseline, BMD at Baseline, race, and treatment by visit interaction included as fixed effects.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: From Baseline up to Week 12

Interventionpercent change (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-0.819
Relugolix Plus Delayed E2/NETA (Group B)-1.919

[back to top]

Number Of Responders With At Least 20 Points Increase From Baseline At Week 24 In UFS-QoL Revised Activities Scale Score

As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. (NCT03103087)
Timeframe: From Baseline through Week 24

InterventionParticipants (Count of Participants)
Relugolix Plus E2/NETA (Group A)78
Placebo (Group C)42

[back to top]

Number Of Responders With At Least 20 Points Decrease in UFS-QoL Bleeding And Pelvic Discomfort Scale Score

"Responder was defined as meeting a meaningful change threshold, set as a 20-point change from Baseline, in the Bleeding And Pelvic Discomfort Scale at Week 24 on the transformed score.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: Baseline, Week 24

InterventionParticipants (Count of Participants)
Relugolix Plus E2/NETA (Group A)79
Placebo (Group C)37

[back to top]

Number Of Participants With Hemoglobin Increase Of ≥ 1 g/dL From Baseline To Week 24 Among Those With Below Lower Limit Of Normal

As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. (NCT03103087)
Timeframe: Week 24

InterventionParticipants (Count of Participants)
Relugolix Plus E2/NETA (Group A)35
Placebo (Group C)18

[back to top]

Number Of Participants With Hemoglobin ≤ 10.5 g/dL At Baseline And Achieved An Increase Of > 2 g/dL At Week 24

As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. (NCT03103087)
Timeframe: From Baseline through Week 24

InterventionParticipants (Count of Participants)
Relugolix Plus E2/NETA (Group A)19
Placebo (Group C)2

[back to top]

Number Of Participants With A ≥ 30% Reduction in NRS Score From Baseline to Last 35 Days of Treatment Who Had Maximum Pain Scores ≥ 4 At Baseline

"Uterine fibroid-associated pain was assessed by a pain NRS. The pain NRS is a validated, single-item, self-reported measure, which asks respondents to rank their pain on an 11-point scale as follows: 0 (no pain), 1 to 3 (mild pain), 4 to 6 (moderate pain), and 7 to 10 (severe pain).~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: Baseline, Week 24

InterventionParticipants (Count of Participants)
Relugolix Plus E2/NETA (Group A)48
Placebo (Group C)34

[back to top]

Percent Change From Baseline At Week 24 In MBL Volume

"MBL volume was measured using the alkaline hematin method. Least square (LS) means for test of difference is Relugolix plus E2/NETA minus Placebo based on mixed-effect model with treatment, visit, region, Baseline MBL, and treatment by visit interaction included as fixed effects.~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: Baseline, Week 24

Interventionpercent change (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-84.3
Placebo (Group C)-15.1

[back to top]

Change From Baseline In Progesterone Serum Concentration At Week 24

As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. (NCT03103087)
Timeframe: Baseline, Week 24

Interventionng/mL (Mean)
Relugolix Plus E2/NETA (Group A)0.12
Placebo (Group C)3.48

[back to top]

Number Of Participants Who Achieved A Maximum NRS Score ≤ 1 For Uterine Fibroid-associated Pain Over The Last 35 Days Of Treatment Who Had Maximum Pain Scores ≥ 4 During The 35 Days Prior To Randomization

"Uterine fibroid-associated pain was assessed by a pain NRS. The pain NRS is a validated, single-item, self-reported measure, which asks respondents to rank their pain on an 11-point scale as follows: 0 (no pain), 1 to 3 (mild pain), 4 to 6 (moderate pain), and 7 to 10 (severe pain).~As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented." (NCT03103087)
Timeframe: From Baseline up to the last 35 days of treatment (up to 24 weeks)

InterventionParticipants (Count of Participants)
Relugolix Plus E2/NETA (Group A)34
Placebo (Group C)17

[back to top] [back to top]

Change From Baseline in DYS at Month 6 Based on Daily Assessment

"Participants assessed DYS (pain during menstruation) and its impact on their daily activities each day of their period in an e-Diary. DYS was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following:~0: No discomfort~Mild discomfort but I was easily able to do the things I usually do~Moderate discomfort or pain that made it difficult to do some of the things I usually do~Severe pain that made it difficult to do the things I usually do.~Pain scores were averaged over the 35 days prior to each visit." (NCT03213457)
Timeframe: Baseline, Month 6

Interventionscore on a scale (Least Squares Mean)
Placebo-0.62
Elagolix + E2/NETA-1.64

[back to top]

Change From Baseline in DYS at Month 3 Based on Daily Assessment

"Participants assessed DYS (pain during menstruation) and its impact on their daily activities each day of their period in an e-Diary. DYS was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following:~0: No discomfort~Mild discomfort but I was easily able to do the things I usually do~Moderate discomfort or pain that made it difficult to do some of the things I usually do~Severe pain that made it difficult to do the things I usually do.~Pain scores were averaged over the 35 days prior to each visit." (NCT03213457)
Timeframe: Baseline, Month 3

Interventionscore on a scale (Least Squares Mean)
Placebo-0.56
Elagolix + E2/NETA-1.54

[back to top]

Change From Baseline in Endometriosis-Associated Pain Score at Month 12 Assessed With Numeric Rating Scale (NRS)

The NRS measured endometriosis-associated pain with and without menstruation on an 11-point scale from 0 = no pain to 10 = worst pain ever. Site staff administered the Overall Endometriosis-Associated Pain questionnaire assessing pain over a 7-day recall period, and recorded the participant's response electronically via a tablet at the time of visit. Pain scores were averaged over the 35 days prior to each visit. (NCT03213457)
Timeframe: Baseline, Month 12

Interventionscore on a scale (Least Squares Mean)
Placebo-3.25
Elagolix + E2/NETA-4.39

[back to top]

Change From Baseline in Endometriosis-Associated Pain Score at Month 3 Assessed With NRS

The NRS measured endometriosis-associated pain with and without menstruation on an 11-point scale from 0 = no pain to 10 = worst pain ever. Site staff administered the Overall Endometriosis-Associated Pain questionnaire assessing pain over a 7-day recall period, and recorded the participant's response electronically via a tablet at the time of visit. Pain scores were averaged over the 35 days prior to each visit. (NCT03213457)
Timeframe: Baseline, Month 3

Interventionscore on a scale (Least Squares Mean)
Placebo-2.33
Elagolix + E2/NETA-3.79

[back to top]

Change From Baseline in Endometriosis-Associated Pain Score at Month 6 Assessed With NRS

The NRS measured endometriosis-associated pain with and without menstruation on an 11-point scale from 0 = no pain to 10 = worst pain ever. Site staff administered the Overall Endometriosis-Associated Pain questionnaire assessing pain over a 7-day recall period, and recorded the participant's response electronically via a tablet at the time of visit. Pain scores were averaged over the 35 days prior to each visit. (NCT03213457)
Timeframe: Baseline, Month 6

Interventionscore on a scale (Least Squares Mean)
Placebo-2.74
Elagolix + E2/NETA-4.12

[back to top]

Change From Baseline in NMPP at Month 3 Based on Daily Assessment

"Participants recorded rescue analgesic medication for endometriosis-associated pain and assessed NMPP and its impact on their daily activities each day in an e-Diary was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following:~0: No discomfort~1: Mild discomfort but I was easily able to do the things I usually do~2: Moderate discomfort or pain that made it difficult to do some of the things I usually do~3: Severe pain that made it difficult to do the things I usually do.~Pain scores and analgesic use were averaged over the 35 days prior to each visit." (NCT03213457)
Timeframe: Baseline, Month 3

Interventionscore on a scale (Least Squares Mean)
Placebo-0.49
Elagolix + E2/NETA-0.65

[back to top]

Change From Baseline in NMPP at Month 6 Based on Daily Assessment

"Participants recorded rescue analgesic medication for endometriosis-associated pain and assessed NMPP and its impact on their daily activities each day in an e-Diary was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following:~0: No discomfort~1: Mild discomfort but I was easily able to do the things I usually do~2: Moderate discomfort or pain that made it difficult to do some of the things I usually do~3: Severe pain that made it difficult to do the things I usually do.~Pain scores and analgesic use were averaged over the 35 days prior to each visit." (NCT03213457)
Timeframe: Baseline, Month 6

Interventionscore on a scale (Least Squares Mean)
Placebo-0.57
Elagolix + E2/NETA-0.78

[back to top]

Change From Baseline in Non-menstrual Pelvic Pain (NMPP) at Month 12 Based on Daily Assessment

"Participants recorded rescue analgesic medication for endometriosis-associated pain and assessed NMPP and its impact on their daily activities each day in an e-Diary was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following:~0: No discomfort~1: Mild discomfort but I was easily able to do the things I usually do~2: Moderate discomfort or pain that made it difficult to do some of the things I usually do~3: Severe pain that made it difficult to do the things I usually do.~Pain scores and analgesic use were averaged over the 35 days prior to each visit." (NCT03213457)
Timeframe: Baseline, Month 12

Interventionscore on a scale (Least Squares Mean)
Placebo-0.64
Elagolix + E2/NETA-0.86

[back to top]

Change From Baseline in Dyspareunia (DYSP) at Month 12 Based on Daily Assessment

"Participants assessed DYSP each day in an e-Diary according to the following response options:~0: None; No discomfort during sexual intercourse~1: Mild; Able to tolerate the discomfort during sexual intercourse~2: Moderate; Intercourse was interrupted due to pain~3: Severe; Avoided intercourse because of pain~Not applicable; I was not sexually active for reasons other than endometriosis or did not have sexual intercourse.~Pain scores were averaged over the 35 days prior to each visit. Responses of Not Applicable were excluded." (NCT03213457)
Timeframe: Baseline, Month 12

Interventionscore on a scale (Least Squares Mean)
Placebo-0.60
Elagolix + E2/NETA-0.70

[back to top]

Change From Baseline to Month 6 in Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue Short Form 6a T-Score

The PROMIS Fatigue Short Form 6a is self-administered and composed of 6 questions to evaluate fatigue over the past 7 days. All questions employ the following five response options: 1 = Never, 2 = Rarely, 3 = Sometimes, 4 = Often, and 5 = Always. The PROMIS Fatigue 6a score is calculated as a T-score, which is a standardized score with a mean of 50 (based on the average for the United States general population) and a standard deviation (SD) of 10. Higher scores indicate higher levels of fatigue. A decrease in score (negative change from baseline) indicates improvement in fatigue. (NCT03213457)
Timeframe: Baseline, Month 6

InterventionT-score (Least Squares Mean)
Placebo-4.71
Elagolix + E2/NETA-7.22

[back to top]

Co-Primary Endpoint: Percentage of Participants With a Response for Dysmenorrhea (DYS) at Months 6 and 12 Based on Daily Assessment

"Participants recorded rescue analgesic use for endometriosis-associated pain daily and DYS (pain during menstruation ) and its impact on daily activities each day of their period in an electronic diary (e-Diary). DYS was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following:~0: No discomfort~1: Mild discomfort but I was easily able to do the things I usually do~2: Moderate discomfort or pain that made it difficult to do some of the things I usually do~3: Severe pain that made it difficult to do the things I usually do.~Pain scores and analgesic use were averaged over 35 days prior to each visit.~Response was defined as a reduction of -0.92 or more from baseline in DYS as well as no increase in rescue analgesic use for endometriosis-associated pain (defined as a < 15% increase in average rescue analgesic pill count and no additional analgesic)." (NCT03213457)
Timeframe: Month 6, Month 12

,
Interventionpercentage of participants (Number)
Month 6Month 12
Elagolix + E2/NETA62.863.8
Placebo23.729.1

[back to top]

Co-Primary Endpoint: Percentage of Participants With a Response for Non-menstrual Pelvic Pain (NMPP) at Months 6 and 12 Based on Daily Assessment

"Participants recorded rescue analgesic medication for endometriosis-associated pain and assessed NMPP and its impact on their daily activities each day in an e-Diary was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following:~0: No discomfort~1: Mild discomfort but I was easily able to do the things I usually do~2: Moderate discomfort or pain that made it difficult to do some of the things I usually do~3: Severe pain that made it difficult to do the things I usually do.~Pain scores and analgesic use were averaged over the 35 days prior to each visit.~Response was defined as a reduction of -0.55 or greater from baseline for NMPP as well as no increase in rescue analgesic use for endometriosis-associated pain (defined as a < 15% increase in average pill count of rescue analgesics and no additional analgesics)." (NCT03213457)
Timeframe: Month 6, Month 12

,
Interventionpercentage of participants (Number)
Month 6Month 12
Elagolix + E2/NETA51.354.3
Placebo36.842.3

[back to top]

Change From Baseline in DYS at Month 12 Based on Daily Assessment

"Participants assessed DYS (pain during menstruation) and its impact on their daily activities each day of their period in an e-Diary. DYS was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following:~0: No discomfort~1: Mild discomfort but I was easily able to do the things I usually do~2: Moderate discomfort or pain that made it difficult to do some of the things I usually do~3: Severe pain that made it difficult to do the things I usually do.~Pain scores were averaged over the 35 days prior to each visit." (NCT03213457)
Timeframe: Baseline, Month 12

Interventionscore on a scale (Least Squares Mean)
Placebo-0.73
Elagolix + E2/NETA-1.73

[back to top]

Change From Baseline in DYSP at Month 3 Based on Daily Assessment

"Participants assessed DYSP each day in an e-Diary according to the following response options:~0: None; No discomfort during sexual intercourse~1: Mild; Able to tolerate the discomfort during sexual intercourse~2: Moderate; Intercourse was interrupted due to pain~3: Severe; Avoided intercourse because of pain~Not applicable; I was not sexually active for reasons other than endometriosis or did not have sexual intercourse.~Pain scores were averaged over the 35 days prior to each visit. Responses of Not Applicable were excluded." (NCT03213457)
Timeframe: Baseline, Month 3

Interventionscore on a scale (Least Squares Mean)
Placebo-0.40
Elagolix + E2/NETA-0.62

[back to top]

Change From Baseline in DYSP at Month 6 Based on Daily Assessment

"Participants assessed DYSP each day in an e-Diary according to the following response options:~0: None; No discomfort during sexual intercourse~1: Mild; Able to tolerate the discomfort during sexual intercourse~2: Moderate; Intercourse was interrupted due to pain~3: Severe; Avoided intercourse because of pain~Not applicable; I was not sexually active for reasons other than endometriosis or did not have sexual intercourse.~Pain scores were averaged over the 35 days prior to each visit. Responses of Not Applicable were excluded." (NCT03213457)
Timeframe: Baseline, Month 6

Interventionscore on a scale (Least Squares Mean)
Placebo-0.54
Elagolix + E2/NETA-0.63

[back to top]

Change From Baseline to Month 12 in Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue Short Form 6a T-Score

The PROMIS Fatigue Short Form 6a is self-administered and composed of 6 questions to evaluate fatigue over the past 7 days. All questions employ the following five response options: 1 = Never, 2 = Rarely, 3 = Sometimes, 4 = Often, and 5 = Always. The PROMIS Fatigue 6a score is calculated as a T-score, which is a standardized score with a mean of 50 (based on the average for the United States general population) and a standard deviation (SD) of 10. Higher scores indicate higher levels of fatigue. A decrease in score (negative change from baseline) indicates improvement in fatigue. (NCT03213457)
Timeframe: Baseline, Month 12

InterventionT-score (Least Squares Mean)
Placebo-6.43
Elagolix + E2/NETA-8.92

[back to top]

Change From Baseline Over Time in Monthly Average Dyspareunia Pain Score

The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

Interventionscore on a scale (Mean)
Change at Month 1Change at Month 2Change at Month 3Change at Month 4Change at Month 5Change at Month 6
Group B0.300.060.070.090.090.29

[back to top]

Change From Baseline Over Time in Monthly Average Dyspareunia Pain Score

The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

,
Interventionscore on a scale (Mean)
Change at Month 1Change at Month 2Change at Month 3Change at Month 4
Group A-0.50-1.44-2.20-2.23
Group C-0.29-0.37-0.03-0.03

[back to top]

Change From Baseline Over Time in Monthly Average DYS Pain Score

"The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.~The analysis was based on a 28-day window. If a participant prematurely discontinued during the open-label period, based on the analysis window, some data might fall into Month 4 analysis." (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

Interventionscore on a scale (Mean)
Change at Month 1Change at Month 2Change at Month 3Change at Month 4Change at Month 5Change at Month 6
Group B-0.04-0.26-0.34-0.06-0.16-0.23

[back to top]

Change From Baseline Over Time in Monthly Average DYS Pain Score

"The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.~The analysis was based on a 28-day window. If a participant prematurely discontinued during the open-label period, based on the analysis window, some data might fall into Month 4 analysis." (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

Interventionscore on a scale (Mean)
Change at Month 1Change at Month 2Change at Month 3Change at Month 4
Group A0.05-0.18-0.50-0.69

[back to top]

Change From Baseline Over Time in Monthly Average Daily Diary Endometriosis-Associated Pain Score Via NRS

The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

Interventionscore on a scale (Mean)
Change at Month 1Change at Month 2Change at Month 3Change at Month 4Change at Month 5Change at Month 6
Group B-0.89-2.02-1.81-1.43-1.40-1.36

[back to top]

Change From Baseline Over Time in Monthly Average Daily Diary Endometriosis-Associated Pain Score Via NRS

The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

,
Interventionscore on a scale (Mean)
Change at Month 1Change at Month 2Change at Month 3Change at Month 4
Group A-0.86-2.40-3.70-6.43
Group C-0.84-1.40-1.34-1.06

[back to top]

Change From Baseline Over Time in Daily Rescue Analgesic Use Across Both Classes of Rescue Analgesics

Based on average pill counts and assessed using a daily e-Diary. Permitted non-steroidal anti-inflammatory drugs (NSAIDs) included naproxen, ibuprofen, diclofenac, and celecoxib. Permitted opioids included hydrocodone + acetaminophen and codeine phosphate + acetaminophen. (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

Interventionpills/day (Mean)
NSAID: Change at Month 1NSAID: Change at Month 2NSAID: Change at Month 3NSAID: Change at Month 4NSAID: Change at Month 5NSAID: Change at Month 6Opioid: Change at Month 1Opioid: Change at Month 2Opioid: Change at Month 3Opioid: Change at Month 4Opioid: Change at Month 5Opioid: Change at Month 6NSAID + Opioid: Change at Month 1NSAID + Opioid: Change at Month 2NSAID + Opioid: Change at Month 3NSAID + Opioid: Change at Month 4NSAID + Opioid: Change at Month 5NSAID + Opioid: Change at Month 6
Group B0.09-0.17-0.430.010.230.63-0.06-0.030.02-0.01-0.050.090.03-0.20-0.41-0.000.180.71

[back to top]

Change From Baseline Over Time in Daily Rescue Analgesic Use Across Both Classes of Rescue Analgesics

Based on average pill counts and assessed using a daily e-Diary. Permitted non-steroidal anti-inflammatory drugs (NSAIDs) included naproxen, ibuprofen, diclofenac, and celecoxib. Permitted opioids included hydrocodone + acetaminophen and codeine phosphate + acetaminophen. (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

,
Interventionpills/day (Mean)
NSAID: Change at Month 1NSAID: Change at Month 2NSAID: Change at Month 3NSAID: Change at Month 4Opioid: Change at Month 1Opioid: Change at Month 2Opioid: Change at Month 3Opioid: Change at Month 4NSAID + Opioid: Change at Month 1NSAID + Opioid: Change at Month 2NSAID + Opioid: Change at Month 3NSAID + Opioid: Change at Month 4
Group A-0.84-1.15-0.96-1.690.12-0.17-0.17-0.34-0.72-1.33-1.13-2.03
Group C-0.670.63-0.71-0.63-0.43-0.51-0.49-0.40-1.10-1.14-1.20-1.03

[back to top]

Change From Baseline in Rescue Analgesic Use Across Both Classes of Rescue Analgesics (NSAIDs/Opioids) at Month 6

Based on average pill counts and assessed using the daily e-Diary. Permitted non-steroidal anti-inflammatory drugs (NSAIDs) included naproxen, ibuprofen, diclofenac, and celecoxib. Permitted opioids included hydrocodone + acetaminophen and codeine phosphate + acetaminophen. (NCT03343067)
Timeframe: Month 0 (baseline), Month 6

Interventionpills/day (Mean)
NSAID: Change at Month 6Opioid: Change at Month 6NSAID + Opioid: Change at Month 6
Group B0.630.090.71

[back to top]

Percentage of Participants With 30% or More Reduction From Baseline Based on the 35 Day Mean of the Daily Diary Endometriosis-Associated Pain Score Via NRS at Month 6

The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. (NCT03343067)
Timeframe: Month 6

Interventionpercentage of participants (Number)
Group B50.0

[back to top]

Change From Baseline in NMPP at Month 6

The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. (NCT03343067)
Timeframe: Month 0 (baseline), Month 6

Interventionscore on a scale (Mean)
Group B-0.13

[back to top]

Change From Baseline in Dyspareunia at Month 6

The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. (NCT03343067)
Timeframe: Month 0 (baseline), Month 6

Interventionscore on a scale (Mean)
Group B0.29

[back to top]

Change From Baseline in DYS at Month 6

The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. (NCT03343067)
Timeframe: Month 0 (baseline), Month 6

Interventionscore on a scale (Mean)
Group B-0.23

[back to top]

Change From Baseline in Daily Diary Endometriosis-Associated Pain Score Via Numeric Rating Scale (NRS) at Month 6

The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. (NCT03343067)
Timeframe: Month 0 (baseline), Month 6

Interventionscore on a scale (Mean)
Group B-1.36

[back to top]

EuroQol-5D 5 Level (EQ-5D-5L) Scores Over Time: Mobility

The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable). (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

Interventionscore on a scale (Mean)
BaselineMonth 3Month 6
Group B1.01.01.0

[back to top]

WPAI:SHP Scores Over Time: Percent Overall Work Impairment Due to Problem

The mean percentage of overall work impairment due to health problem (based on the WPAI questionnaire) is presented, and is calculated as: Absenteeism (%) + extent to which health problem decreased productivity (%)* [number of hours worked / (number of hours of work missed due to health problem + number of hours worked)]. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. (NCT03343067)
Timeframe: Month 0 (baseline), Month 6

,
Interventionpercent overall work impairment (Mean)
BaselineMonth 6
Group A0.610.30
Group B0.560.30

[back to top]

WPAI:SHP Scores Over Time: Percent Impairment While Working Due to Problem

Presenteeism (the extent to which health problem decreased productivity) is presented as the mean percentage of impairment while working due to health problem, and is calculated as: 100*scale value of question 5 on the WPAI (between 0 and 10) / 10. WPAI:SHP is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. (NCT03343067)
Timeframe: Month 0 (baseline), Month 6

,
Interventionpercent impairment while working (Mean)
BaselineMonth 6
Group A0.570.30
Group B0.530.30

[back to top]

WPAI:SHP Scores Over Time: Percent Activity Impairment Due to Problem

Activity impairment due to health problem (the extent to which health problem affected the ability to perform usual daily activities) is presented as the mean percentage of activity impairment, and is calculated as 100*scale value of WPAI question 6 (between 0 and 10) / 10. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. (NCT03343067)
Timeframe: Month 0 (baseline), Month 6

,,
Interventionpercentage impairment of activity (Mean)
BaselineMonth 6
Group A0.660.40
Group B0.670.30
Group C0.700.70

[back to top]

Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) Scores Over Time: Percent Work Missed Due to Problem

Absenteeism is presented as the mean percentage of work time missed due to health problem (as reported on the WPAI:SHP), and is calculated as: 100*number of hours of work missed due to health problem / (number of hours of work missed due to health problem + number of hours worked). WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. (NCT03343067)
Timeframe: Month 0 (baseline), Month 6

,
Interventionpercent of work time missed (Mean)
BaselineMonth 6
Group A0.160.00
Group B0.080.00

[back to top]

PROMIS Fatigue Short Form 6a Scores Over Time

The PROMIS Fatigue Short Form 6a is self-administered and composed of 6 questions to evaluate fatigue. Possible scores range from 6 to 30, 6 = not at all (no fatigue), and 30 = very much (most fatigue). (NCT03343067)
Timeframe: Month 0 (baseline), Month 6

,,
Interventionscore on a scale (Mean)
BaselineMonth 6
Group A22.115.3
Group B19.311.0
Group C27.021.0

[back to top]

Percent Change From Baseline to Each Month During the Treatment Period for NMPP

The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

Interventionpercentage change of units on a scale (Mean)
Percent Change at Month 1Percent Change at Month 2Percent Change at Month 3Percent Change at Month 4Percent Change at Month 5Percent Change at Month 6
Group B4.22-34.21-38.03-44.49-28.40-17.23

[back to top]

Percent Change From Baseline to Each Month During the Treatment Period for NMPP

The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

,
Interventionpercentage change of units on a scale (Mean)
Percent Change at Month 1Percent Change at Month 2Percent Change at Month 3Percent Change at Month 4
Group A-11.81-37.53-38.26-71.21
Group C16.0711.9022.6219.05

[back to top]

Percent Change From Baseline to Each Month During the Treatment Period for Dyspareunia

The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

Interventionpercentage change of units on a scale (Mean)
Percent Change at Month 1Percent Change at Month 2Percent Change at Month 3Percent Change at Month 4Percent Change at Month 5Percent Change at Month 6
Group B-15.27-15.26-21.63-12.67-14.86-18.08

[back to top]

Percent Change From Baseline to Each Month During the Treatment Period for Dyspareunia

The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

,
Interventionpercentage change of units on a scale (Mean)
Percent Change at Month 1Percent Change at Month 2Percent Change at Month 3Percent Change at Month 4
Group A0.146.6060.88106.25
Group C-9.52-12.38-0.95-0.95

[back to top]

Percent Change From Baseline to Each Month During the Treatment Period for DYS

The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

Interventionpercent change of units on a scale (Mean)
Percent Change at Month 1Percent Change at Month 2Percent Change at Month 3Percent Change at Month 4Percent Change at Month 5Percent Change at Month 6
Group B-7.89-75.00-85.71-16.67-40.48-57.14

[back to top]

Percent Change From Baseline to Each Month During the Treatment Period for DYS

The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

Interventionpercent change of units on a scale (Mean)
Percent Change at Month 1Percent Change at Month 2Percent Change at Month 3Percent Change at Month 4
Group A1.67-27.45-62.92-80.00

[back to top]

Percent Change From Baseline to Each Month During the Treatment Period for Daily Diary Endometriosis-Associated Pain Score Via NRS

The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

Interventionpercentage change of score on a scale (Mean)
Percent Change at Month 1Percent Change at Month 2Percent Change at Month 3Percent Change at Month 4Percent Change at Month 5Percent Change at Month 6
Group B-19.61-56.25-53.05-38.00-35.81-33.56

[back to top]

Percent Change From Baseline to Each Month During the Treatment Period for Daily Diary Endometriosis-Associated Pain Score Via NRS

The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

,
Interventionpercentage change of score on a scale (Mean)
Percent Change at Month 1Percent Change at Month 2Percent Change at Month 3Percent Change at Month 4
Group A-14.10-37.82-43.98-70.98
Group C-11.34-18.99-18.22-14.34

[back to top]

Patient Global Impression of Change (PGIC) Scores Over Time

The PGIC is a 7-point response scale where participants rate their endometriosis related pain as: very much improved (1), much improved (2), minimally improved (3), not changed (4), minimally worse (5), much worse (6), very much worse (7). (NCT03343067)
Timeframe: Months 1, 2, 3, 4, 5, 6

Interventionscore on a scale (Mean)
Month 1Month 2Month 3Month 4Month 5Month 6
Group B2.31.32.02.02.51.0

[back to top]

Patient Global Impression of Change (PGIC) Scores Over Time

The PGIC is a 7-point response scale where participants rate their endometriosis related pain as: very much improved (1), much improved (2), minimally improved (3), not changed (4), minimally worse (5), much worse (6), very much worse (7). (NCT03343067)
Timeframe: Months 1, 2, 3, 4, 5, 6

Interventionscore on a scale (Mean)
Month 1Month 2Month 3Month 4
Group C2.02.05.02.0

[back to top]

Patient Global Impression of Change (PGIC) Scores Over Time

The PGIC is a 7-point response scale where participants rate their endometriosis related pain as: very much improved (1), much improved (2), minimally improved (3), not changed (4), minimally worse (5), much worse (6), very much worse (7). (NCT03343067)
Timeframe: Months 1, 2, 3, 4, 5, 6

Interventionscore on a scale (Mean)
Month 1Month 2Month 3
Group A2.92.02.0

[back to top]

Overall Endometriosis-Associated Pain Via NRS (7-Day Recall) Scores Over Time

The endometriosis-associated pain questionnaire is an 11-point NRS assessing overall endometriosis-associated pain over a 7-day recall period. Participants assessed their endometriosis-associated pain on a scale of 0 to 10, with 0 = no pain and 10 = worst pain ever. (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

Interventionscore on a scale (Mean)
BaselineMonth 1Month 2Month 3Month 4Month 5Month 6
Group B9.07.72.75.33.38.04.0

[back to top]

Overall Endometriosis-Associated Pain Via NRS (7-Day Recall) Scores Over Time

The endometriosis-associated pain questionnaire is an 11-point NRS assessing overall endometriosis-associated pain over a 7-day recall period. Participants assessed their endometriosis-associated pain on a scale of 0 to 10, with 0 = no pain and 10 = worst pain ever. (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

Interventionscore on a scale (Mean)
BaselineMonth 1Month 2Month 3Month 4
Group C7.08.05.08.07.0

[back to top]

Overall Endometriosis-Associated Pain Via NRS (7-Day Recall) Scores Over Time

The endometriosis-associated pain questionnaire is an 11-point NRS assessing overall endometriosis-associated pain over a 7-day recall period. Participants assessed their endometriosis-associated pain on a scale of 0 to 10, with 0 = no pain and 10 = worst pain ever. (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

Interventionscore on a scale (Mean)
BaselineMonth 1Month 2Month 3
Group A8.25.74.59.0

[back to top]

Number of Analgesic Use Responders and Non-Responders Over Time

"Based only on reduction of rescue analgesics used. Responders were defined as:~participants with no analgesic use at screening and no analgesic use added~participants with NSAID only use at screening and NSAID dose stopped, decreased, or stable (<15% increase) and no opioid use added~participants with opioid only use at screening and opioid dose stopped, decreased, or stable (<15% increase), opioid dose stopped and NSAID substituted (any dose), opioid dose decreased and NSAID added (any dose)~participants with NSAID + opioid use at screening and any of the following: NSAID dose stopped + opioid analgesic use stopped, decreased, or stable (<15% increase); NSAID dose decreased + opioid analgesic use stopped, decreased, or stable (<15% increase); NSAID dose stable (< 15% increase) + opioid analgesic use stopped, decreased, or stable (<15% increase); NSAID dose increased by >15% + opioid analgesic use stopped; NSAID dose increased by >15% + opioid analgesic dose decreases." (NCT03343067)
Timeframe: Months 1, 2, 3, 4, 5, 6

,,
InterventionParticipants (Count of Participants)
Month 1: ResponderMonth 1: Non-ResponderMonth 2: ResponderMonth 2: Non-ResponderMonth 3: ResponderMonth 3: Non-ResponderMonth 4: ResponderMonth 4: Non-ResponderMonth 5: ResponderMonth 5: Non-ResponderMonth 6: ResponderMonth 6: Non-Responder
Group A524120100000
Group B212112212102
Group C101010100000

[back to top]

Health Endometriosis Treatment Satisfaction Questionnaire (ETSQ) Scores Over Time

The 6-item ETSQ was developed to assess patient-reported satisfaction with effects on endometriosis pain, dysmenorrhea, dyspareunia, amount of bleeding tolerability and overall treatment satisfaction. The ETSQ has a 7 point response scale. The range for this scale is 0 to 36, with lower ETSQ scores reflecting lower levels of satisfaction with endometriosis treatment. (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

Interventionscore on a scale (Mean)
BaselineMonth 3Month 6
Group B18.0025.4731.00

[back to top]

Health Endometriosis Treatment Satisfaction Questionnaire (ETSQ) Scores Over Time

The 6-item ETSQ was developed to assess patient-reported satisfaction with effects on endometriosis pain, dysmenorrhea, dyspareunia, amount of bleeding tolerability and overall treatment satisfaction. The ETSQ has a 7 point response scale. The range for this scale is 0 to 36, with lower ETSQ scores reflecting lower levels of satisfaction with endometriosis treatment. (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

,
Interventionscore on a scale (Mean)
BaselineMonth 3
Group A19.7122.25
Group C18.0025.00

[back to top]

EuroQol-5D 5 Level (EQ-5D-5L) Scores Over Time: Mobility

The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable). (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

,
Interventionscore on a scale (Mean)
BaselineMonth 3
Group A1.41.3
Group C1.02.0

[back to top]

EQ-5D-5L VAS Scores Over Time: Health Today

The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate VAS indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable). (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

Interventionscore on a scale (Mean)
BaselineMonth 3Month 6
Group B53.385.094.0

[back to top]

EQ-5D-5L VAS Scores Over Time: Health Today

The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate VAS indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable). (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

,
Interventionscore on a scale (Mean)
BaselineMonth 3
Group A79.772.8
Group C72.070.0

[back to top]

EQ-5D-5L Scores Over Time: Usual Activities

The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable). (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

Interventionscore on a scale (Mean)
BaselineMonth 3Month 6
Group B1.31.71.0

[back to top]

EQ-5D-5L Scores Over Time: Usual Activities

The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable). (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

,
Interventionscore on a scale (Mean)
BaselineMonth 3
Group A2.01.5
Group C1.02.0

[back to top]

EQ-5D-5L Scores Over Time: Self-Care

The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable). (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

Interventionscore on a scale (Mean)
BaselineMonth 3Month 6
Group B1.01.01.0

[back to top]

EQ-5D-5L Scores Over Time: Self-Care

The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable). (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

,
Interventionscore on a scale (Mean)
BaselineMonth 3
Group A1.01.0
Group C1.01.0

[back to top]

EQ-5D-5L Scores Over Time: Pain/Discomfort

The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable). (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

Interventionscore on a scale (Mean)
BaselineMonth 3Month 6
Group B2.71.71.0

[back to top]

EQ-5D-5L Scores Over Time: Pain/Discomfort

The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable). (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

,
Interventionscore on a scale (Mean)
BaselineMonth 3
Group A2.72.0
Group C4.03.0

[back to top]

EQ-5D-5L Scores Over Time: Anxiety/Depression

The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable). (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

Interventionscore on a scale (Mean)
BaselineMonth 3Month 6
Group B1.31.01.0

[back to top]

EQ-5D-5L Scores Over Time: Anxiety/Depression

The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable). (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

,
Interventionscore on a scale (Mean)
BaselineMonth 3
Group A1.01.0
Group C1.01.0

[back to top]

Endometriosis Health Profile-30 (EHP-30) Scores Over Time: Pain

The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status. (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

Interventionscore on a scale (Mean)
BaselineMonth 3Month 6
Group B47.7317.4227.27

[back to top]

Endometriosis Health Profile-30 (EHP-30) Scores Over Time: Pain

The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status. (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

,
Interventionscore on a scale (Mean)
BaselineMonth 3
Group A59.4238.07
Group C59.0938.64

[back to top]

EHP-30 Scores Over Time: Social Support

The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status. (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

Interventionscore on a scale (Mean)
BaselineMonth 3Month 6
Group B45.8316.6725.00

[back to top]

EHP-30 Scores Over Time: Social Support

The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status. (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

,
Interventionscore on a scale (Mean)
BaselineMonth 3
Group A48.2117.19
Group C50.0018.75

[back to top]

EHP-30 Scores Over Time: Sexual Intercourse

The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status. (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

Interventionscore on a scale (Mean)
BaselineMonth 3Month 6
Group B62.5045.0030.00

[back to top]

EHP-30 Scores Over Time: Sexual Intercourse

The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status. (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

,
Interventionscore on a scale (Mean)
BaselineMonth 3
Group A70.0045.00
Group C60.0060.00

[back to top]

EHP-30 Scores Over Time: Self-Image

The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status. (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

Interventionscore on a scale (Mean)
BaselineMonth 3Month 6
Group B36.118.3316.67

[back to top]

EHP-30 Scores Over Time: Self-Image

The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status. (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

,
Interventionscore on a scale (Mean)
BaselineMonth 3
Group A50.0043.75
Group C75.008.33

[back to top]

EHP-30 Scores Over Time: Emotional Well-Being

The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status. (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

Interventionscore on a scale (Mean)
BaselineMonth 3Month 6
Group B50.0023.6125.00

[back to top]

EHP-30 Scores Over Time: Emotional Well-Being

The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status. (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

,
Interventionscore on a scale (Mean)
BaselineMonth 3
Group A29.7618.75
Group C45.8337.50

[back to top]

EHP-30 Scores Over Time: Control and Powerlessness

The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status. (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

Interventionscore on a scale (Mean)
BaselineMonth 3Month 6
Group B56.9426.398.33

[back to top]

EHP-30 Scores Over Time: Control and Powerlessness

The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status. (NCT03343067)
Timeframe: Month 0 (baseline), Months 3, 6

,
Interventionscore on a scale (Mean)
BaselineMonth 3
Group A71.4336.46
Group C41.6725.00

[back to top]

Change From Baseline Over Time in Monthly Average NMPP Pain Score

The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

Interventionscore on a scale (Mean)
Change at Month 1Change at Month 2Change at Month 3Change at Month 4Change at Month 5Change at Month 6
Group B-0.07-0.30-0.30-0.34-0.27-0.13

[back to top]

Change From Baseline Over Time in Monthly Average NMPP Pain Score

The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. (NCT03343067)
Timeframe: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

,
Interventionscore on a scale (Mean)
Change at Month 1Change at Month 2Change at Month 3Change at Month 4
Group A-0.13-0.48-0.70-1.34
Group C0.390.290.540.46

[back to top]

Change From The Pivotal Phase 3 Study Baseline In Each Of The Non-Pain EHP-30 Domains At Week 52

Assessed using the following non-pain domains of the EHP-30 questionnaire: Control and Powerlessness (questions 12 through 17), Emotional Well-Being (questions 18 through 23), Social Support (questions 24 through 27), and Self-Image (questions 28 through 30). The score for each domain ranged from 0 to 100. Higher scores represent a greater impact of endometriosis. The LS mean was presented by pivotal study treatment group and by visit. (NCT03654274)
Timeframe: Week 52

,,
Interventionscore on a scale (Least Squares Mean)
Control and PowerlessnessEmotional Well-beingSocial SupportSelf Image
Placebo (Group C)-39.5-23.7-28.7-22.8
Relugolix Plus Delayed E2/NETA (Group B)-40.1-24.4-28.9-23.1
Relugolix Plus E2/NETA (Group A)-43.7-26.7-28.8-26.4

[back to top]

Percent Change From The Pivotal Phase 3 Study Baseline In BMD At Lumbar Spine (L1-L4), Femoral Neck, And Total Hip At Week 104

Assessed by dual-energy X-ray absorptiometry (DXA) scan at lumbar spine, total hip, and femoral neck (same leg for each participant) at each designated time point. All participants who completed treatment or terminated from the study early were required to return for a 6-month post-treatment follow-up (PTFU) and a 12-month PTFU DXA scan (except if participant was beyond 14 months from last day on treatment). Participants were also to have clinical laboratory evaluations (vitamin D, thyroid stimulating hormone, parathyroid hormone, creatinine, calcium, and phosphorous) at the 6-month and 12-month PTFU only if the PTFU DXA scans showed a bone loss of ≥3% at the lumbar spine and/or total hip compared with the parent study baseline. (NCT03654274)
Timeframe: Week 104

,,
Interventionpercent change (Least Squares Mean)
Lumbar Spine (L1-L4)Femoral NeckTotal Hip
Placebo (Group C)-0.09-0.050.69
Relugolix Plus Delayed E2/NETA (Group B)-0.56-0.440.10
Relugolix Plus E2/NETA (Group A)-0.450.240.82

[back to top]

Percent Change From The Pivotal Phase 3 Study Baseline In BMD At Lumbar Spine (L1-L4), Femoral Neck, And Total Hip At Week 52

Assessed by dual-energy X-ray absorptiometry (DXA) scan at lumbar spine, total hip, and femoral neck (same leg for each participant) at each designated time point. All participants who completed treatment or terminated from the study early were required to return for a 6-month post-treatment follow-up (PTFU) and a 12-month PTFU DXA scan (except if participant was beyond 14 months from last day on treatment). Participants were also to have clinical laboratory evaluations (vitamin D, thyroid stimulating hormone, parathyroid hormone, creatinine, calcium, and phosphorous) at the 6-month and 12-month PTFU only if the PTFU DXA scans showed a bone loss of ≥3% at the lumbar spine and/or total hip compared with the parent study baseline. (NCT03654274)
Timeframe: Week 52

,,
Interventionpercent change (Least Squares Mean)
Lumbar Spine (L1-L4)Femoral NeckTotal Hip
Placebo (Group C)-0.090.060.27
Relugolix Plus Delayed E2/NETA (Group B)-1.09-0.84-0.52
Relugolix Plus E2/NETA (Group A)-0.69-0.21-0.10

[back to top]

Percentage Of Participants With Improvement, No Change, Or Worsening From Baseline In PGA Score For Function At Week 104

"The PGA for functional impairment is a 1-item questionnaire designed to assess participant's impression of how their pain affected their usual activities. The participants responded to the question: How much were your daily activities limited by endometriosis over the last 4 weeks? using a 5-point response scale; each response was given a numerical score: not at all (0), minimally (1), moderately (2), significantly (3), or very significantly (4)." (NCT03654274)
Timeframe: Week 104

,,
Interventionpercentage of participants (Number)
Improvement (-1 to -4)No Change (0)Deterioration (+1 to +4)
Placebo (Group C)91.28.80
Relugolix Plus Delayed E2/NETA (Group B)92.07.30.7
Relugolix Plus E2/NETA (Group A)92.76.70.6

[back to top]

Percentage Of Participants With Improvement, No Change, Or Worsening From Baseline In PGA Score For Function At Week 52

"The PGA for functional impairment is a 1-item questionnaire designed to assess participant's impression of how their pain affected their usual activities. The participants responded to the question: How much were your daily activities limited by endometriosis over the last 4 weeks? using a 5-point response scale; each response was given a numerical score: not at all (0), minimally (1), moderately (2), significantly (3), or very significantly (4)." (NCT03654274)
Timeframe: Week 52

,,
Interventionpercentage of participants (Number)
Improvement (-1 to -4)No Change (0)Deterioration (+1 to +4)
Placebo (Group C)86.110.03.9
Relugolix Plus Delayed E2/NETA (Group B)86.912.60.5
Relugolix Plus E2/NETA (Group A)88.98.13.0

[back to top]

Percentage Of Participants With Improvement, No Change, Or Worsening From Baseline In PGA Score For Overall Pelvic Pain At Week 104

The PGA for pelvic pain severity is a 1-item questionnaire designed to assess participant's impression of the severity of their pain. The questionnaire used a 5-point response scale; each response was given a numerical score: absent (0), mild (1), moderate (2), severe (3), or very severe (4). (NCT03654274)
Timeframe: Week 104

,,
Interventionpercentage of participants (Number)
Improvement (-1 to -4)No Change (0)Deterioration (+1 to +4)
Placebo (Group C)80.416.73.0
Relugolix Plus Delayed E2/NETA (Group B)82.215.82.1
Relugolix Plus E2/NETA (Group A)85.513.80.6

[back to top]

Percentage Of Participants With Improvement, No Change, Or Worsening From Baseline In PGA Score For Overall Pelvic Pain At Week 52

The PGA for pelvic pain severity is a 1-item questionnaire designed to assess participant's impression of the severity of their pain. The questionnaire used a 5-point response scale; each response was given a numerical score: absent (0), mild (1), moderate (2), severe (3), or very severe (4). (NCT03654274)
Timeframe: Week 52

,,
Interventionpercentage of participants (Number)
Improvement (-1 to -4)No Change (0)Deterioration (+1 to +4)
Placebo (Group C)72.623.04.4
Relugolix Plus Delayed E2/NETA (Group B)69.926.23.9
Relugolix Plus E2/NETA (Group A)81.514.73.9

[back to top]

Change From Pivotal Phase 3 Study Baseline In Predose Serum Concentrations Of Estradiol At Week 104

Blood samples were collected from participants for estradiol measurements at each specified timepoints. Estradiol concentrations were measured using an immuno-enzymatic assay based on a commercially available kit. (NCT03654274)
Timeframe: Week 104

Interventionpg/mL (Mean)
Relugolix Plus E2/NETA (Group A)-51.72
Relugolix Plus Delayed E2/NETA (Group B)-74.68
Placebo (Group C)-64.39

[back to top]

Change From Pivotal Phase 3 Study Baseline In NMPP Functional Impairment Score At Week 52

Assessed using the participant-modified Biberoglu and Behrman 4-point scale for pelvic pain recorded daily in an electronic diary. Participants reported their pain daily in an electronic diary using the following response options: Severe (requires strong analgesics), Moderate (noticeable pelvic pain), Mild (occasional pelvic pain), or No pain (no pain during past 24 hours). Participants gave a possible score of 0 (no pain) to 3 (severe). The LS mean was presented by pivotal study treatment group and by visit. (NCT03654274)
Timeframe: Week 52

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-1.0
Relugolix Plus Delayed E2/NETA (Group B)-1.0
Placebo (Group C)-1.0

[back to top]

Change From Pivotal Phase 3 Study Baseline In NMPP Functional Impairment Score At Week 104

Assessed using the participant-modified Biberoglu and Behrman 4-point scale for pelvic pain recorded daily in an electronic diary. Participants reported their pain daily in an electronic diary using the following response options: Severe (requires strong analgesics), Moderate (noticeable pelvic pain), Mild (occasional pelvic pain), or No pain (no pain during past 24 hours). Participants gave a possible score of 0 (no pain) to 3 (severe). The LS mean was presented by pivotal study treatment group and by visit. (NCT03654274)
Timeframe: Week 104

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-1.2
Relugolix Plus Delayed E2/NETA (Group B)-1.1
Placebo (Group C)-1.1

[back to top]

"Percentage Of Participants Who Are Better Or Much Better On The PGIC For NMPP At Week 52"

The PGIC for NMPP is a 1-item questionnaire designed to assess participant's impression of change in the severity of pain when they are not menstruating. The questionnaire used a 7-point response scale: much better, better, a little better, the same, a little worse, worse, or much worse. (NCT03654274)
Timeframe: Week 52

Interventionpercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)85.5
Relugolix Plus Delayed E2/NETA (Group B)86.1
Placebo (Group C)79.1

[back to top]

"Percentage Of Participants Who Are Better Or Much Better On The PGIC For Dyspareunia At Week 52"

The PGIC for dyspareunia is a 1-item questionnaire designed to assess participant's impression of change in the severity of their pain during sexual intercourse. The questionnaire used a 7-point response scale: much better, better, a little better, the same, a little worse, worse, or much worse. (NCT03654274)
Timeframe: Week 52

Interventionpercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)61.0
Relugolix Plus Delayed E2/NETA (Group B)61.9
Placebo (Group C)60.0

[back to top]

"Percentage Of Participants Who Are Better Or Much Better On The Patient Global Impression Of Change (PGIC) For Dysmenorrhea At Week 52"

The PGIC for dysmenorrhea is a 1-item questionnaire designed to assess participant's impression of change in the severity of pain during their menstrual cycle. The questionnaire used a 7-point response scale: much better, better, a little better, the same, a little worse, worse, or much worse. (NCT03654274)
Timeframe: Week 52

Interventionpercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)89.1
Relugolix Plus Delayed E2/NETA (Group B)87.1
Placebo (Group C)83.0

[back to top]

Change From Pivotal Phase 3 Study Baseline In Predose Serum Concentrations Of Estradiol At Week 52

Blood samples were collected from participants for estradiol measurements at each specified timepoints. Estradiol concentrations were measured using an immuno-enzymatic assay based on a commercially available kit. (NCT03654274)
Timeframe: Week 52

Interventionpg/mL (Mean)
Relugolix Plus E2/NETA (Group A)-55.22
Relugolix Plus Delayed E2/NETA (Group B)-77.76
Placebo (Group C)-62.07

[back to top]

Change From The Pivotal Phase 3 Study Baseline In Each Of The Non-Pain EHP-30 Domains At Week 104

Assessed using the following non-pain domains of the EHP-30 questionnaire: Control and Powerlessness (questions 12 through 17), Emotional Well-Being (questions 18 through 23), Social Support (questions 24 through 27), and Self-Image (questions 28 through 30). The score for each domain ranged from 0 to 100. Higher scores represent a greater impact of endometriosis. The LS mean was presented by pivotal study treatment group and by visit. (NCT03654274)
Timeframe: Week 104

,,
Interventionscore on a scale (Least Squares Mean)
Control and PowerlessnessEmotional Well-beingSocial SupportSelf Image
Placebo (Group C)-41.9-25.6-29.7-25.2
Relugolix Plus Delayed E2/NETA (Group B)-43.7-26.5-24.9-25.8
Relugolix Plus E2/NETA (Group A)-47.5-30.7-33.2-29.5

[back to top]

Percentage Of Participants Who Have A Reduction Of At Least 20 Points In The EHP-30 Pain Domain Scores From The Pivotal Phase 3 Study Baseline At Week 104

Assessed using the Pain Domain of the EHP-30 questionnaire. The EHP-30 questionnaire was completed on an electronic tablet (eTablet) device. Participants reported the frequency (never, rarely, sometimes, often, and always) with which they had difficulty with activities such as standing, sitting, walking, sleeping, and performing jobs around the house because of pain. The Pain Domain normalized scores ranged from 0 to 100, with higher scores denoting greater functional impact of pain. (NCT03654274)
Timeframe: Week 104

Interventionpercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)88.6
Relugolix Plus Delayed E2/NETA (Group B)85.4
Placebo (Group C)86.1

[back to top]

Percentage Of Participants Who Have A Reduction Of At Least 20 Points In The EHP-30 Pain Domain Scores From The Pivotal Phase 3 Study Baseline At Week 52

Assessed using the Pain Domain of the EHP-30 questionnaire. The EHP-30 questionnaire was completed on an electronic tablet (eTablet) device. Participants reported the frequency (never, rarely, sometimes, often, and always) with which they had difficulty with activities such as standing, sitting, walking, sleeping, and performing jobs around the house because of pain. The Pain Domain normalized scores ranged from 0 to 100, with higher scores denoting greater functional impact of pain. (NCT03654274)
Timeframe: Week 52

Interventionpercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)83.6
Relugolix Plus Delayed E2/NETA (Group B)81.2
Placebo (Group C)79.5

[back to top]

Percentage Of Participants Who Meet The Dysmenorrhea Responder Criteria At Week 104

Assessed using an NRS score (11-point scale) for pain recorded daily in an electronic diary. A participant was defined as a responder if the NRS score for dysmenorrhea declined from baseline to Week 104 by at least 2.8 points without increased use of protocol-specified analgesics for pelvic pain at Week 104 relative to baseline. Participants rated their pelvic pain on a scale from 0 to 10, with 0 indicating no pain and 10 indicating pain as bad as you can imagine. (NCT03654274)
Timeframe: Week 104

Interventionpercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)84.8
Relugolix Plus Delayed E2/NETA (Group B)83.0
Placebo (Group C)80.4

[back to top]

Change From The Pivotal Phase 3 Study Baseline In Function Impairment On The PGA For Function At Week 104

"The PGA for functional impairment is a 1-item questionnaire designed to assess participant's impression of how their pain affected their usual activities. The participants responded to the question: How much were your daily activities limited by endometriosis over the last 4 weeks? using a 5-point response scale; each response was given a numerical score: not at all (0), minimally (1), moderately (2), significantly (3), or very significantly (4). The LS mean was presented by pivotal study treatment group and by visit." (NCT03654274)
Timeframe: Week 104

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-1.9
Relugolix Plus Delayed E2/NETA (Group B)-1.9
Placebo (Group C)-1.8

[back to top]

Percentage Of Participants Who Meet The Dysmenorrhea Responder Criteria At Week 52

Assessed using an NRS score (11-point scale) for pain recorded daily in an electronic diary. A participant was defined as a responder if the NRS score for dysmenorrhea declined from baseline to Week 52 by at least 2.8 points without increased use of protocol-specified analgesics for pelvic pain at Week 52 relative to baseline. Participants rated their pelvic pain on a scale from 0 to 10, with 0 indicating no pain and 10 indicating pain as bad as you can imagine. (NCT03654274)
Timeframe: Week 52

Interventionpercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)84.8
Relugolix Plus Delayed E2/NETA (Group B)82.2
Placebo (Group C)75.6

[back to top]

Percentage Of Participants Who Meet The NMPP Responder Criteria At Week 104

Assessed using an NRS score (11-point scale) for pain recorded daily in an electronic diary. A participant was defined as a responder if the NRS score for NMPP declined from baseline to Week 104 by at least 2.1 points without increased use of protocol-specified analgesics for pelvic pain at Week 104 relative to baseline. Participants rated their pelvic pain on a scale from 0 to 10, with 0 indicating no pain and 10 indicating pain as bad as you can imagine. (NCT03654274)
Timeframe: Week 104

Interventionpercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)75.8
Relugolix Plus Delayed E2/NETA (Group B)71.7
Placebo (Group C)73.1

[back to top]

Percentage Of Participants Who Meet The NMPP Responder Criteria At Week 52

Assessed using an NRS score (11-point scale) for pain recorded daily in an electronic diary. A participant was defined as a responder if the NRS score for NMPP declined from baseline to Week 52 by at least 2.1 points without increased use of protocol-specified analgesics for pelvic pain at Week 52 relative to baseline. Participants rated their pelvic pain on a scale from 0 to 10, with 0 indicating no pain and 10 indicating pain as bad as you can imagine. (NCT03654274)
Timeframe: Week 52

Interventionpercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)73.6
Relugolix Plus Delayed E2/NETA (Group B)70.4
Placebo (Group C)68.0

[back to top]

Change From The Pivotal Phase 3 Study Baseline In Dysmenorrhea Functional Impairment Score At Week 104

Assessed using the participant-modified Biberoglu and Behrman 5-point scale for dysmenorrhea recorded daily in an electronic diary. Participants were to report their pain as related to functional impairment daily in an electronic diary using the following response options: Severe (in bed all day, incapacitation), Moderate (in bed part of the day, some loss of work efficiency), Mild (some loss of work efficiency), No pain (no pain associated with menstruation during past 24 hours), or did not menstruate during the past 24 hours. Participants gave a possible score of 0 (no pain) to 4 (did not menstruate). The LS mean was presented by pivotal study treatment group and by visit. (NCT03654274)
Timeframe: Week 104

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-1.3
Relugolix Plus Delayed E2/NETA (Group B)-1.3
Placebo (Group C)-1.2

[back to top]

Change From The Pivotal Phase 3 Study Baseline In Dysmenorrhea Functional Impairment Score At Week 52

Assessed using the participant-modified Biberoglu and Behrman 5-point scale for dysmenorrhea recorded daily in an electronic diary. Participants were to report their pain as related to functional impairment daily in an electronic diary using the following response options: Severe (in bed all day, incapacitation), Moderate (in bed part of the day, some loss of work efficiency), Mild (some loss of work efficiency), No pain (no pain associated with menstruation during past 24 hours), or did not menstruate during the past 24 hours. Participants gave a possible score of 0 (no pain) to 4 (did not menstruate). The LS mean was presented by pivotal study treatment group and by visit. (NCT03654274)
Timeframe: Week 52

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-1.3
Relugolix Plus Delayed E2/NETA (Group B)-1.3
Placebo (Group C)-1.2

[back to top]

Change From The Pivotal Phase 3 Study Baseline In The Mean Dysmenorrhea NRS Score At Week 104

Assessed using an NRS score (11-point scale) for pain recorded daily in an electronic diary. Participants rated their pelvic pain on a scale from 0 to 10, with 0 indicating no pain and 10 indicating pain as bad as you can imagine. The LS mean was presented by pivotal study treatment group and by visit. (NCT03654274)
Timeframe: Week 104

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-5.9
Relugolix Plus Delayed E2/NETA (Group B)-5.7
Placebo (Group C)-5.6

[back to top]

Change From The Pivotal Phase 3 Study Baseline In Function Impairment On The PGA For Function At Week 52

"The PGA for functional impairment is a 1-item questionnaire designed to assess participant's impression of how their pain affected their usual activities. The participants responded to the question: How much were your daily activities limited by endometriosis over the last 4 weeks? using a 5-point response scale; each response was given a numerical score: not at all (0), minimally (1), moderately (2), significantly (3), or very significantly (4). The LS mean was presented by pivotal study treatment group and by visit." (NCT03654274)
Timeframe: Week 52

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-1.6
Relugolix Plus Delayed E2/NETA (Group B)-1.6
Placebo (Group C)-1.6

[back to top]

Change From The Pivotal Phase 3 Study Baseline In Severity Scores On The Patient Global Assessment (PGA) For Overall Pelvic Pain At Week 104

The PGA for pelvic pain severity is a 1-item questionnaire designed to assess participant's impression of the severity of their pain. The questionnaire used a 5-point response scale; each response was given a numerical score: absent (0), mild (1), moderate (2), severe (3), or very severe (4). The LS mean was presented by pivotal study treatment group and by visit. (NCT03654274)
Timeframe: Week 104

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-1.4
Relugolix Plus Delayed E2/NETA (Group B)-1.4
Placebo (Group C)-1.3

[back to top]

Change From The Pivotal Phase 3 Study Baseline In Severity Scores On The Patient Global Assessment (PGA) For Overall Pelvic Pain At Week 52

The PGA for pelvic pain severity is a 1-item questionnaire designed to assess participant's impression of the severity of their pain. The questionnaire used a 5-point response scale; each response was given a numerical score: absent (0), mild (1), moderate (2), severe (3), or very severe (4). The LS mean was presented by pivotal study treatment group and by visit. (NCT03654274)
Timeframe: Week 52

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-1.3
Relugolix Plus Delayed E2/NETA (Group B)-1.2
Placebo (Group C)-1.2

[back to top]

Change From The Pivotal Phase 3 Study Baseline In The Endometriosis Health Profile (EHP)-30 Pain Domain Scores At Week 104

Assessed using the pain domain of the EHP-30 questionnaire. The EHP-30 questionnaire was completed on an electronic tablet (eTablet) device. Participants reported the frequency (never, rarely, sometimes, often, and always) with which they had difficulty with activities such as standing, sitting, walking, sleeping, and performing jobs around the house because of pain. The Pain Domain normalized scores ranged from 0 to 100, with higher scores denoting greater functional impact of pain. The least squares (LS) mean was presented by pivotal study treatment group and by visit. (NCT03654274)
Timeframe: Week 104

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-41.3
Relugolix Plus Delayed E2/NETA (Group B)-38.9
Placebo (Group C)-37.7

[back to top]

Change From The Pivotal Phase 3 Study Baseline In The Endometriosis Health Profile (EHP)-30 Pain Domain Scores At Week 52

Assessed using the pain domain of the EHP-30 questionnaire. The EHP-30 questionnaire was completed on an electronic tablet (eTablet) device. Participants reported the frequency (never, rarely, sometimes, often, and always) with which they had difficulty with activities such as standing, sitting, walking, sleeping, and performing jobs around the house because of pain. The Pain Domain normalized scores ranged from 0 to 100, with higher scores denoting greater functional impact of pain. The least squares (LS) mean was presented by pivotal study treatment group and by visit. (NCT03654274)
Timeframe: Week 52

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-37.7
Relugolix Plus Delayed E2/NETA (Group B)-36.1
Placebo (Group C)-35.1

[back to top]

Change From The Pivotal Phase 3 Study Baseline In The Mean Dysmenorrhea NRS Score At Week 52

Assessed using an NRS score (11-point scale) for pain recorded daily in an electronic diary. Participants rated their pelvic pain on a scale from 0 to 10, with 0 indicating no pain and 10 indicating pain as bad as you can imagine. The LS mean was presented by pivotal study treatment group and by visit. (NCT03654274)
Timeframe: Week 52

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-5.9
Relugolix Plus Delayed E2/NETA (Group B)-5.7
Placebo (Group C)-5.3

[back to top]

Change From The Pivotal Phase 3 Study Baseline In The Mean Dyspareunia Functional Impairment At Week 104

Assessed using the participant-modified Biberoglu and Behrman 5-point scale for dyspareunia recorded daily in an electronic diary. Participants were to report their pain during intercourse daily using the following response options: Severe (avoids intercourse because of pain), Moderate (intercourse painful to the point of causing interruption), Mild (tolerated pain), No pain (no pain during intercourse), or No intercourse (no intercourse for other reasons). Participants gave a possible score of 0 (no pain) to 3 (severe). The LS mean was presented by pivotal study treatment group and by visit. (NCT03654274)
Timeframe: Week 104

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-1.0
Relugolix Plus Delayed E2/NETA (Group B)-0.9
Placebo (Group C)-1.0

[back to top]

Change From The Pivotal Phase 3 Study Baseline In The Mean Dyspareunia Functional Impairment At Week 52

Assessed using the participant-modified Biberoglu and Behrman 5-point scale for dyspareunia recorded daily in an electronic diary. Participants were to report their pain during intercourse daily using the following response options: Severe (avoids intercourse because of pain), Moderate (intercourse painful to the point of causing interruption), Mild (tolerated pain), No pain (no pain during intercourse), or No intercourse (no intercourse for other reasons). Participants gave a possible score of 0 (no pain) to 3 (severe). The LS mean was presented by pivotal study treatment group and by visit. (NCT03654274)
Timeframe: Week 52

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-0.9
Relugolix Plus Delayed E2/NETA (Group B)-0.9
Placebo (Group C)-0.8

[back to top]

Change From The Pivotal Phase 3 Study Baseline In The Mean Dyspareunia NRS Scores At Week 104

Assessed using an NRS score (11-point scale) for pain recorded daily in an electronic diary. Participants were to report whether they had vaginal sexual intercourse and rated their level of pelvic pain during intercourse on a scale from 0 to 10, with 0 indicating no pain and 10 indicating pain as bad as you can imagine. The LS mean was presented by pivotal study treatment group and by visit. (NCT03654274)
Timeframe: Week 104

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-3.5
Relugolix Plus Delayed E2/NETA (Group B)-2.9
Placebo (Group C)-3.4

[back to top]

Change From The Pivotal Phase 3 Study Baseline In The Mean Dyspareunia NRS Scores At Week 52

Assessed using an NRS score (11-point scale) for pain recorded daily in an electronic diary. Participants were to report whether they had vaginal sexual intercourse and rated their level of pelvic pain during intercourse on a scale from 0 to 10, with 0 indicating no pain and 10 indicating pain as bad as you can imagine. The LS mean was presented by pivotal study treatment group and by visit. (NCT03654274)
Timeframe: Week 52

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-3.3
Relugolix Plus Delayed E2/NETA (Group B)-3.0
Placebo (Group C)-3.0

[back to top]

Change From The Pivotal Phase 3 Study Baseline In The Mean NMPP NRS Score At Week 104

Assessed using an NRS score (11-point scale) for pain recorded daily in an electronic diary. Participants rated their pelvic pain on a scale from 0 to 10, with 0 indicating no pain and 10 indicating pain as bad as you can imagine. The LS mean was presented by pivotal study treatment group and by visit. (NCT03654274)
Timeframe: Week 104

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-4.0
Relugolix Plus Delayed E2/NETA (Group B)-3.5
Placebo (Group C)-3.8

[back to top]

Change From The Pivotal Phase 3 Study Baseline In The Mean NMPP NRS Score At Week 52

Assessed using an NRS score (11-point scale) for pain recorded daily in an electronic diary. Participants rated their pelvic pain on a scale from 0 to 10, with 0 indicating no pain and 10 indicating pain as bad as you can imagine. The LS mean was presented by pivotal study treatment group and by visit. (NCT03654274)
Timeframe: Week 52

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-3.6
Relugolix Plus Delayed E2/NETA (Group B)-3.4
Placebo (Group C)-3.4

[back to top]

Change From The Pivotal Phase 3 Study Baseline In The Mean Overall Pelvic Pain NRS Score At Week 104

Assessed using an NRS score (11-point scale) for overall pain recorded daily in an electronic diary. Participants rated their overall pelvic pain on a scale from 0 to 10, with 0 indicating no pain and 10 indicating pain as bad as you can imagine. The LS mean was presented by pivotal study treatment group and by visit. (NCT03654274)
Timeframe: Week 104

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-4.2
Relugolix Plus Delayed E2/NETA (Group B)-3.9
Placebo (Group C)-4.0

[back to top]

Change From The Pivotal Phase 3 Study Baseline In The Mean Overall Pelvic Pain NRS Score At Week 52

Assessed using an NRS score (11-point scale) for overall pain recorded daily in an electronic diary. Participants rated their overall pelvic pain on a scale from 0 to 10, with 0 indicating no pain and 10 indicating pain as bad as you can imagine. The LS mean was presented by pivotal study treatment group and by visit. (NCT03654274)
Timeframe: Week 52

Interventionscore on a scale (Least Squares Mean)
Relugolix Plus E2/NETA (Group A)-3.9
Relugolix Plus Delayed E2/NETA (Group B)-3.6
Placebo (Group C)-3.6

[back to top]

Percentage Of Participants Not Using Analgesics For Endometriosis-associated Pain At Week 104

Assessed based on usage of study-specified analgesics for endometriosis-associated pain recorded daily in an electronic diary. Participants received protocol-specified analgesics for treatment of endometriosis-associated pain as needed for pain but not prophylactically. (NCT03654274)
Timeframe: Week 104

Interventionpercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)75.1
Relugolix Plus Delayed E2/NETA (Group B)76.5
Placebo (Group C)76.0

[back to top]

Percentage Of Participants Not Using Opioids For Endometriosis-associated Pain At Week 104

Assessed based on usage of study-specified opioids for endometriosis-associated pain recorded daily in an electronic diary. Participants received protocol-specified opioids for treatment of endometriosis-associated pain as needed for pain but not prophylactically. (NCT03654274)
Timeframe: Week 104

Interventionpercentage of participants (Number)
Relugolix Plus E2/NETA (Group A)91.0
Relugolix Plus Delayed E2/NETA (Group B)88.3
Placebo (Group C)90.5

[back to top]

PGIC Score (Painful Periods)

Patient's Global Impression of Change (PGIC) scale will be used to rate painful periods. This is a 7 point scale ranging from 1 (much worse) to 7 (much better). (NCT03970330)
Timeframe: 4, 8, 12 and 16 weeks

,
Interventionunits on a scale (Median)
4 weeks8 weeks12 weeks16 weeks
Low-Dose Naltrexone4.04.04.04.0
Placebo6.56.56.54.5

[back to top]

Ibuprofen Use

Average # of ibuprofen 200 mg pills per week during the study treatment period (NCT03970330)
Timeframe: 12 weeks

Interventionpills/week (Mean)
Low-Dose Naltrexone5.5
Placebo1.2

[back to top]

Oxycodone Use

Number of subjects who used oxycodone at any time during the study (NCT03970330)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Low-Dose Naltrexone0
Placebo0

[back to top]

EHP-30 Score

Quality of life measured by the validated Endometriosis Health Profile (EHP-30) questionnaire. Scores range from 0 (best health status) to 100 (worst health status). (NCT03970330)
Timeframe: Baseline, 4, 8, 12, and 16 weeks

,
Interventionscore on a scale (Mean)
BaselineWeek 4Week 8Week 12Week 16
Low-Dose Naltrexone56.535.534.934.135.7
Placebo27.625.116.018.628.9

[back to top]

PGIC Score (Dyspareunia)

Patient's Global Impression of Change (PGIC) scale will be used to rate pelvic pain during sex. This is a 7 point scale ranging from 1 (much worse) to 7 (much better). (NCT03970330)
Timeframe: 4, 8, 12 and 16 weeks

,
Interventionunits on a scale (Median)
Week 4Week 8Week 12Week 16
Low-Dose Naltrexone4.04.04.04.0
Placebo6.06.06.05.0

[back to top]

PGIC Score (Nonmenstrual Pelvic Pain)

Patient's Global Impression of Change (PGIC) scale will be used to rate nonmenstrual pelvic pain. This is a 7 point scale ranging from 1 (much worse) to 7 (much better). (NCT03970330)
Timeframe: 4, 8, 12 and 16 weeks

,
Interventionunits on a scale (Median)
Week 4Week 8Week 12Week 16
Low-Dose Naltrexone5.04.04.04.0
Placebo6.56.56.55.5

[back to top]

Pain Score Area Under the Curve (AUC)

Pain is reported daily using the Visual Analog Scale, a 100mm horizontal line on which the patient's pain intensity is represented by a point between the extremities of 0 (no pain) and 100 (worst pain). The final outcome measure will be calculated as area under the curve from randomization through 12-weeks of intervention. AUC was calculated using the trapezoid rule. Calculated AUC per subject across this 12-week period can range from 0 - 8300. (NCT03970330)
Timeframe: 12 weeks

Interventionunits on a scale*days (Mean)
Low-Dose Naltrexone2461
Placebo1338

[back to top]